

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<u>http://bmjopen.bmj.com</u>).

If you have any questions on BMJ Open's open peer review process please email <u>info.bmjopen@bmj.com</u>

BMJ Open

Connected device and therapeutic patient education to promote physical activity among women with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045448
Article Type:	Protocol
Date Submitted by the Author:	12-Oct-2020
Complete List of Authors:	Touillaud, Marina; Léon Bérard Cancer Centre, Department of Preventio Cancer Environment; INSERM UA8 "Radiations: Defense, Health and Environment", Léon Bérard Cancer Centre Fournier, Baptiste; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment Pérol, Olivia; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment; INSERM UA8 "Radiations: Defense, Health and Environment", Léon Bérard Cancer Centre Delrieu, Lidia; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment; Claude Bernard Lyon 1 University, Inter-Universit: Laboratory of Human Movement Biology EA7424 Maire, Aurélia; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment Belladame, Elodie; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment Pérol, David; Léon Bérard Cancer Centre, Department of Prevention Cancer Environment Pérol, David; Léon Bérard Cancer Centre, Department of Clinical Research and Innovation Perrier, Lionel; Léon Bérard Cancer Centre, Direction of Clinical Researc and Innovation; University of Lyon, GATE Lyon Saint-Etienne UMR-CNR 5824 Preau, Marie; Lyon 2 University, GRePS EA4163 Institute of Psychology LEROY, Tanguy; Lyon 2 University, GRePS EA4163 Institute of Psychology Fassier, Jean-Baptiste; Hospices Civils de Lyon, Claude Bernard Lyon 1 University, UMRESTTE UMR T 9405 Fillol, Florie; Biomouv Pascal, Sébastien; Biomouv Durand, Thierry; Léon Bérard Cancer Centre, Department of Hospital Information Fervers, Béatrice; Léon Bérard Cancer Centre, Department of Preventio Cancer Environment; INSERM UA8 "Radiations: Defense, Health and Environment", Léon Bérard Cancer Centre
Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, MEDICAL EDUCATION & TRAINING

1 2	
3 4	SCHOLAR ONE [™]
5 6	Manuscripts
7 8	
9	
10 11	
12 13	
14	
15 16	
17 18	
19 20	
21	
22 23	
24 25	
26	
27 28	
29 30	
31 32	
33	
34 35	
36 37	
38 39	
40	
41 42	
43 44	
45 46	
47	
48 49	
50 51	
52 53	
54	
55 56	
57 58	
59 60	For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xht
00	· · · · · · · · · · · · · · · · · · ·



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

2		
3 4	1	Connected device and therapeutic patient education to promote physical activity among women
5 6	2	with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised
7 8	3	controlled trial
9 10 11	4	
12 13	5	Marina Touillaud ^{1,2} , Baptiste Fournier ¹ , Olivia Pérol ^{1,2} , Lidia Delrieu ^{1,3} , Aurélia Maire ¹ , Elodie
14 15	6	Belladame ¹ , David Pérol ⁴ , Lionel Perrier ^{4,5} , Marie Préau ⁶ , Tanguy Leroy ⁶ , Jean-Baptiste Fassier ⁷ , Florie
16 17 18	7	Fillol ⁸ , Sébastien Pascal ⁸ , Thierry Durand ⁹ , Béatrice Fervers ^{1,2}
19 20	8	
21 22	9	¹ Department of Prevention Cancer Environment, Léon Bérard Cancer Centre, Lyon, France
23 24 25	10	² INSERM UA8 "Radiations: Defense, Health and Environment", Léon Bérard Cancer Centre, Lyon,
26	11	France
27 28 29	12	³ Inter-University Laboratory of Human Movement Biology EA7424, Claude Bernard Lyon 1 University,
30 31	13	University of Lyon, Villeurbanne, France
32 33	14	⁴ Direction of Clinical Research and Innovation, Léon Bérard Cancer Centre, Lyon, France
34 35 36	15	⁵ GATE Lyon Saint-Etienne, UMR-CNRS 5824, University of Lyon, Ecully, France
37 38	16	⁶ GRePS EA4163 Institute of Psychology, Lyon 2 University, Bron, France
39 40	17	⁷ Hospices Civils de Lyon, Claude Bernard Lyon 1 University, UMRESTTE UMR T 9405, Lyon, France
41 42 43	18	⁸ Biomouv, Paris, France
44 45	19	⁹ Department of Hospital Information, Léon Bérard Cancer Centre, Lyon, France
46 47	20	
48 49	21	Correspondence to:
50 51	22	Dr Béatrice Fervers; beatrice.fervers@lyon.unicancer.fr
52 53 54 55 56 57 58 59 60	23	
		1

24 ABSTRACT

Introduction: Despite safety and benefits of physical activity during treatment of localized breast cancer, successful exercise strategies remain to be determined. Primary objective of the DISCO trial is to evaluate the efficacy of two 6-month exercise interventions concomitant to adjuvant treatments, either alone or combined, on the physical activity level of breast cancer patients, compared to usual care: an exercise program using a connected device (activity tracker, smartphone application, website) and a therapeutic patient education intervention. Secondary objectives are to evaluate adherence to interventions, their impact at 6 and 12 months, representations and acceptability of interventions, and to assess the cost-effectiveness of the interventions using quality-adjusted life year.

Methods and analysis: This is a 2x2 factorial, multicentre, phase III randomised controlled trial. The study population (with written informed consent) will consist of 432 women diagnosed with primary localized invasive breast carcinoma and eligible for adjuvant chemotherapy, hormonotherapy and/or radiotherapy. They will be randomly allocated between one of four arms: (i) web-based connected device (evolving target number of daily steps and individualized, semi-supervised, adaptive program of two walking and one muscle strengthening sessions per week in autonomy), (ii) therapeutic patient education (one educational diagnosis, two collective educational sessions, one evaluation), (iii) combination of both interventions and (iv) control. All participants will benefit from the international physical activity recommendations. Assessments (baseline, 6 and 12 months) will include physical fitness tests, anthropometrics measures, body composition (CT-scan, impedancemetry), self-administered questionnaires [physical activity profile (RPAQ), quality of life (EORTC QLQ-C30, EQ-5D-5L), fatigue (PFS-12), social deprivation (EPICES), lifestyle, physical activity barriers, occupational status] and biological parameters (blood draw).

46 Ethics and dissemination: This study was reviewed and approved by the French Ethics Committee. The
47 findings will be disseminated to the scientific and medical community via publications in peer-reviewed
48 journals and conference presentations.

49 Registration: ClinicalTrials.gov NCT03529383; 05/17/2018.
 60

1		
2 3	50	
4 5		
6	51	Keywords: Breast cancer, Physical activity, Sitting time, Activity tracker, Connected device, Web-
7 8	52	based, eHealth, Therapeutic patient education, Randomised controlled trial
9 10 11	53	
12 13	54	Word count: 8445
14 15	55	
16 17 18	56	Strengths and limitations of this study
19 20	57	- This study findings will provide novel data on the efficacy of two innovative interventions
21 22	58	promoting physical activity during breast cancer adjuvant treatment (a web-based connected
23 24	59	device and therapeutic patient education, either alone or combined) developing autonomy of
25 26 27	60	patients in their practice of physical activity.
27 28 29	61	- The cost-effectiveness evaluation planned in the DISCO trial will provide valuable information
30 31	62	for decision makers given limited evidence for cost-effectiveness of physical activity in the
32 33	63	treatment of cancers.
34 35	64	- While the connected device intervention is semi-supervised, the exercise program has been
36 37 38	65	designed according to the preferences of women with breast cancer so as not to leave patients
39 40	66	in total autonomy. It provides organisational flexibility to patients that may facilitate
41 42	67	adherence, as well as to overcome barriers due to distance of facilities.
43 44	68	- Despite the potential benefits of connected devices in cancer care, their use may face
45 46 47	69	important issues, such as ethical challenges related to the security of sensitive data storage,
48 49	70	technical challenges related to technological robustness and reliability, exacerbating access
50 51	71	disparities, and self-assessment of the participant's fatigue or health condition.
52 53	72	- The primary outcome measure is based on a declarative evaluation of physical activity that
54 55 56	73	confers methodological limits to the study; but the validated questionnaire was chosen
56 57 58	74	according for its easy implementation for cancer patients compared to accelerometer
59 60		
60		

75 monitoring and its relevance for the primary outcome, although the performance and
76 reliability of activity trackers are increasingly validated.

is

For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml

INTRODUCTION

Breast cancer is the leading cause of cancer in women worldwide with 1.6 million new cases diagnosed each year,¹ representing more than a third of all new cancer cases in women. In France, breast cancer also represents the leading cause of cancer incidence and mortality among women, with approximately 58,000 new cases and 12,000 breast cancer deaths estimated in 2018.² Despite very good prognosis worldwide with an overall survival of 85% at 5 years (87% in France) and 71% at 10 years (78% in France) for all stages combined,³⁻⁵ a large number of patients with breast cancer experience adverse effects of cancer and its treatments such as fatigue, impaired quality of life, anxiety or weight gain.^{6–8}

In women with breast cancer, deterioration of physical activity level and decline in cardiorespiratory fitness are frequent.^{9,10} Lack of physical activity, obesity and weight gain have been shown to increase the risk of cancer-related comorbidities and treatments adverse effects, to worsen long-term health and to cause poor prognosis.¹¹⁻¹³ The benefits of physical activity are well recognized in primary cancer prevention¹⁴ and numerous studies have shown the safety¹⁵ and benefits of physical activity performed concomitant to breast cancer treatments. These benefits include reduced fatigue¹⁶⁻¹⁸ and comorbidities¹⁹, improved quality of life^{20,21} and physical functioning,^{10,16,18,21} as well as possibly reduced risk of recurrence²² and improved overall and specific survival with a positive dose-response relationship.^{13,22,23} Despite these benefits and international evidence-based guidelines of physical activity prescription for clinicians and their patients, accessibility to exercise programs and implementing the guidelines in the cancer care process remain a challenge for patients and health care providers.^{24–26} While a growing number of facilities offer physical activity programs to cancer patients, distance from home constitutes a barrier to regular exercise during cancer treatments.²⁵ Successful exercise strategies during and beyond cancer treatment remain to be determined in clinical trials.²⁷ The recent development of connected devices such as activity trackers offers a real opportunity in oncology to promote and monitor patients' physical activity.²⁸ While adherence to lifestyle interventions is a major challenge, connected activity trackers and smartphone applications enable

> structured monitoring of health parameters and provide feedback to patients. A systematic review of randomised controlled trials of physical activity interventions using new technologies such as activity trackers in cancer patients (including five studies in breast cancer) has shown that patients significantly increased their number of steps per day in the majority of the studies.²⁹ Recent reviews of intervention studies conducted among breast cancer patients have also shown that patients increased their physical activity when they used activity trackers.^{30,31} Overall, connected activity trackers receive increasing interest for being systematically integrated into clinical oncology practice.^{32,33} But more research is needed, especially clinical trials, to demonstrate the effectiveness of these tools and to respond to the preferences of breast cancer patients.^{34–36}

Therapeutic patient education has emerged in the 1990s in response to the recognition of the need to support patients in the self-management of their chronic diseases, such as diabetes and asthma.^{37,38} According to the WHO, therapeutic patient education aims to "help patients acquire or maintain the skills they need to best manage their lives with a chronic disease".³⁹ In the cancer field, several cancer-specific programs of therapeutic patient education have been set up to manage pain, fatigue, side effects of treatment (chemotherapy, surgery) or compliance to treatment.^{40–43} By enhancing knowledge and skills level, therapeutic patient education may greatly contribute to increase patients' autonomy in their disease management. Despite the performance in modifying long-term individual behaviours and adherence to oral cancer treatments,⁴³ the benefits of therapeutic patient education

Several biological mechanisms have been proposed to explain the effects of physical activity on breast
 cancer risk and outcome. These mechanisms suggest an influence of physical activity on several
 signalling pathways involved in tumour development and progression, including the insulin signalling
 pathway, chronic inflammation (involving inflammatory cytokines) and endocrine hormone
 regulation.⁴⁶⁻⁴⁸ Based on the data in the literature, it is not possible to conclude for a causal relationship
 between the metabolic effects of physical activity and the impact on survival, and biological effects of
 physical activity remain to be elucidated.⁴⁸

on physical activity levels in cancer patients early after diagnosis has been poorly investigated.^{44,45}

Page 9 of 48

BMJ Open

In this context, given the accumulating evidence for the benefits and safety of regular exercise during treatments of localized breast cancer, it is necessary to systematically encourage patients to remain or become physically active from the time of diagnosis and to implement and assess the most appropriate strategies of physical activity in clinical practice. The aim of the DISCO trial is to propose exercise during breast cancer treatment through two innovative types of interventions, a web-based connected device and therapeutic patient education, which aim to develop patients' autonomy in their practice of physical activity. The primary objective of the DISCO trial is to evaluate the efficacy of two interventions concomitant to adjuvant treatments, either alone or combined, on the physical activity level of breast cancer patients at the end of the 6-month interventions, compared to usual care: one is an exercise program using a connected device (comprising an activity tracker linked to a smartphone application and a website and providing an individualized, semi-supervised, technology-based exercise program) and the other is a therapeutic patient education intervention. The research hypothesis is that patients participating in the 6-month connected device or therapeutic education intervention will be more likely to achieve the international physical activity recommendations, compared to women receiving physical activity recommendations only (usual care). The international recommendations of the World Health Organization (WHO) for health are to do at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic physical activity or an equivalent combination each week, and musclestrengthening activities at least two days a week.⁴⁹ Secondary objectives are: (i) to evaluate the adherence to the interventions; the impact of the interventions on physical fitness, physical activity profile, anthropometrics, quality of life, fatigue, biological parameters, occupational status and lifestyle factors; the efficacy of the 6-month interventions on physical activity level at 12 months; the representations and acceptability of activity tracker and of therapeutic patient education; and ii) to assess the cost-effectiveness of the interventions. If one of the interventions is individually effective, the efficacy of the combination of both interventions at 6 and 12 months will be evaluated.

METHODS AND DESIGN

156 Trial design

The DISCO (acronym for "dispositif connecté", i.e., connected device in English) trial is a 2x2 prospective, multicentre, factorial, randomised, controlled and open-label study (phase III), conducted by the Léon Bérard comprehensive cancer centre (Lyon, France) among women receiving treatment for localized breast cancer. The clinical protocol was designed and written according to the SPIRIT guidelines (see Supplementary file 1). The flowchart of the study is presented in Figure 1. Patients will be randomly assigned to one of the four arms of the study according to the 2×2 factorial design (1:1:1:1 ratio). They will all receive international recommendations on physical activity,⁴⁹ and: (i) women allocated to the "connected device" arm will benefit from a 6-month individualized, semi-supervised exercise program carried out autonomously, consisting of an evolving goal of daily number of steps using an activity tracker and of two sessions of brisk walking and one session of muscle strengthening per week, using dedicated smartphone application and website; (ii) women allocated to the "therapeutic patient education" arm will benefit from four therapeutic education sessions on exercise; (iii) women allocated to the "combined" arm will benefit from both interventions in parallel; (iv) women allocated to the "control" arm will receive usual care.

172 Eligibility criteria for participants

Inclusion criteria include: being a female 18 to 75 years old; diagnosed with a first primary non-metastatic invasive breast carcinoma histologically confirmed; treated with curative surgery and requiring adjuvant treatment (chemotherapy, hormonotherapy, radiotherapy) that will be realised in one of the investigating centres; providing a medical certificate of no contraindication to exercise; being available and willing to participate in the study for the duration of the interventions and follow-up; using a personal smartphone compatible with the application (iOS operating system from version 9.3, Android operating system from version 5.0, no Microsoft operating system) and having a computer with Internet access; being able to understand, read and write French; and being affiliated with a social security scheme.

BMJ Open

Non-inclusion criteria include: recurrent, metastatic or inflammatory breast cancer; personal history or co-existence of other primary cancer (except of in situ cancer regardless of the site, basal cell skin cancer and non-mammary cancer in complete remission for more than 5 years); presenting a contraindication to exercise according to the investigator (such as cardiorespiratory or bone pathologies, non-stabilized chronic diseases such as diabetes, malnutrition, etc.); presenting severe malnutrition according to the criteria of the French National Health Authority (i.e., for women ≤70 years: weight loss \geq 15% in 6 months or \geq 10% in 1 month; for women >70 years: weight loss \geq 15% in 6 months or $\geq 10\%$ in 1 month, and body mass index <18 kg/m²);⁵⁰ being unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study; pregnant or breastfeeding or of childbearing age without effective contraception for the duration of the study.

193 Recruitment

Recruitment started on May 2018. Participants will be recruited at several national comprehensive cancer centres, clinics or hospitals located in France (see ClinicalTrials.gov NCT03529383), which will ensure adequate participant enrolment to reach the target sample size in a timely manner. Inclusion of patients will be carried out after surgery and confirmation of the indication of adjuvant treatment. The study will be proposed to patients at the postoperative, pre-chemotherapy or pre-radiotherapy consultation (by the surgeon, oncologist or radiotherapist investigator, respectively) depending on the patient's treatment plan. At this visit, the investigator will check all eligibility criteria and propose to the eligible patients to participate in the study, explain the objectives and study process and give them an information notice. After sufficient time for reflection, eligible patients who agree to participate will date and sign an informed consent and will be included prior to the onset of adjuvant therapy (or within one month thereafter). The number of eligible patients refusing to participate in the study and reason for non-participation will be recorded.

59 207 Randomisation60

Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity.⁵¹ Their weight, size and prescribed adjuvant treatments will be collected from the patient's medical record.

Participants will be randomised using EnnovClinical[®] software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria:^{52,53} body mass index (BMI) (<25 kg/m², \geq 25 and <30 kg/m², \geq 30 kg/m²), baseline physical activity level from RPAQ (<150 min/week, ≥150 min/week of moderate-to-vigorous physical activity) and prescribed adjuvant treatments at inclusion (i.e., chemotherapy + hormone therapy \pm radiotherapy, hormone therapy \pm radiotherapy, chemotherapy \pm radiotherapy, radiotherapy only).

INTERVENTIONS

At baseline, all participants will benefit from the international recommendations in terms of physical activity for promoting health in the general population⁴⁹ delivered by a certified exercise instructor.

Intervention with connected device

Participants randomised to the "connected device" arm will benefit from a 6-month exercise program. The connected device consists of an activity tracker (connected wristband, LS417-F model, CARE Fitness, Bobigny, France) that participants will wear daily, a dedicated smartphone application and a dedicated website proposing an individualized, semi-supervised exercise program adapted to cancer patients (developed by BIOMOUV, Paris, France). This automated web- and mobile-based exercise program will aim to support participants to enhance physical activity in two ways: doing structured physical activity sessions and increasing daily physical activity (number of steps). Physical activity sessions will be automated generated by an algorithm based on the patient profile (described below). The participants will receive notifications informing them of a new structured physical activity session available on the website or mobile application, or alerting them when a session was not carried out

BMJ Open

and inviting them to execute it when possible. Participants will receive a free 6-month subscription tothe program.

-Setting up the connected device: At the end of the baseline assessment, the certified exercise instructor will introduce the participants to the customized exercise program and will give them the activity tracker and a user guide for the connected device. Then, the certified exercise instructor will explain the functioning of the activity tracker, the dedicated smartphone application and the dedicated website, as well as assist the participants to install the application on their smartphone. The participants will be registered in the customized exercise program by the certified exercise instructor. The registration will consist of completing a web-based questionnaire about personal and health data to determine the participant profile (age, weight, height, level of aerobic and muscular strength, treatment, symptoms, availabilities for exercise sessions and sport materials).

-Baseline level of aerobic and muscular strength for the individualisation of the exercise program: The physical fitness tests performed at baseline will be used to classify the participants at the start of the exercise program according to their aerobic level (for the walking sessions) and their muscular strength level (for the strengthening sessions). The aerobic level categories will be determined by the distance performed during the 6-minute walk test (6MWT): aerobic group 1 (<460 meters), aerobic group 2 (460 to 580 meters) and aerobic group 3 (>580 meters). The muscular strength level will be determined by the number of sit-ups performed on a chair in 30 seconds during the Sit-to-stand test: muscular strength group 1 (≤10 repetitions), muscular strength group 2 (11 to 14 repetitions) and muscular strength group 3 (\geq 15 repetitions). Thresholds were based on average values reached by women on treatment for breast cancer for the 6MWT (pooled mean value, 523 m) and the Sit-to-stand test (pooled mean value, 13 repetitions);⁵⁴ these values were checked for consistency with percentile scores obtained at the 6MWT and Sit-to-stand test in community-dwelling older women,⁵⁵ then the percentiles were used to determine the thresholds for the three groups.

57 257 — Exercise program: The 6-month exercise program will be semi-supervised by the certified exercise
 58
 59 258 instructor through an individual follow-up of participants (see 'Participant follow-up' part and
 60

'Continuous monitoring' part). It will be carried out autonomously by the participants at home by using the smartphone application and the website. The program is based on three structured unsupervised sessions per week alternating two types of exercise: two walking sessions (by following oral instructions given via the smartphone application) and one muscle strengthening session (by using videos accessible on the website). The levels of the first walking and muscle strengthening sessions will be determined by the fitness tests performed at baseline (see 'Baseline level' part). Then, subsequent sessions will be programmed according to the participant's availability days and strengthening exercises will be adapted according to sport materials available to the participants at home (e.g., Swiss ball, sports mat, stick, weight, etc.). Each session will include: 1) a warm-up period of 5 minutes; 2) a body session of 10 to 35 minutes of strengthening exercises developing, or 10 to 50 minutes of walking sessions (mixing continuous and/or intermittent effort); 3) a 5-minute recovery period, consisting of stretching and relaxation during strength training sessions, or a cool down during walking sessions. Sessions will be of moderate-to-high intensity (\geq 3 and \leq 9 METs).

The three structured unsupervised exercise sessions per week are configured by a unique algorithm hosted by an accredited personal healthcare data host (Orange Business Services, Paris, France), to plan the exercise sessions and determine the exercise level in an adapted and progressive manner. At the beginning of each session, the duration and intensity of the session will be determined according to the perceived difficulties (evaluated by a Borg scale) and participant's emotional state (recorded by an emoji) in the previous session, and will be modified or postponed according to the level of fatigue (evaluated by a Borg scale), the level of dyspnea (evaluated by a Borg scale), the presence or absence of unusual muscle pain and the presence or absence of unusual nausea/diarrhea. In case of a severe adverse event related to disease or treatment (i.e., joint disability, osteoarthritis, cachexia, hand-foot syndrome, aplasia, diuretic, axillary node dissection, pace-maker, chemotherapy, targeted therapy, hormone therapy, radiotherapy, COPD, diabetes) or temporary contraindication to exercise, declared by the participant on her device, the program and sessions will be adapted or suspended until the participant's health improves.

Page 15 of 48

BMJ Open

In addition, participants will have the opportunity to perform additional exercise sessions according to
their preferences and lifestyle, outside the program. Participants will be asked to record these sessions
through the smartphone application or the website: type of activity (e.g., walking, hiking, cycling) from
a list adapted from the Ainsworth's Compendium,⁵⁶ duration and intensity.

-Number of daily steps: Participants will be advised to wear the activity tracker daily and regularly (preferably daily) launch the application, which will automatically synchronize with the activity tracker via Bluetooth connection and will collect the number of steps. The target number of steps will be 3,000 steps per day at the program onset, and then will be set on the basis of the daily average steps during the first week after inclusion. The target number of daily steps will evolve automatically every three weeks based on the average number of daily steps achieved during the previous three weeks, and will be updated automatically in the application. Consistent with principles of exercise training and progression,^{57,58} after each 3-week cycle, if the objective of steps per day is reached by the participant, the target objective will increase by 15% during the following 3-week-cycle, within a maximum target of 10,000 daily steps. If the average number of daily steps does not meet the objective, the target will remain unchanged in the next cycle.

-Participant follow-up: A telephone follow-up will be carried out by the certified exercise instructor at 10 days, 2 months and 4 months after randomisation to ensure the proper functioning of the connected device, review the use of the connected device, review the conduct of the sessions and answer the participants' questions. Participants will be orally encouraged to remain physically active on a daily basis (reminder of the benefits and recommendations of physical activity, success and satisfaction during the exercise sessions). During the 6-month intervention, the participants will have the opportunity to contact the certified exercise instructor or the clinical research assistant at any time, by e-mail (directly through the website) or by telephone for any question or assistance with the connected device.

—Continuous monitoring: The certified exercise instructor will monitor the use of the connected device
 310 by the participants and their progress in the program through a dedicated professional website that
 60

provides real-time access to the participants' data. On this website, an automatically generated daily event table will inform the certified exercise instructor of the occurrence of disabilities reported by the participants that may lead to modify their program (e.g., severe fatigue, dyspnea, unusual muscle pain) or if participants have not performed their planned sessions or used their activity tracker for seven consecutive days. Upon these alerts, the certified exercise instructor will contact the participants to precisely analyse the reported disabilities, advice participants, identify the causes of non-use of the connected device, solve possible technical problems or reinforce participant's motivation if necessary. End of the intervention: At the end of the 6-month program, participants will keep their activity tracker to be encouraged to continue regularly exercising in autonomy. Upon their request, continued subscription to the dedicated application and website will be offered for six other months, with no individual follow-up anymore.

323 Intervention of therapeutic patient education

Participants randomised to the therapeutic patient education arm will benefit from a therapeutic patient education intervention, in addition to the international recommendations in terms of physical activity. The intervention is part of the therapeutic patient education program set up at the Léon Bérard cancer centre and validated by the Regional Health Agency ("Agence Régionale de Santé Rhône-Alpes") and will be disseminated in the investigating centres according to the criteria of the Regional Health Agency. The therapeutic patient education intervention consists in four sessions that will be scheduled according to participants' availability during their follow-up visits as part of their usual clinical management over a 6-month period.

First, participants will be invited to an initial 1-hour individual session of educational diagnosis with a health professional trained in therapeutic patient education. This session will assess their needs and establish a contract of objectives to reach. Then, participants will be invited to participate in two collective educational sessions of 1h30 each (group of 10 patients maximum). These sessions will be composed of theoretical and practical workshops to help them understand their physical activity in

BMJ Open

3	337	their daily life and implement the necessary means to practice regular exercise in autonomy. Finally,
4	557	their duity me and implement the necessary means to proceed regular excluse in autonomy. Finally,
5 6	338	an educational evaluation will be conducted during a 1-hour individual session, during which the
7 8	339	participants will identify whether they have achieved their individual objectives set at the time of the
9 10 11	340	educational diagnosis.
12 13	341	
14 15	342	Combined interventions
16 17	343	Participants randomised to the 'combined intervention' arm will benefit from a combination of the
18 19 20	344	connected device intervention and the therapeutic patient education intervention in parallel for
20 21 22	345	6 months.
23 24	346	
25 26	347	STUDY OUTCOMES
27 28	348	The primary endpoint will be the proportion of women who achieve at 6 months the internationally
29 30 31	349	recommended level of physical activity (at least 150 min/week of moderate-to-vigorous physical
32 33	350	activity, i.e., intensity ≥3 METs) assessed according to the RPAQ self-administered questionnaire.
34 35	351	Secondary endpoints will be:
36 37	352	1. Assessment of the efficacy of the programs at 12 months (i.e., proportion of women who achieve
38 39 40	353	the internationally recommended level of physical activity);
41 42	354	2. Assessment of the adherence to the interventions at 6 months (proportion of participants who are
43 44	355	compliant to the program, participation rate in planned sessions);
45 46	356	3. Assessment of the impact between baseline and 6 months and between 6-12 months of the
47 48 49	357	interventions on physical activity profile (change in time spent in different intensities of physical
50 51	358	activity and time spent in sedentary activities), physical fitness (change in results to the 6-minute walk
52 53	359	test, hand-grip test, sit-to-stand test, sit-and-reach flexibility test and single-leg stance test),
54 55	360	anthropometrics (change in weight, waist and hip circumferences, BMI, fat mass, lean body mass,
56 57	361	muscle mass, dry lean mass and body water), quality of life (change in scores obtained from the EORTC
58 59 60	362	QLQ-C30 questionnaire and its BR-23 module), fatigue condition (change in scores obtained from the
~~		

> 363 PFS-12 questionnaire), health-related quality of life (change in scores obtained from the EQ-5D-5L 364 questionnaire), social deprivation (change in scores obtained from the EPICES self-administered 365 questionnaire), occupational status (proportion of participants who changed their employment status, 366 with return to work and who perceived difficulty at work obtained from a self-administered 367 questionnaire) and lifestyle factors (proportion of participants who change their tobacco use and 368 alcohol intake obtained from a self-administered questionnaire).

4. Assessment of the impact of the interventions on biological parameters between baseline and
 6 months (change in serum circulating levels of endocrine factors [insulin, IGF1, estradiol], change in
 plasma circulating levels of cytokines [inflammatory cytokines: IL-6, TNF, and CRP; adipokines:
 adiponectin and leptin], proportion of participants with a modification on vitamin D status).

373 5. Assessment of the representations and acceptability of activity tracker and of therapeutic patient
 374 education, at baseline, 6 and 12 months (proportion of participants who accept the connected device
 375 and who accept the therapeutic program, according to scores obtained from a self-administered
 376 qualitative questionnaire used in social psychology science).

6. Assessment of refusal rate among eligible patients (proportion of patients who refuse to participate).
7. Assessment of the cost-utility and the cost-effectiveness of implementing each intervention at
12 months, using clinical data (treatments received, patients' diary on medical consultations), hospital
costs (national data) and benefit in physical activity level.

¹³ 381

382 EVALUATIONS

The initial assessment (T0) will be performed prior to randomisation for minimization purposes. Three evaluations will then be conducted at baseline (T1), 6 months (T2) and 12 months (T3). All study participants will then be followed at 6 months ±1 month post-randomisation (corresponding to the end of participation in the interventions for women in the connected device, therapeutic patient education and combined arms) and at 12 months ±1 month post-randomisation (corresponding to a follow-up period of 6 months post-interventions). Assessments will be carried out by a clinical research

BMJ Open

2		
3 4	389	assistant and a certified exercise instructor. The clinical research assistant will contact participants by
5 6	390	phone to invite them to follow-up visits and to promote participant retention and complete follow-up.
7 8 9	391	Participants will have no compensation for participation and all study visits will be scheduled on days
9 10 11	392	of medical or health-related appointments.
12 13	393	All evaluations (baseline, 6 and 12 months) will include physical fitness tests, anthropometrics
14 15	394	measures, self-administered questionnaires and a non-fasting blood draw (baseline and 6 months
16 17	395	only). Data will be recorded using an electronic case report form (eCRF).
18 19 20	396	
20 21 22	397	DATA COLLECTION
23 24	398	The study outcome measures and their schedule are summarised in Table 1.
25 26	399	Socio-demographic and clinical data
27 28 29	400	Demographic and clinical data, including month/year of birth, age at diagnosis, family status, level of
30 31	401	education, hormonal status, tumour histology and personal history of breast cancer will be collected
32 33	402	at baseline. Family status, potential cancer progression and all treatments received for cancer will be
34 35	403	collected at 6 and 12 months. All data will be extracted from patients' electronic medical records,
36 37 38	404	except family status and level of education that will be self-reported in a questionnaire.
39 40	405	Occupational status will be assessed using a self-administered questionnaire asking employment
41 42	406	status, occupation, size of the company, perceived intensity of the physical effort at work, evolution
43 44	407	of employment status at return to work. ⁵⁹
45 46 47	408	
47 48 49	409	Anthropometrics and body composition
50 51	410	The standing height (cm), body weight (kg) and waist (cm) and hip (cm) circumferences will be
52 53	411	measured using standardized procedures and BMI will be calculated as the body weight in kilograms
54 55	412	divided by the square of the height in meters (kg/m ²). The waist circumference will be measured
56 57 58	413	midway between the last floating rib and the iliac crest. The hip circumference will be measured at the
59 60	414	tip of the pubis. Body composition will be measured by bioelectronic impedancemetry (Biody XPert

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
22	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
55	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
50	

ZM II, eBiody, eBIODY SAS, La Ciotat, France) to assess fat mass (in kg), lean body mass (in kg), muscle
mass (in kg), dry lean mass (in kg), total body water (in L), intracellular fluid (in L) and extracellular fluid
(in L).

0 418

1

419 Physical fitness

420 Cardiorespiratory fitness will be evaluated by the walking endurance during the 6MWT (distance
421 covered in metres) with perceived difficulty using Borg scale.⁶⁰ During this test, participants will be
422 asked to perform the maximum walk shuttle distance on a 30-metre long flat corridor in 6 minutes.

The lower limb muscle strength will be measured using the sit-to-stand test (number of sit-ups on a
chair in 30 seconds). During this test, participants will be asked to sit down on a chair and get up as
many times as possible during 30 seconds.⁶¹

Hand prehensile strength will be measured using hand dynamometry (Jamar Plus Digital Hand Dynamometer, Patterson Medical, Huthwaite, UK), which is a validated index of the isometric strength of the hand and forearm muscles.⁶² During this hand-grip test, participants will be asked to squeeze the handgrip as strongly as possible to obtain the maximal force (in kg). Two measures will be performed on each hand and the best performance registered.

Flexibility of lower limbs will be measured using the sit-and-reach flexibility test (Deluxe Baseline flexibility test, 3B Scientific, Bartenheim, France).⁶³ In this test, participants will be seated on the floor on a mat with their legs stretched out straight ahead. They will be asked to lean forward as far as possible and the distance between fingertips and toes will be measured (in cm) (i.e., by considering the level of the feet as recording zero, any measure that does not reach the toes is negative and any measure beyond the toes is positive).

437 The balance will be measured using the bilateral unipodal equilibrium test.⁶⁴ The participants will stand
 438 and be asked to lift a foot and hold the position for a maximum of 60 seconds, then to do the same
 439 exercise on the other foot (duration held in equilibrium, 2 times 60 seconds).

Page 21 of 48

BMJ Open

441	Physical activity level, sitting time and achievement of physical activity recommendations
442	The validated self-administered questionnaire RPAQ will be used to measure the self-reported physical
443	activity. ^{51,65} RPAQ was designed to assess usual physical activity in the last four weeks and covers three
444	activity domains: domestic physical activity, including sitting time that is a good proxy of sedentary
445	behaviour; occupational physical activity, including transportation to and from work; and recreational
446	physical activity. RPAQ gives specific scores in the metabolic equivalent of task (MET) unit for activities
447	of very low intensity (<1.5 METs, i.e., sedentary activities), low intensity (1.5 to <3 METs), moderate
448	intensity (3 to <6 METs) and high intensity (≥6 METs, i.e., vigorous activities) within each domain during
449	the past four weeks. Questions will be coded and converted in MET-minute per four weeks according
450	to the Compendium of Physical Activities ⁵⁶ by multiplying the number of METs by the duration and
451	frequency of each activity. Then, the global score of physical activity will be obtained by adding the
452	number of MET-minutes per four weeks in each intensity and each domain. The physical activity profile
453	will be defined as the time spent in physical activities of low, moderate and high intensities. The
454	physical activity level will be defined by the overall weekly physical activity (average expressed in MET-
455	hour/week).
456	Achievement of international physical activity guidelines will be computed for each individual by
457	dividing the time spent in moderate-to-vigorous physical activity (i.e., \geq 3 METs) into two categories: ⁴⁹
458	<150 min/week of moderate-to-vigorous physical activity (i.e., under physical activity guidelines); ≥150
459	min/week of moderate-to-vigorous physical activity (i.e., reaching physical activity guidelines).
460	
461	Patient-reported outcomes
462	The quality of life will be measured using the European Organization for Research and Treatment of
463	Cancer (EORTC) Quality-Of-Life Questionnaire (QLQ-C30) and its specific module for breast cancer (BR-
464	23).66 The QLQ-C30 is a 30-item validated self-administered questionnaire that evaluates five
465	functioning domains (i.e., physical, role, emotional, cognitive and social), a global quality-of-life

466 domain, three symptom domains (i.e., pain, fatigue and nausea) and six single items (i.e., dyspnea,

insomnia, anorexia, diarrhea, constipation and financial impact). Each item is associated with a score ranging from 0 to 100. For the functioning and global quality-of-life scales, a higher score corresponds to a better functioning level. For scales related to symptoms, a lower score corresponds to a better functioning level. The BR-23 module gathers data about perceived body image, sexual functioning, sex enjoyment, arm symptoms, breast symptoms and systemic therapy side effects.

The health-related quality of life will be assessed using the EQ-5D-5L questionnaire.⁶⁷ This standardized self-administered questionnaire describes five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression) being rated using five levels (i.e., no, slight, moderate, severe and extreme problems) and comprises a 0-100 visual analogue scale recording the self-rated health (where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine').

Fatigue will be assessed using the Piper Fatigue Scale-12 (PFS-12), a 12-item self-reported questionnaire with four subscales (i.e., behavioural, affective, sensory and cognitive/mood aspects of fatigue):⁶⁸ the higher the score, the worse the fatigue. All items together will produce a total score for fatigue that will be used to define categories as follows: no fatigue (score=0), mild fatigue (score 1-3), moderate fatigue (score 4-6) and severe fatigue (score 7-10).

Social deprivation will be assessed using the EPICES (Evaluation of Deprivation and Inequalities in Health Examination Centres) score.⁶⁹ The score will be computed by adding each question coefficient to the intercept whenever the answer is "yes." The score ranges from 0 to 100 (i.e., the higher the score, the greater the deprivation level) with the threshold for deprivation at 30.

Lifestyle factors, assessed using a self-administered questionnaire, include tobacco status (i.e., never, former, current smoker), lifetime and current tobacco use (expressed in pack-years) and alcohol intake over the past 6 months (usual frequency of consumption [i.e., never, less than 1/month, 1-3 times/month, 1-6 times/week, daily] of different categories of alcoholic beverages [i.e., wine, beer, cider, aperitif wine, cocktail/punch, aniseed alcohol, spirits] as well as the usual number of glasses). The amount of alcohol will be computed by multiplying the frequency of consumption by the amount

1 2		
3 4	493	of glasses and alcohol content of each type of alcoholic beverage. The average daily alcohol intake over
5 6	494	the past 6 months (in g/day) will be computed by summing the amount of alcohol from each beverage.
7 8	495	
9 10 11	496	Determinants of Physical activity
12 13	497	The 21-item self-administered questionnaire "Barriers to Being Active Quiz" will qualitatively assess
14 15	498	barriers to regular practice of physical activity. ⁷⁰
16 17	499	Uses, representations and motivation towards physical activity will be assessed within the study
18 19 20	500	population using a self-administered questionnaire available online. Acceptability of connected
21 22	501	devices and acceptability of therapeutic patient education will be assessed among participants
23 24	502	randomised to the corresponding arms using a paper-based self-administered questionnaire. These
25 26	503	questionnaires will be built in accordance with the Unified Theory of Acceptance and Use of
27 28 29	504	Technology (UTAUT), ⁷¹ which is a specification of the Theory of Planned Behaviour ⁷² designed to
30 31	505	explain and predict the probability of behaviour change among individuals faced with new
32 33	506	technologies. The Theory of Planned Behaviour has been massively used during the last two decades
34 35	507	to promote health behaviours such as physical activity. Besides, items wording will be based on the
36 37 28	508	results of individual and collective interviews conducted for that purpose and designed to identify
38 39 40	509	social representations ⁷³ of health protection and physical activity incentive devices.
41 42	510	
43 44	511	Biological assessments
45 46	512	A non-fasting blood sample (one 10-ml EDTA tube and one 10-ml dry tube) will be collected at baseline
47 48 49	513	and 6 months. In particular, blood will be drawn at baseline before the onset of adjuvant treatments,
50 51	514	otherwise the two blood samples will not be collected. The following biological factors will be assessed
52 53	515	in the blood samples: circulating serum levels of endocrine factors (IGF-1, insulin, estradiol), circulating
54 55	516	plasma levels of inflammatory cytokines (IL-6, TNF $lpha$, CRP) and circulating plasma levels of adipokines
56 57	517	(adiponectin, leptin).
58 59 60	518	

519 STATISTICAL ANALYSIS

520 Sample size determination

The efficacy rate assumptions are μ =40 %, μ + μ A=55 % and μ + μ B=65 % for the "control", "therapeutic patient education" and "connected device" arm modalities, respectively. The expected benefit in the "therapeutic patient education" arm compared to the "control" arm is 15% (40% efficacy in the "control" arm versus 55% efficacy in the "therapeutic patient education" arm). The expected benefit in the "connected device" arm compared to the "control" arm is 25% (40% efficacy in the "control" arm versus 65% efficacy in the "connected device" arm).²²

The sample size is calculated to allow the two comparisons of interest to be tested bilaterally at the 0.025 threshold. Assuming that the "therapeutic patient education" intervention and the "connected device" intervention act independently (additive model), the sample size required to compare therapeutic patient education (i.e., participants assigned to the "therapeutic patient education" and "combined" arms) versus no therapeutic patient education (i.e., participants assigned to the "control" and "connected device" arms) is given by the following formula:

 $\frac{1}{5}$ 533 [μ + (μ + μ B)] / 2, versus [(μ + μ A) + (μ + μ A + μ B)/2]

534 that is, (40 % + 65 %) / 2 = 52,5 %, versus (55 % + 80 %) / 2 = 67,5 %

With a first species risk α =0.025 and a power of 80% in bilateral situation, the number of patients to include per treatment arm to demonstrate the efficacy of the therapeutic patient education will be 108 (or 432 for the four treatment arms) (nQuery V6.0, Chi-two test with continuity correction). This number of patients will also allow a power greater than 95% to evaluate the effectiveness of the S39 "connected device" intervention, always with a risk α =0.025 in bilateral situation.

⁰ 540

Data analysis plan

The following populations will be defined for statistical analyses: i) the intent-to-treat (ITT) population,
 which includes all randomised participants in the study; ii) the per-protocol population, which consists
 of a subgroup of participants from the ITT population who had no major protocol violations and who

BMJ Open

followed the procedure for the duration of the study. Analyses in the ITT population will be performed for all the study endpoints; analysis in the per-protocol population will be performed for exploratory purposes. The randomisation date will be considered as the reference date in all delay calculations, unless otherwise specified. Baseline data will be described in the ITT population and presented by randomisation arm. For the

primary outcome, proportions will be estimated for the two targeted comparisons: (i) participants who received the connective device vs. participants who did not; (ii) participants who benefited from the therapeutic patient education intervention vs. participants who did not. Results will be presented with their 95% confidence interval. The use of a 2x2 factorial design will allow to test, respectively: the efficacy of the intervention with a connected device (compared to the absence of a connected device); the efficacy of the therapeutic patient education intervention (compared to no therapeutic patient education); and the interest of combining the two intervention modalities (i.e., connected device and therapeutic patient education) compared to the intervention with the connected device only or the intervention with therapeutic patient education only. The analysis strategy will therefore be as follows:⁷⁴ 1) searching first for an interaction by a specific interaction test, performed at the significance level of 0.05 (Chi-square test or use of an interaction term in a logistic model); 2) in the absence of interaction, testing each of the two bilateral interest comparisons at the 0.025 threshold, namely the efficacy of the intervention with connected device and the efficacy of the therapeutic patient education intervention; 3) in case of efficacy of either one of the intervention modalities, evaluating the interest of the combination of the two interventions compared to the intervention with connected device only or the intervention with therapeutic patient education only.

For secondary outcome variables, the efficacy of the program at 12 months, as well as according to stratification criteria, will be analysed similarly to the primary outcome. The adherence to the interventions will be studied by the proportion of compliant participants and participation rate in planned sessions. Changes in physical activity profile, physical fitness, anthropometrics, quality of life, fatigue, social deprivation and biological parameters will be analysed by the absolute and/or relative

variations of each of these endpoints; these variations will be compared between an intervention and the absence of this intervention, for each intervention, and between their combination and either intervention, using a parametric test. Occupational status and lifestyle factors will be analysed by comparing proportion of participants between interventions or their combination. Representations and acceptability of activity tracker and of therapeutic patient education will be analysed by comparing proportion of participants between randomisation and follow-up assessments. A method for imputing missing data will be considered if necessary.

578 Statistical analyses will be performed using SAS[®] software version 9.4 or later.

580 Medico-economic analysis

The cost-effectiveness analysis will be conducted alongside the trial using the French national health insurance perspective. The time horizon will be 12 months. Hence, neither costs nor effectiveness will be discounted. Mean costs and effectiveness will be derived for all four strategies under consideration: connected device, therapeutic patient education, combined and control arms. Incremental Cost-Effectiveness Ratios (ICERs) will be expressed in cost per quality-adjusted life year (QALY) gained using EQ-5D-5L to estimate utility, cost per life year gained, cost per BMI unit lost and cost per centimetre of waist-to-hip circumference lost. One-way sensitivity analyses will be conducted by varying resource consumption and unit cost parameters and graphically illustrated in a Tornado diagram. The uncertainty surrounding the ICERs will be also captured by a probabilistic analysis using non-parametric bootstrap methods as recommended by the French National Authority for Health.⁷⁵

591 ر

592 ADVERSE EVENTS

All participants will continuously report the occurrence of adverse events regarding neuropathies and
 joint pain in their patient's notebook, which will be collected at 6 and 12 months. Those equipped with
 the connected device will also report potential adverse events before and after each session of their

1 2		
3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	596	exercise program (see <i>Connected device</i>). Due to the low risks associated with the interventions, ¹⁵ data
	597	monitoring will not be conducted for other adverse events.
	598	
	599	DATA MANAGEMENT
	600	The database for clinical data and randomisation will be created using EnnovClinical® software. Its
	601	access will be secured (personal identification and password protection) for maintaining confidentiality
	602	at all times. Individual participants will not be identified in any reports of this trial. All data from the
18 19 20	603	connected device will be merge to the clinical database at the end of the study. Investigators and data
20 21 22	604	analysts will have access to the final dataset.
23 24	605	Data monitoring will be provided by the trial steering committee, including overall project supervision,
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42	606	progress monitoring, advice on scientific credibility, and ensuring the integrity and appropriate running
	607	of the project. The clinical research assistant will verify all consent forms, compliance with established
	608	protocol and procedures, and data quality in the eCRF. The research team will make biannual reports
	609	to the trial steering committee.
	610	
	611	PATIENT AND PUBLIC INVOLVEMENT
	612	An association of breast cancer patients' representatives (Europa Donna France,
	613	http://www.europadonna.fr/) was involved in preparing the conduct of interventions and evaluations,
43 44	614	in particular by considering patients' expectations, experience and desire for global care. The
45 46	615	association will be involved in plans to disseminate the study results to breast cancer patients, study
47 48 49 50 51	616	participants and wider patient communities concerned.
	617	
52 53	618	ETHICS AND DISSEMINATION
54 55 56 57 58 59 60	619	The study protocol was approved by the French ethics committee (Comité de Protection des Personnes
	620	Est I, ID RCB 2017-A03360-53, 1 st February 2018) and its database was reported to the French National
	621	Commission for Data Protection and Liberties (CNIL, ref. MR-001 no. 2016177, 13 th December 2016).

Substantial protocol modifications will be submitted to the ethics committee for approval and protocol
amendment. The trial is prospectively registered on http://www.ClinicalTrials.gov (NCT number:
NCT03529383, 17th May 2018).

The study findings will be widely disseminated through the clinical community by publications in international, peer-reviewed journals and by presentations at national and international conferences. They will also be communicated to patients through associations of patients' representatives and science-based information websites. They will be useful for improving clinical care of cancer patients and provide health professionals, institutions and public authorities with useful information for implementing exercise programs for cancer patients. The study sponsors will disseminate the study findings to their stakeholders.

633 DISCUSSION

This article presents the protocol for the DISCO trial, which aims to evaluate the efficacy of a web-based connected device intervention and of a therapeutic patient education intervention, either alone or combined, on the physical activity levels of breast cancer patients undergoing adjuvant treatment, as well as to assess the cost-effectiveness of the interventions. In the short term, the expected results are to develop autonomy of breast cancer patients in their practice of physical activity, as well as to identify the best strategies of physical activity during breast cancer adjuvant treatments to increase and sustain physical activity levels in patients, overall or in specific subgroups according to BMI, baseline physical activity level and type of adjuvant treatment. In the medium term, the goal of the DISCO trial is to disseminate innovative programs in supportive cancer care, based on evidence-based practice, to systematically integrate exercise in breast cancer cares.

644 While an increasing number of studies have demonstrated the benefits of exercise in breast cancer 645 patients, the routine implementation in the cancer care process lacks behind evidence and practice 646 guidelines.^{76–78} While the prescription of physical activity in supervised programs have been shown 647 superior compared to non-supervised programs,^{21,79} semi-supervised interventions seem to yield Page 29 of 48

1 2

BMJ Open

3
4
5
6
7
8
9
10
11
12
13
14
15
15
16 17
17
18
19 20
20
21
21 22 23
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
41
42 43
45 44
44 45
46 47
48
49
50
51
52
53
54
55
56
57
58
59
60

648 comparable or superior benefits than supervised programs.⁸⁰ Therefore, the semi-supervised exercise 649 program of the DISCO trial through continuous follow-up has been designed according to the 650 preferences of women with breast cancer so as not to leave patients in total autonomy.^{35,81} Connected 651 devices are tools developed over the last 10 years that are very promising for promoting physical 652 activity in the general population and in chronic diseases such as cancer^{82,83} and for developing 653 distance-based physical activity interventions.⁸⁴

654 The semi-supervised home-based physical activity program of the DISCO trial using the connected 655 device provides flexibility to patients that may facilitate adherence, as well as to overcome barriers 656 due to distance of facilities from women's home and spatial inequalities of access.²⁶ Connected devices 657 allow proposing a tailored physical activity program to patients regardless of their place of residence, 658 and enable patients to practice physical activities of their choice, at a time that suits them. Therefore, 659 they may reduce geographical and organisational barriers in the access of patients to exercise, a key 660 issue to improve their engagement in regular and sustained physical activity.²⁶ To overcome 661 motivational barriers to physical activity in oncology, the use of mobile devices has reported benefits 662 such as patient's engagement, as they can help patients staying physically active over the medium and long term.^{85,86} Moreover, while some studies have shown that breast cancer patients achieve higher 663 664 fitness levels during supervised training compared to unsupervised training, low and medium levels of 665 supervision have been shown to be effective and may represent less resource-intensive options for 666 effective and longer term behaviour change strategies based on exercise in cancer patients and survivors.80,87 667

Activity trackers have become increasingly popular in recent years. They have been reported to be pleasant to wear, with positive patients' experience, easy to use and to have a strongly motivational role through real-time display of the number of steps.⁸⁸ Also, walking is an inexpensive activity that can be performed anywhere and does not require specific skills. A study that assessed preferences for technology-supported interventions in breast cancer survivors has reported that 63% would like to use

a physical activity mobile application and 90% would find a physical activity tracker useful to monitor
and increase physical activity.³⁴

Despite the potential benefits of connected devices in cancer care, their use may face important issues. First, their use raises important ethical challenges, related to the sensitivity of data and the security of data storage.⁸⁹ To ensure that data transfer and storage guarantee informational privacy and patient safety,⁹⁰ an activity tracker made in France (i.e., allowing storing health data in France) and an accredited national health data host were chosen for the DISCO trial. Particularly, insuring medical data security is a reassuring choice for patients to participate in this new kind of medical research. Second, connected devices may raise technical challenges, related to technological robustness, reliability of data collection and processing, and ease of use. Therefore, an activity tracker with step display on the screen, user-friendly interface, good reliability and good price-performance ratio was chosen in the DISCO trial. Third, connected devices may create or exacerbate access disparities related to technological literacy and economic means, as well as reliable access to internet in rural or isolated areas.⁸⁹ Fourth, medical reasons are usually not easy to control in patients' adherence to exercise programs. Reliance upon self-assessment of the participant's fatigue, evaluation of the participant before and after each session on the remote monitoring, up as the source of information about the participant's health, can result in the ignorance of aspects of the participant's health that cannot easily be monitored.89

Therapeutic patient education has been suggested to increase physical activity in patients with chronic diseases⁴⁵ and to improve multiple health outcomes, including behavioural interventions combined with physical activity.⁹¹ Therapeutic patient education interventions might be promising for promoting a physically active lifestyle in cancer patients as it helps patients establish changes in lifestyle and reinforce self-management.⁹¹ Therapeutic patient education differs from patient education in its intrinsic structure. Patient education is directed towards informing and teaching patients how to manage their condition or disease. In contrast, by its structure, therapeutic patient education differs from patient education in the self-management conferred on the patient.³⁹ Therefore, therapeutic

Page 31 of 48

BMJ Open

patient education is more broadly directed towards how the patient accepts his/her condition and manages his/her problems on a daily basis and the impact of the disease on personal, family, professional and social life. Yet, in oncology, few therapeutic patient education studies targeting pain, fatigue, toxicities or treatment adherence are ongoing, and evaluations are rarely published.⁴⁰ To our knowledge, only one program of therapeutic patient education specific to physical activity have been evaluated in cancer patients.⁴⁴ However, a recent qualitative study has shown the value of promoting therapeutic patient education to better understand the attitudes towards physical activity of women with breast cancer to promote regular exercise, which is a guarantee of a better quality of life.⁹² As the DISCO trial was designed to evaluate the efficacy of two interventions, the primary outcome was based on the physical activity level of the participants comparatively to international recommendations. The primary outcome measure was chosen according to the RPAQ questionnaire for its easy implementation. The authors acknowledge that this declarative evaluation confers methodological limits to the study. But the RPAQ questionnaire has been validated against objective methods (i.e., combined accelerometry and heart rate monitoring)⁶⁵ to evaluate moderate-to-vigorous physical activities, which is relevant for the primary outcome. No objective measures of physical activity were planned because of organisational and logistic difficulties to equip and follow participants for one week (i.e., the usual duration of monitoring with an accelerometer such as Actigraph[™]).⁹³ Such a test would even be particularly overwhelming for cancer patients during the demanding period of adjuvant treatment onset. Additionally, the number of daily steps reported by the activity tracker was not chosen as primary outcome because the activity tracker used in the study was not validated for monitoring physical activity in research or for medical purposes when the study was designed, although its reliability was checked against other devices (data not shown). However, the performance and reliability of smart devices tends to be increasingly validated.⁹⁴ To understand results of the DISCO clinical study, it is essential to study beliefs about connected

over time. In therapeutic education, beliefs and representations are essential to the success of the

devices and their appropriation by the patients, in order to understand why behaviours tend to fade

2		
3 4	725	intervention. Moreover, with connected devices, only technical dimensions are not sufficient to
5 6	726	understand and highlight why individuals adopt or misuses connected devices. ^{71,72}
7 8	727	There is still limited evidence or contrasting conclusions surrounding the cost-effectiveness of
9 10 11	728	interventions promoting physical activity among women with breast cancer from studies conducted in
12 13	729	France, the Netherland and Australia. ^{95–100} In various chronic conditions other than cancer, there is
14 15	730	now clear evidence in favour of exercise-based programs for the treatment of various chronic
16 17	731	conditions such as musculoskeletal, rheumatologic disorders, and cardiovascular diseases. ¹⁰¹ As more
18 19 20	732	research is needed to evaluate the cost-effectiveness of physical activity in the treatment of cancers,
21 22	733	particularly breast cancer, the economic evaluation planned in the DISCO trial will add useful
23 24	734	information.
25 26	735	In conclusion, the study findings will provide valuable information on the efficacy of exercise
27 28	736	interventions during breast cancer treatments, overcoming current barriers of access to facilities. They
29 30 31	737	will further guide the development of evidence-based innovative interventions, to systematically
32 33	738	include physical activity in the breast cancer care process. Finally, the economic evaluation planned in
34 35	739	the DISCO trial will provide useful information for decision makers.
36 37	740	
38 39 40	741	Supplementary file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol.
40 41 42	742	
43 44	743	Abbreviations
45 46	744	BMI: body mass index;
47 48 49	745	eCRF: electronic case report form;
50 51	746	EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality-Of-Life
52 53	747	Questionnaire;
54 55	748	EPICES: Evaluation of Deprivation and Inequalities in Health Examination Centres (questionnaire);
56 57 58	749	ITT: intent-to-treat;
59 60	750	MET: metabolic equivalent of task;

2		
3 4	751	PFS-12: Piper Fatigue Scale-12;
5 6	752	RPAQ: Recent Physical Activity Questionnaire;
7 8	753	WHO: World Health Organization;
9 10 11	754	6MWT: six-minute walk test.
12 13	755	
14 15	756	Acknowledgments
16 17	757	The authors are thanksful to Romain Buono, Meyssane Djebali, Carmen Dupuis, Stephany Fiore, Emilie
18 19	758	Rémir, Cécile Dalban, Antonin Poullet, Renaud Meyrand, Rodolf Mongondry, Magali Dubois, Solène
20 21 22	759	Poirey, Valentine Bertollin, Amélie Dupré, Apolline Michel, Axel Lion, Magalie Hureau and Morgane
23 24	760	Sejallon for their contribution to the conduct of the DISCO trial at the Léon Bérard cancer centre. The
25 26	761	authors are also grateful to Mrs Françoise Picard from Europa Donna France, association of breast
27 28	762	cancer patients' representatives, for her active participation, advice and support in the DISCO trial.
29 30 31	763	
51		
32	764	Authors' contributions
	764 765	Authors' contributions BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the
32 33 34 35 36 37		
32 33 34 35 36 37 38 39	765	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the
32 33 34 35 36 37 38 39 40 41	765 766	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological
32 33 34 35 36 37 38 39 40 41 42 43	765 766 767	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise
32 33 34 35 36 37 38 39 40 41 42	765 766 767 768	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	765 766 767 768 769	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50	765 766 767 768 769 770	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational status. All authors were involved in in planning the methods and measurement and a priori analysis
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52	765 766 767 768 769 770 771	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational status. All authors were involved in in planning the methods and measurement and a priori analysis planning. MT and BFo wrote initial draft of the manuscript. All authors reviewed and provided
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	765 766 767 768 769 770 771 771	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational status. All authors were involved in in planning the methods and measurement and a priori analysis planning. MT and BFo wrote initial draft of the manuscript. All authors reviewed and provided
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	765 766 767 768 769 770 771 772 773	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational status. All authors were involved in in planning the methods and measurement and a priori analysis planning. MT and BFo wrote initial draft of the manuscript. All authors reviewed and provided comprehensive contribution to the manuscript, and approved the final manuscript.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56	765 766 767 768 769 770 771 772 773 774	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational status. All authors were involved in in planning the methods and measurement and a priori analysis planning. MT and BFo wrote initial draft of the manuscript. All authors reviewed and provided comprehensive contribution to the manuscript, and approved the final manuscript.

2		
3 4	777	Foundation for Medical Research ("Fondation pour la Recherche Médicale", grant no.
5 6	778	DOC20161136212), "Métropole de Lyon / Cancéropôle Lyon Auvergne Rhône-Alpes" (CLARA) (grant
7 8	779	no. 2016 Projet Structurant) and AG2R La Mondiale.
9 10 11	780	
12 13	781	Competing interests
14 15	782	None declared.
16 17	783	
18 19 20	784	Ethics approval
20 21 22	785	Ethics approval was provided by the French Ethics Committee (Comité de Protection des Personnes
23 24	786	Est I).
25 26 27	787	
27 28 29	788	References
30	789	1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:
31	790	GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
32 33	791	CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
34	792	2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. Estimations nationales de l'incidence et de la
35	793	mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres
36		
37	794	des cancers du réseau Francim. Synthèse. Santé publique France; 2019:20. https://www.e-
38	795	cancer.fr/content/download/266450/3759432/file/Synthese_Estimations%20nationales%20in
39	796	cidence%20et%20mortalite%20par%20cancer_juillet_2019.pdf
40		
41	797	3. Cowppli-Bony A, Uhry Z, Remontet L, et al. Survival of solid cancer patients in France, 1989-
42	798	2013: a population-based study. Eur J Cancer Prev. 2017;26(6):461-468.
43	799	doi:10.1097/CEJ.000000000000372
44		
45	800	4. Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-
46	801	14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of
47	802	18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> .
48	803	2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
49	005	2010,331(10123).1023 1073. 00.1010/30140 0730(17)33320 3
50	804	5. Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis
51		
52 53 54	805 806	for European women with breast cancer in 2000-2002. <i>Int J Cancer</i> . 2013;132(10):2404-2412. doi:10.1002/ijc.27895
55	807	6. Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer
56 57 58 59	808	survivors. <i>Cancer</i> . 2012;118(8 Suppl):2261-2269. doi:10.1002/cncr.27475
60		

2			
3	809	7.	Makari-Judson G, Braun B, Jerry DJ, Mertens WC. Weight gain following breast cancer
4	810		diagnosis: Implication and proposed mechanisms. World J Clin Oncol. 2014;5(3):272-282.
5 6	811		doi:10.5306/wjco.v5.i3.272
7	042	0	
8	812	8.	Galizia D, Milani A, Geuna E, et al. Self-evaluation of duration of adjuvant chemotherapy side
9	813 814		effects in breast cancer patients: A prospective study. <i>Cancer Med</i> . 2018;7(9):4339-4344. doi:10.1002/cam4.1687
10 11	014		d01.10.1002/ca114.108/
12	815	9.	Foucaut A-M, Berthouze SE, Touillaud M, et al. Deterioration of Physical Activity Level and
13	816		Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. <i>Cancer Nurs</i> . 2015;38(4):E1-
14	817		9. doi:10.1097/NCC.00000000000187
15			
16 17	818	10.	Møller T, Andersen C, Lillelund C, et al. Physical deterioration and adaptive recovery in
18	819		physically inactive breast cancer patients during adjuvant chemotherapy: a randomised
19	820		controlled trial. <i>Sci Rep</i> . 2020;10(1):9710. doi:10.1038/s41598-020-66513-9
20	821	11.	Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast
21	822	11.	cancer-systematic literature review and meta-analysis of 82 follow-up studies. Ann Oncol.
22 23	823		2014;25(10):1901-1914. doi:10.1093/annonc/mdu042
24	010		
25	824	12.	Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast
26	825		Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. J Natl Cancer
27 28	826		Inst. 2015;107(12):djv275. doi:10.1093/jnci/djv275
28	027	10	MaTiaman A. Friedenssieh CNA Katanaamuk DT, at al. Dhusiaal Activity in Canaan Drayantian
30	827 828	13.	McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. <i>Med Sci Sports Exerc</i> . 2019;51(6):1252-1261.
31	828 829		doi:10.1249/MSS.00000000001937
32	025		doi.10.1243/W35.0000000001337
33 34	830	14.	WCRF/AICR. Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. The Third
35	831		Expert Report. World Cancer Research Fund International/American Institute for Cancer
36	832		Research; 2018. https://www.wcrf.org/dietandcancer
37			
38 39	833	15.	Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in
40	834 835		patients with advanced cancer: a systematic review. <i>Support Care Cancer</i> . 2017;25(10):3031-3050. doi:10.1007/s00520-017-3827-0
41	835		3050. d01:10.1007/\$00520-017-3827-0
42	836	16.	Juvet LK, Thune I, Elvsaas IK ϕ , et al. The effect of exercise on fatigue and physical functioning
43	837		in breast cancer patients during and after treatment and at 6 months follow-up: A meta-
44 45	838		analysis. Breast. 2017;33:166-177. doi:10.1016/j.breast.2017.04.003
46			
47	839	17.	Lipsett A, Barrett S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant
48	840		radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-
49 50	841		analysis. <i>Breast</i> . 2017;32:144-155. doi:10.1016/j.breast.2017.02.002
51	842	18.	Coughlin SS, Caplan LS, Williams V. Home-based physical activity interventions for breast
52	843	20.	cancer patients receiving primary therapy: a systematic review. Breast Cancer Res Treat.
53	844		2019;178(3):513-522. doi:10.1007/s10549-019-05424-4
54 55			
55 56	845	19.	Kang D-W, Lee E-Y, An KY, Min J, Jeon JY, Courneya KS. Associations between physical activity
57	846		and comorbidities in Korean cancer survivors. <i>J Cancer Surviv</i> . 2018;12(4):441-449.
58	847		doi:10.1007/s11764-018-0683-y
59 60			
00			

2			
3 4 5 6	848 849 850	20.	Zeng Y, Huang M, Cheng ASK, Zhou Y, So WKW. Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors. <i>Breast Cancer</i> . 2014;21(3):262-274. doi:10.1007/s12282-014-0521-7
7 8 9 10	851 852 853	21.	Buffart LM, Kalter J, Sweegers MG, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treat Rev.</i> 2017;52:91-104. doi:10.1016/j.ctrv.2016.11.010
11 12 13 14 15	854 855 856	22.	Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. <i>Acta Oncol</i> . 2015;54(5):635-654. doi:10.3109/0284186X.2014.998275
16 17 18 19	857 858 859	23.	Friedenreich CM, Stone CR, Cheung WY, Hayes SC. Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis. <i>JNCI Cancer Spectr</i> . 2020;4(1):pkz080. doi:10.1093/jncics/pkz080
20 21 22 23 24	860 861 862	24.	Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical Activity and Cancer Outcomes: A Precision Medicine Approach. <i>Clinical Cancer Research</i> . 2016;22(19):4766-4775. doi:10.1158/1078-0432.CCR-16-0067
25 26 27 28	863 864 865	25.	Demark-Wahnefried W, Schmitz KH, Alfano CM, et al. Weight management and physical activity throughout the cancer care continuum. <i>CA Cancer J Clin</i> . 2018;68(1):64-89. doi:10.3322/caac.21441
29 30 31 32 33 34	866 867 868 869	26.	Foucaut A-M, Morelle M, Kempf-Lépine A-S, et al. Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Support Care Cancer</i> . 2019;27(9):3449-3461. doi:10.1007/s00520-019-4658-y
35 36 37 38	870 871 872	27.	Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. <i>Cochrane Database Syst Rev.</i> 2018;9:CD010192. doi:10.1002/14651858.CD010192.pub3
39 40 41 42	873 874 875	28.	Lunde P, Nilsson BB, Bergland A, Kværner KJ, Bye A. The Effectiveness of Smartphone Apps for Lifestyle Improvement in Noncommunicable Diseases: Systematic Review and Meta-Analyses. J Med Internet Res. 2018;20(5):e162. doi:10.2196/jmir.9751
43 44 45 46 47	876 877 878	29.	Schaffer K, Panneerselvam N, Loh KP, et al. Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. <i>J Natl</i> <i>Compr Canc Netw</i> . 2019;17(1):57-63. doi:10.6004/jnccn.2018.7082
48 49 50 51	879 880 881	30.	Coughlin SS, Caplan LS, Stone R. Use of consumer wearable devices to promote physical activity among breast, prostate, and colorectal cancer survivors: a review of health intervention studies. <i>J Cancer Surviv</i> . 2020;14(3):386-392. doi:10.1007/s11764-020-00855-1
52 53 54 55	882 883 884	31.	Dorri S, Asadi F, Olfatbakhsh A, Kazemi A. A Systematic Review of Electronic Health (eHealth) interventions to improve physical activity in patients with breast cancer. <i>Breast Cancer</i> . 2020;27(1):25-46. doi:10.1007/s12282-019-00982-3
56 57 58 59 60	885 886	32.	Beg MS, Gupta A, Stewart T, Rethorst CD. Promise of Wearable Physical Activity Monitors in Oncology Practice. <i>J Oncol Pract</i> . 2017;13(2):82-89. doi:10.1200/JOP.2016.016857

1 2			
3 4 5	887 888	33.	Schinköthe T. Individualized eHealth Support for Oncological Therapy Management. <i>Breast Care</i> . 2019;14(3):130-134. doi:10.1159/000500900
6 7 8 9	889 890 891	34.	Phillips SM, Conroy DE, Keadle SK, et al. Breast cancer survivors' preferences for technology- supported exercise interventions. <i>Support Care Cancer</i> . 2017;25(10):3243-3252. doi:10.1007/s00520-017-3735-3
10 11 12 13 14	892 3! 893 894	35.	Phillips SM, Courneya KS, Welch WA, et al. Breast cancer survivors' preferences for mHealth physical activity interventions: findings from a mixed methods study. <i>J Cancer Surviv</i> . 2019;13(2):292-305. doi:10.1007/s11764-019-00751-3
15 16 17 18	895 896 897	36.	Nielsen AM, Welch WA, Gavin KL, et al. Preferences for mHealth physical activity interventions during chemotherapy for breast cancer: a qualitative evaluation. <i>Support Care Cancer</i> . 2020;28(4):1919-1928. doi:10.1007/s00520-019-05002-w
19 20 21	898 899	37.	Lacroix A, Assal J-P. L'éducation thérapeutique des patients: accompagner les patients avec une maladie chronique : nouvelles approches. 3rd ed.; 2011.
22 23 24	900 901	38.	Fabre S. Evaluating therapeutic patient education: Objectives and criteria. <i>Joint Bone Spine</i> . 2017;84(2):121-123. doi:10.1016/j.jbspin.2016.11.002
25 26 27 28 29 30	902 903 904 905	39.	World Health Organization. <i>Therapeutic Patient Education: Continuing Education Programmes for Health Care Providers in the Field of Prevention of Chronic Diseases. Report of a WHO Working Group</i> . World Health Organization, Regional Office for Europe; 1998:76. https://apps.who.int/iris/handle/10665/108151
31 32 33 34	906 907 908	40.	Buiret G, Chidiac F, Pujo K, Combe C. [How to reconcile therapeutic patient education and care pathology in oncology: Application in head and neck neoplams]. <i>Bull Cancer</i> . 2019;106(5):468-478. doi:10.1016/j.bulcan.2019.02.008
35 36 37 38 39	909 910 911	41.	Bourmaud A, Anota A, Moncharmont C, et al. Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study. <i>Br J Cancer</i> . 2017;116(7):849-858. doi:10.1038/bjc.2017.31
40 41 42	912 913	42.	Pérol D, Toutenu P, Lefranc A, et al. [Therapeutic education in oncology: involving patient in the management of cancer]. <i>Bull Cancer</i> . 2007;94(3):267-274.
43 44 45 46 47	914 915 916 917	43.	Arthurs G, Simpson J, Brown A, Kyaw O, Shyrier S, Concert CM. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review. <i>JBI Database System Rev Implement Rep</i> . 2015;13(5):244-292. doi:10.11124/jbisrir-2015-2057
48 49 50 51 52 53	918 919 920 921	44.	Carayol M, Delpierre C, Bernard P, Ninot G. Population-, intervention- and methodology- related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for breast cancer: a meta-regression analysis. <i>Psychooncology</i> . 2015;24(7):737-747. doi:10.1002/pon.3727
54 55 56 57	922 923 924	45.	Conn VS, Hafdahl AR, Brown SA, Brown LM. Meta-analysis of patient education interventions to increase physical activity among chronically ill adults. <i>Patient Educ Couns</i> . 2008;70(2):157-172. doi:10.1016/j.pec.2007.10.004
58 59 60	925 926	46.	Meneses-Echávez JF, Correa-Bautista JE, González-Jiménez E, et al. The Effect of Exercise Training on Mediators of Inflammation in Breast Cancer Survivors: A Systematic Review with

1 2			
2	927		Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1009-1017. doi:10.1158/1055-
4	928		9965.EPI-15-1061
5			
6 7	929	47.	Kang D-W, Lee J, Suh S-H, Ligibel J, Courneya KS, Jeon JY. Effects of Exercise on Insulin, IGF
8	930		Axis, Adipocytokines, and Inflammatory Markers in Breast Cancer Survivors: A Systematic
9	931		Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2017;26(3):355-365.
10	932		doi:10.1158/1055-9965.EPI-16-0602
11			
12	933	48.	Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM.
13 14	934		Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J
15	935		Natl Cancer Inst. 2012;104(11):815-840. doi:10.1093/jnci/djs207
16	936	49.	World Health Organization. Global Recommendations on Physical Activity for Health. World
17	937	131	Health Organization; 2011:60.
18	938		http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf
19 20			
21	939	50.	Haute Autorité de Santé. Recommandations professionnelles - Stratégie de prise en charge en
22	940		cas de dénutrition protéino-énergétique chez la personne âgée [Professional recommendations
23	941		- Management strategy in case of protein-energy malnutrition in the Elderly]. Haute Autorité
24 25	942		de Santé; 2007:25. https://www.has-
25 26	943		sante.fr/upload/docs/application/pdf/denutrition_personne_agee_2007
27	944		_recommandations.pdf
28	945	51.	Besson H, Brage S, Jakes RW, Ekelund U, Wareham NJ. Estimating physical activity energy
29	946	51.	expenditure, sedentary time, and physical activity intensity by self-report in adults. Am J Clin
30 31	947		Nutr. 2010;91(1):106-114. doi:10.3945/ajcn.2009.28432
32			
33	948	52.	Pocock SJ, Simon R. Sequential Treatment Assignment with Balancing for Prognostic Factors in
34	949		the Controlled Clinical Trial. <i>Biometrics</i> . 1975;31(1):103-115. doi:10.2307/2529712
35	950	53.	Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for
36 37	950 951	55.	allocation to clinical trials. a review. <i>Control Clin Trials</i> . 2002;23(6):662-674.
38	952		doi:10.1016/s0197-2456(02)00242-8
39	552		
40	953	54.	Neil-Sztramko SE, Kirkham AA, Hung SH, Niksirat N, Nishikawa K, Campbell KL. Aerobic
41	954		capacity and upper limb strength are reduced in women diagnosed with breast cancer: a
42 43	955		systematic review. <i>J Physiother</i> . 2014;60(4):189-200. doi:10.1016/j.jphys.2014.09.005
44			
45	956	55.	Rikli RE, Jones CJ. Functional Fitness Normative Scores for Community-Residing Older Adults,
46	957 059		Ages 60-94. <i>Journal of Aging and Physical Activity</i> . 1999;7(2):162-181. doi:10.1123/japa.7.2.162
47 48	958		uu.10.1125/Japa.7.2.102
40 49	959	56.	Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a
50	960		second update of codes and MET values. <i>Med Sci Sports Exerc</i> . 2011;43(8):1575-1581.
51	961		doi:10.1249/MSS.0b013e31821ece12
52			
53 54	962	57.	Campbell KL, Neil SE, Winters-Stone KM. Review of exercise studies in breast cancer survivors:
55	963		attention to principles of exercise training. Br J Sports Med. 2012;46(13):909-916.
56	964		doi:10.1136/bjsports-2010-082719
57	965	58.	Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription
58 59	965 966	50.	in exercise-oncology research. J Cachexia Sarcopenia Muscle. 2015;6(2):115-124.
60	967		doi:10.1002/jcsm.12042
-			

1								
2 3 4 5 6	968 969 970	59.	Fassier J-B, Durand M-J, Caillard J-F, Roquelaure Y, Loisel P. Results of a feasibility study: barriers and facilitators in implementing the Sherbrooke model in France. <i>Scand J Work Environ Health</i> . 2015;41(3):223-233. doi:10.5271/sjweh.3489					
7 8 9	971 972	60.	Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. <i>Int J Sports Med</i> . 2013;34(7):631-636. doi:10.1055/s-0032-1323746					
10 11 12 13 14	973 974 975)74	Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. <i>Res Q Exerc Sport</i> . 1999;70(2):113-119. doi:10.1080/02701367.1999.10608028					
15 16 17 18 19	976 977 978 979	62.	Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodríguez L, Fernández-de-Las-Peñas C, Ruiz JR, Arroyo-Morales M. The handgrip strength test as a measure of function in breast cancer survivors: relationship to cancer-related symptoms and physical and physiologic parameters. <i>Am J Phys Med Rehabil</i> . 2012;91(9):774-782. doi:10.1097/PHM.0b013e31825f1538					
20 21 22 23 24	980 981 982	63.	Wells KF, Dillon EK. The Sit and Reach—A Test of Back and Leg Flexibility. <i>Research Quarterly American Association for Health, Physical Education and Recreation</i> . 1952;23(1):115-118. doi:10.1080/10671188.1952.10761965					
24 25 26 27 28	983 984 985	64.	Bohannon RW. Single Limb Stance Times: A Descriptive Meta-Analysis of Data From Individuals at Least 60 Years of Age. <i>Topics in Geriatric Rehabilitation</i> . 2006;22(1):70-77. doi:10.1097/00013614-200601000-00010					
29 30 31 32	986 987 988	65.	Golubic R, May AM, Benjaminsen Borch K, et al. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. <i>PLoS ONE</i> . 2014;9(3):e92829. doi:10.1371/journal.pone.0092829					
33 34 35 36 37	989 990 991	66.	Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. <i>J Clin Oncol</i> . 1995;13(5):1249-1254. doi:10.1200/JCO.1995.13.5.1249					
37 38 39 40 41	992 993 994	67.	Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Qual Life Res</i> . 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4					
42 43 44 45	995 996 997	68.	Reeve BB, Stover AM, Alfano CM, et al. The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2012;136(1):9-20. doi:10.1007/s10549-012-2212-4					
46 47 48	998 999	69.	Labbe E, Blanquet M, Gerbaud L, et al. A new reliable index to measure individual deprivation: the EPICES score. <i>Eur J Public Health</i> . 2015;25(4):604-609. doi:10.1093/eurpub/cku231					
49 50 51 52 53	1000 1001 1002	70.	Centers for Disease Control and Prevention. Overcoming Barriers to Physical Activity: Barriers to Being Active Quiz-What keeps you from being more active? Published online 2007. https://www.cdc.gov/diabetes/ndep/pdfs/8-road-to-health-barriers-quiz-508.pdf					
54 55 56	1003 1004	71.	Venkatesh, Morris, Davis, Davis. User Acceptance of Information Technology: Toward a Unified View. <i>MIS Quarterly</i> . 2003;27(3):425. doi:10.2307/30036540					
57 58 59 60	1005 1006	72.	Ajzen I. The theory of planned behavior. <i>Organizational Behavior and Human Decision Processes</i> . 1991;50(2):179-211. doi:10.1016/0749-5978(91)90020-T					
00			27					

3 4 5 6 7 8	1007 1008 1009 1010	73.	Jodelet, D. Interconnections between social representations and intervention. In: <i>Social Representations in the "Social Arena."</i> A. De Rosa. Routledge; 2012:77-88. https://www.academia.edu/36160041/Jodelet_D2012Interconnections_between_social _representations_and_intervention
9 10 11	1011 1012	74.	Green S, Liu P-Y, O'Sullivan J. Factorial design considerations. <i>J Clin Oncol</i> . 2002;20(16):3424- 3430. doi:10.1200/JCO.2002.03.003
12 13 14 15 16	1013 1014 1015 1016	75.	Haute Autorité de Santé. <i>Guide méthodologique - Choix méthodologique pour l'évaluation économique à la HAS [Methodological guide - Methodological choices for economic evaluation at the National Health Authority</i>]. Haute Autorité de Santé; 2011:83. https://www.has-sante.fr/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
17 18 19	1017 1018	76.	Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. <i>CA Cancer J Clin</i> . 2012;62(4):243-274. doi:10.3322/caac.21142
20 21 22 23 24	1019 1020 1021	77.	Institut National du Cancer. <i>Plan cancer 2014-2019 : priorités et objectifs</i> . Institut National du Cancer; 2015:210. http://www.e-cancer.fr/Plan-cancer/Plan-cancer-2014-2019-priorites-et- objectifs
25 26 27	1022 1023	78.	Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. <i>Clin</i> <i>Nutr</i> . 2017;36(1):11-48. doi:10.1016/j.clnu.2016.07.015
28 29 30 31 32	1024 1025 1026 1027	79.	Sweegers MG, Altenburg TM, Chinapaw MJ, et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. <i>Br J Sports Med</i> . 2018;52(8):505-513. doi:10.1136/bjsports-2017-097891
33 34 35 36 37 38	1028 1029 1030 1031	80.	Bluethmann SM, Vernon SW, Gabriel KP, Murphy CC, Bartholomew LK. Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2015;149(2):331-342. doi:10.1007/s10549-014-3255-5
39 40 41 42	1032 1033 1034	81.	Delrieu L, Vallance JK, Morelle M, et al. Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>Eur J Cancer Care (Engl)</i> . 2020;29(1):e13169. doi:10.1111/ecc.13169
43 44 45 46 47	1035 1036 1037	82.	Quintiliani LM, Mann DM, Puputti M, Quinn E, Bowen DJ. Pilot and Feasibility Test of a Mobile Health-Supported Behavioral Counseling Intervention for Weight Management Among Breast Cancer Survivors. <i>JMIR Cancer</i> . 2016;2(1):e4. doi:10.2196/cancer.5305
48 49 50 51	1038 1039 1040	83.	Delrieu L, Pialoux V, Pérol O, et al. Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR Mhealth Uhealth</i> . 2020;8(1):e12306. doi:10.2196/12306
52 53 54 55	1041 1042 1043	84.	Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of distance- based physical activity interventions for cancer survivors (2013-2018): We still haven't found what we're looking for. <i>Cancer Treat Rev</i> . 2018;69:188-203. doi:10.1016/j.ctrv.2018.07.012
56 57 58 59 60	1044 1045 1046	85.	Cadmus-Bertram LA, Marcus BH, Patterson RE, Parker BA, Morey BL. Randomized Trial of a Fitbit-Based Physical Activity Intervention for Women. <i>Am J Prev Med</i> . 2015;49(3):414-418. doi:10.1016/j.amepre.2015.01.020


1 2			
3 4 5 6	1047 1048 1049	86.	Lavallée JF, Abdin S, Faulkner J, Husted M. Barriers and facilitators to participating in physical activity for adults with breast cancer receiving adjuvant treatment: A qualitative metasynthesis. <i>Psychooncology</i> . 2019;28(3):468-476. doi:10.1002/pon.4980
7 8 9 10 11	1050 1051 1052	87.	Westphal T, Rinnerthaler G, Gampenrieder SP, et al. Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. <i>Cancer Med</i> . 2018;7(12):5962-5972. doi:10.1002/cam4.1851
12 13 14 15	1053 1054 1055	88.	O'Brien T, Troutman-Jordan M, Hathaway D, Armstrong S, Moore M. Acceptability of wristband activity trackers among community dwelling older adults. <i>Geriatr Nurs</i> . 2015;36(2 Suppl):S21-25. doi:10.1016/j.gerinurse.2015.02.019
16 17 18	1056 1057	89.	Ho A, Quick O. Leaving patients to their own devices? Smart technology, safety and therapeutic relationships. <i>BMC Med Ethics</i> . 2018;19(1):18. doi:10.1186/s12910-018-0255-8
19 20 21 22 23	1058 1059 1060	90.	European Union (EU), European Economic Area (EEA). General Data Protection Regulation (EU). Published online May 4, 2016. https://ec.europa.eu/info/law/law-topic/data-protection-rules_en
23 24 25 26	1061 1062	91.	Lagger G, Pataky Z, Golay A. Efficacy of therapeutic patient education in chronic diseases and obesity. <i>Patient Educ Couns</i> . 2010;79(3):283-286. doi:10.1016/j.pec.2010.03.015
27 28 29 30 31	1063 1064 1065 1066	92.	Mino J-C, Lefève C. Improved understanding of the experience of physical activity after a cancer from a philosophy of health perspective [Mieux comprendre l'expérience de l'activité physique après un cancer grâce à la philosophie de la santé]. <i>Santé Publique</i> . 2016;28 Suppl 1:S101-107.
32 33 34 35	1067 1068 1069	93.	Peddle-McIntyre CJ, Cavalheri V, Boyle T, et al. A Review of Accelerometer-based Activity Monitoring in Cancer Survivorship Research. <i>Med Sci Sports Exerc</i> . 2018;50(9):1790-1801. doi:10.1249/MSS.000000000001644
36 37 38 39 40	1070 1071 1072	94.	Degroote L, De Bourdeaudhuij I, Verloigne M, Poppe L, Crombez G. The Accuracy of Smart Devices for Measuring Physical Activity in Daily Life: Validation Study. <i>JMIR Mhealth Uhealth</i> . 2018;6(12):e10972. doi:10.2196/10972
41 42 43 44 45	1073 1074 1075 1076	95.	Mourgues C, Gerbaud L, Leger S, et al. Positive and cost-effectiveness effect of spa therapy on the resumption of occupational and non-occupational activities in women in breast cancer remission: a French multicentre randomised controlled trial. <i>Eur J Oncol Nurs</i> . 2014;18(5):505-511. doi:10.1016/j.ejon.2014.04.008
46 47 48 49 50	1077 1078 1079	96.	Mewes JC, Steuten LMG, Duijts SFA, et al. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. <i>J Cancer Surviv</i> . 2015;9(1):126-135. doi:10.1007/s11764-014-0396-9
50 51 52 53 54	1080 1081 1082	97.	Gordon LG, DiSipio T, Battistutta D, et al. Cost-effectiveness of a pragmatic exercise intervention for women with breast cancer: results from a randomized controlled trial. <i>Psychooncology</i> . 2017;26(5):649-655. doi:10.1002/pon.4201
55 56 57 58 59 60	1083 1084 1085	98.	van Waart H, van Dongen JM, van Harten WH, et al. Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>Eur J Health Econ</i> . 2018;19(6):893-904. doi:10.1007/s10198-017-0936-0

1 2			
3 4 5 6 7 8 9 10 11	1086 1087 1088 1089	99.	Perrier L, Foucaut A-M, Morelle M, et al. Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Support Care Cancer</i> . 2020;28(6):2829-2842. doi:10.1007/s00520-019-05078-4
	1090 1091 1092	100.	Khan KA, Mazuquin B, Canaway A, Petrou S, Bruce J. Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer. <i>Breast Cancer Res Treat</i> . 2019;176(1):37-52. doi:10.1007/s10549-019-05235-7
12 13 14 15 16 17	1093 1094 1095 1096	101.	Guillon M, Rochaix L, Dupont J-CK. COST-EFFECTIVENESS OF INTERVENTIONS BASED ON PHYSICAL ACTIVITY IN THE TREATMENT OF CHRONIC CONDITIONS: A SYSTEMATIC LITERATURE REVIEW. Int J Technol Assess Health Care. 2018;34(5):481-497. doi:10.1017/S0266462318000533
17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41	1097		

	Assessments	Tools	Baseline	6 months	12 mont
			+1month	±1month	±1mont
Demo	graphic and clinical data	Patient's medical record			
-	Month/year of birth		Х		
-	Age at diagnosis		Х		.,
-	Employment status		Х	Х	Х
-	Personal history of breast cancer		X		
-	Current treatment		X	Х	Х
-	Hormonal receptor status		X		
-	Tumour histology		Х	v	v
- سطند س ۸	Disease progression			Х	Х
Anthr	opometrics	Cauga	v		
-	Height Weight	Gauge Scale	X X	х	х
-	Waist-to-hip circumference	Measuring tape	X	×	X
_	Body composition: fat mass, lean	Bioelectronic impedancemetry	×	×	X
_	mass, dry lean mass, body water	bioelectronic impedancemeny	~	~	~
Physic	cal fitness		Х	Х	Х
-	Walking endurance with perceived	6MWT and Borg scale			
	difficulty				
-	Lower limb muscle strength	Sit-to-stand test			
-	Hand prehensile strength	Hand-grip test			
-	Flexibility of lower limbs	Sit-and-reach flexibility test			
-	Balance	Bilateral unipodal equilibrium			
		test			
-	cal activity level, sitting time and	RPAQ Questionnaire	Х	Х	Х
	vement of physical activity				
recom	nmendations				
Detter					
Patier	nt-reported outcomes		V	V	V
Patier -		EORTC QLQ-C30 questionnaire	Х	х	х
Patier -	nt-reported outcomes Quality of life	and BR-23 module			
Patier - -	nt-reported outcomes Quality of life Health-related quality of life	and BR-23 module EQ-5D-5L Questionnaire	х	х	х
Patier - - -	nt-reported outcomes Quality of life Health-related quality of life Fatigue	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire	X X		X X
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability	and BR-23 module EQ-5D-5L Questionnaire	х	х	х
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire	X X X	X X	X X X
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity,	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire	X X	х	X X
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire	X X X	x x x	x x x
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	X X	X X X
-	nt-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity,	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms),	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms), acceptability of therapeutic patient	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms), acceptability of therapeutic patient education (only for patients in the	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x x
-	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms), acceptability of therapeutic patient education (only for patients in the "therapeutic patient education" and	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x
- - Deter -	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms), acceptability of therapeutic patient education (only for patients in the "therapeutic patient education" and "combined" arms)	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered	X X X	x x x	x x x
- - Deter -	ht-reported outcomes Quality of life Health-related quality of life Fatigue Social vulnerability minants of physical activity Barriers to regular physical activity, lifestyle Uses, representations and motivation towards physical activity, acceptability of activity trackers (only for patients in the "connected device" and "combined" arms), acceptability of therapeutic patient education (only for patients in the "therapeutic patient education" and	and BR-23 module EQ-5D-5L Questionnaire PFS-12 questionnaire EPICES questionnaire Self-administered questionnaire Online self-administered questionnaire	X X X X	X X X X	x x x

1 2						
3 4		Assessments	Tools	Baseline +1month	6 months ±1month	12 months ±1month
5 6 7 8 9 10		 Plasmatic inflammatory cytokines (IL-6, TNFα, CRP) Plasmatic adipokines (adiponectin, leptin) Vitamin D status 				
11 12 13	-	Compliance with each intervention (only for patients in the "connected device",	Connected device and/or patient's record		х	
14 15	-	"therapeutic patient education" and "combined" arms)				
16	1000	Adverse events (neuropathies, joint pain)	Patient's diary		Х	Χ
17 18	1099	Notes. 6MWT: six-minute walk test				
10	1100					
20	1100					
21						
22						
23 24						
25						
26						
27						
28						
29 30						
30 31						
32						
33						
34						
35						
36 37						
38						
39						
40						
41						
42						
43 44						
45						
46						
47						
48						
49 50						
51						
52						
53						
54						
55 56						
56 57						
58						
59						
60						

Figure 1 Flow chart of participants through the DISCO trial.





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormation		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2, 26
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	8, ethics copy
Funding	4	Sources and types of financial, material, and other support	30, funding copy_
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 31-32
responsibilities	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	31
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	31
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	1

BMJ Open

1 2	Introduction			
3 4 5 6 7 8 9	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	7
		6b	Explanation for choice of comparators	7
	Objectives	7	Specific objectives or hypotheses	7
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8
13 14 15 16 17 18	Methods: Participa	nts, inte	erventions, and outcomes	
	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8-9
22 23 24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9-15
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	12-13
28 29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	13-14
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34 35 36 37 38 39 40 41 42	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	17, Table 1
	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9, 16-17, Figure1, Table1
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	:

1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	22
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8
6 7	Methods: Assignm	ent of ir	nterventions (for controlled trials)	
8 9	Allocation:			
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10
6 7 8 9	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10
0 1 2	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9-10
23 24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A
30 31	Methods: Data coll	ection,	management, and analysis	
32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	17-21
38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17
41 42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	3

Page 49 of 48

BMJ Open

1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	7, 24
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the 23 statistical analysis plan can be found, if not in the protocol	3-24
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses) 10	0, 23-24
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation) 23	3-24
14 15	Methods: Monitorin	g		
16 17 18 19 20	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of 25 whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	5
21 22 23 24 25 26 27 28 29 30		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim Na results and make the final decision to terminate the trial	/A
	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse 14 events and other unintended effects of trial interventions or trial conduct	4, 24-25
	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	5
31 32	Ethics and dissemi	nation		
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval 2,	, 25-26, 32
37 38 39 40 41	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	6
42 43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

	Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8	
		26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A	
	Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	25	
	Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	32	
	Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	25	
	Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A	
	Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	25-26	
		31b	Authorship eligibility guidelines and any intended use of professional writers	31	
		31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A	
	Appendices				
	Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	9	
	Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	21	
	Amendments to the p	rotocol	that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarifical should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Co-NoDerivs 3.0 Unported" license.		
 2 3 4 5			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		5

BMJ Open

Connected device and therapeutic patient education to promote physical activity among women with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045448.R1
Article Type:	Protocol
Date Submitted by the Author:	13-Mar-2021
Complete List of Authors:	Touillaud, Marina; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment" Fournier, Baptiste; Centre Léon Bérard, Department of Prevention Cancer Environment Pérol, Olivia; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment" Delrieu, Lidia; Centre Léon Bérard, Department of Prevention Cancer Environment; Université Claude Bernard Lyon 1, Inter-University Laboratory of Human Movement Biology EA7424 Maire, Aurélia; Centre Léon Bérard, Department of Prevention Cancer Environment Belladame, Elodie; Centre Léon Bérard, Department of Prevention Cancer Environment Pérol, David; Centre Léon Bérard, Department of Prevention Cancer Environment Périol, David; Centre Léon Bérard, Department of Clinical Research and Innovation Perrier, Lionel; Centre Léon Bérard, Direction of Clinical Research and Innovation; GATE, UMR-CNRS 5824, University of Lyon Preau, Marie; Lumière University Lyon 2, GRePS EA4163 Institute of Psychology LEROY, Tanguy; Lumière University Lyon 2, GRePS EA4163 Institute of Psychology Fassier, Jean-Baptiste; Hospices Civils de Lyon, UMRESTTE UMR T9405, Université Claude Bernard Lyon 1 Fillol, Florie; Biomouv Pascal, Sébastien; Biomouv Durand, Thierry; Centre Léon Bérard, Department of Hospital Information Fervers, Béatrice; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment"
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Sports and exercise medicine, Nutrition and metabolism, Health economics, Sociology

Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, MEDICAL EDUCATION & TRAINING
	SCHOLAR ONE [™]
	Manuscripts
For peer review	only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

BMJ Open

2		
3 4	1	Connected device and therapeutic patient education to promote physical activity among women
5 6	2	with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised
7 8	3	controlled trial
9 10 11	4	
12 13	5	Marina Touillaud ^{1,2} , Baptiste Fournier ¹ , Olivia Pérol ^{1,2} , Lidia Delrieu ^{1,3} , Aurélia Maire ¹ , Elodie
14 15	6	Belladame ¹ , David Pérol ⁴ , Lionel Perrier ^{4,5} , Marie Préau ⁶ , Tanguy Leroy ⁶ , Jean-Baptiste Fassier ⁷ , Florie
16 17	7	Fillol ⁸ , Sébastien Pascal ⁸ , Thierry Durand ⁹ , Béatrice Fervers ^{1,2}
18 19 20	8	
20 21 22	9	¹ Department of Prevention Cancer Environment, Léon Bérard Cancer Centre, Lyon, France
23 24	10	² UMR 1296 INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and
25 26	11	Environment", Léon Bérard Cancer Centre, Lyon, France
27 28	12	³ Inter-University Laboratory of Human Movement Biology EA7424, Claude Bernard Lyon 1 University,
29 30 31	13	University of Lyon, Villeurbanne, France
32 33	14	⁴ Direction of Clinical Research and Innovation, Léon Bérard Cancer Centre, Lyon, France
34 35	15	⁵ GATE Lyon Saint-Etienne, UMR-CNRS 5824, University of Lyon, Ecully, France
36 37	16	⁶ GRePS EA4163 Institute of Psychology, Lyon 2 University, Bron, France
38 39 40	17	⁷ Hospices Civils de Lyon, Claude Bernard Lyon 1 University, UMRESTTE UMR T 9405, Lyon, France
41 42	18	⁸ Biomouv, Paris, France
43 44	19	⁹ Department of Hospital Information, Léon Bérard Cancer Centre, Lyon, France
45 46	20	
47 48 49	21	Correspondence to:
50 51	22	Dr Béatrice Fervers; beatrice.fervers@lyon.unicancer.fr
52 53 54 55 56 57 58 59 60	23	
		1

24 ABSTRACT

> Introduction: Despite safety and benefits of physical activity during treatment of localized breast cancer, successful exercise strategies remain to be determined. The primary objective of the DISCO trial is to evaluate the efficacy of two 6-month exercise interventions, either single or combined, concomitant to adjuvant treatments, on the physical activity level of breast cancer patients, compared to usual care: an exercise program using a connected device (activity tracker, smartphone application, website) and a therapeutic patient education intervention. Secondary objectives are to evaluate adherence to interventions, their impact at 6 and 12 months, representations and acceptability of interventions, and to assess the cost-effectiveness of the interventions using quality-adjusted life years. Methods and analysis: This is a 2x2 factorial, multicentre, phase III randomised controlled trial. The study population (with written informed consent) will consist of 432 women diagnosed with primary localized invasive breast carcinoma and eligible for adjuvant chemotherapy, hormonotherapy and/or radiotherapy. They will be randomly allocated between one of four arms: (i) web-based connected device (evolving target number of daily steps and an individualized, semi-supervised, adaptive program of two walking and one muscle strengthening sessions per week in autonomy), (ii) therapeutic patient education (one educational diagnosis, two collective educational sessions, one evaluation), (iii) combination of both interventions, (iv) control. All participants will receive the international physical activity recommendations. Assessments (baseline, 6 and 12 months) will include physical fitness tests, anthropometrics measures, body composition (CT-scan, bioelectrical impedance), self-administered questionnaires [physical activity profile (RPAQ), quality of life (EORTC QLQ-C30, EQ-5D-5L), fatigue (PFS-12), social deprivation (EPICES), lifestyle, physical activity barriers, occupational status] and biological parameters (blood draw).

46 Ethics and dissemination: This study was reviewed and approved by the French Ethics Committee. The
47 findings will be disseminated to the scientific and medical community via publications in peer-reviewed
48 journals and conference presentations.

Registration: ClinicalTrials.gov NCT03529383; 05/17/2018.
 60

BMJ Open

1		
2		
3	50	
4		
5 6	51	Keywords: Breast cancer, Physical activity, Sitting time, Activity tracker, Connected device, Web-
7 8	52	based, eHealth, Therapeutic patient education, Randomised controlled trial
9		
10	53	
11		
12	54	Word count: 8445
13		
14	55	
15		
16 17	56	Strengths and limitations of this study
18		The second second strategies and the formation of the second second second second second second second second s
19	57	- This randomized clinical trial with four arms has the advantage to evaluate the efficacy of two
20		
21 22	58	interventions, either single or their combination, using a 2x2 factorial design, ensuring a higher
22		
24	59	statistical power than a classic trial with three arms, for a similar sample size.
25		
26	60	- While the connected device intervention is semi-supervised, the exercise program has been
27		
28	61	designed according to the preferences of women with breast cancer so as not to leave patients
29		
30	62	in total autonomy and to provide organisational flexibility to patients to facilitate adherence.
31		
32	63	- Despite the potential benefits of connected devices in cancer care, their use may face
33 34		
35	64	important issues, such as ethical challenges related to the security of sensitive data storage,
36		
37	65	technical challenges related to technological robustness and reliability, exacerbating access
38		
39	66	disparities, and self-assessment of the participant's fatigue or health condition.
40		
41	67	- The primary outcome measure is based on a declarative evaluation of physical activity that
42		
43	68	confers methodological limits to the study, but the validated questionnaire was chosen
44 45		
45 46	69	according for its easy implementation for cancer patients compared to accelerometer
47		
48	70	monitoring and its relevance for the primary outcome.
49	, 0	
50		
51		
52		
53		
54		
55 56		
56		

71 INTRODUCTION

Breast cancer is the leading cause of cancer in women worldwide with 1.6 million new cases diagnosed each year,¹ representing more than a third of all new cancer cases in women. In France, breast cancer also represents the leading cause of cancer incidence and mortality among women, with approximately 58,000 new cases and 12,000 breast cancer deaths estimated in 2018.² Despite a very good prognosis worldwide with overall survival of 85% at 5 years (87% in France) and 71% at 10 years (78% in France) for all stages combined, $^{3-5}$ a large number of patients with breast cancer experience adverse effects of cancer and its treatments such as fatigue, impaired quality of life, anxiety or weight gain.6-8

In women with breast cancer, deteriorations of physical activity level and cardiorespiratory fitness are frequent.^{9,10} Physical activity is defined as any bodily movement produced by skeletal muscles that requires energy expenditure, including any daily life activity of household, occupation, recreation (e.g., sports) or transportation. Exercise is a subset of physical activity that is planned, structured and repetitive, in the purpose of improving or maintaining physical fitness.¹¹ After a breast cancer diagnosis, lack of physical activity, obesity and weight gain have been shown to increase the risk of cancer-related comorbidities and treatment adverse effects, to worsen long-term health and to cause poor prognosis.^{12–14} The benefits of physical activity have been well recognized in primary cancer prevention.¹⁵ Numerous studies have shown the safety¹⁶ and benefits of physical activity performed concomitantly with breast cancer treatments. These benefits include reduced fatigue^{17–19} and comorbidities²⁰, improved quality of life^{21,22} and physical functioning,^{10,17,19,22} as well as possibly reduced risk of recurrence²³ and improved overall and specific survival with a positive dose-response relationship.^{14,23,24} Despite these benefits and international evidence-based guidelines of physical activity prescription for clinicians and their patients, accessibility to exercise programs and implementing the guidelines in the cancer care process remain a challenge for patients and health care providers.^{25–27} While a growing number of facilities offer exercise programs to cancer patients, distance

BMJ Open

3 4	
5	
6	
7	
8	
9 10	
10	
11	
12	1
13	
14	1
15 16	
16 17	1
17 18	
19	1
20	
21	1
22	
23	
24	-
20 21 22 23 24 25 26 27 28	
26	-
2/	
20 20	-
29 30	
31	-
32	
33	-
34	
35	-
36	
37	-
38	
39 40	-
40 41	
42	-
43	
44	-
45	
46	-
47	
48	1
49 50	
50 51	1
51 52	
53	-
54	
55	-
56	
57	-
58	
59	

96 from home constitutes a barrier to regular exercise during cancer treatments.²⁶ Successful exercise
 97 strategies during and beyond cancer treatment remain to be determined in clinical trials.²⁸

98 The recent development of connected devices such as activity trackers offers a real opportunity in oncology to promote and monitor patients' physical activity.²⁹ While adherence to lifestyle 99 100 interventions is a major challenge, connected activity trackers and smartphone applications enable 101 structured monitoring of health parameters and provide feedback to patients. A systematic review of 102 randomised controlled trials of physical activity interventions using new technologies such as activity 103 trackers in cancer patients (including five studies in breast cancer) has shown that patients significantly 104 increased their number of steps per day in the majority of the studies.³⁰ Recent reviews of intervention 105 studies conducted among breast cancer patients have also shown that patients increased their physical activity when they used activity trackers.^{31,32} Overall, connected activity trackers receive increasing 106 107 interest for being systematically integrated into clinical oncology practice.^{33,34} Yet, more research is 108 needed, especially clinical trials, to demonstrate the effectiveness of these tools and to respond to the 109 preferences of breast cancer patients.^{35–37}

110 Therapeutic patient education has emerged in the 1990s in response to the recognition of the need 111 to support patients in the self-management of their chronic diseases, such as diabetes and asthma.^{38,39} 112 According to the World Health Organization (WHO), therapeutic patient education aims to "help patients acquire or maintain the skills they need to best manage their lives with a chronic disease".⁴⁰ 113 114 In the cancer field, several cancer-specific programs of therapeutic patient education have been set up 115 to manage pain, fatigue, side effects of treatment (chemotherapy, surgery) or compliance to treatment.^{41–44} By enhancing relevant knowledge and skills, therapeutic patient education may greatly 116 117 contribute to increasing patients' autonomy in their disease management. Despite the performance in modifying long-term individual behaviours and adherence to cancer treatments,⁴⁴ the benefits of 118 119 therapeutic patient education on physical activity levels in cancer patients early after diagnosis has been poorly investigated.^{45,46} The research on therapeutic patient education in the breast cancer and 120 121 exercise context is limited to date and warrants further research. 60

Several biological mechanisms have been proposed to explain the effects of physical activity on breast cancer risk and outcome. Preclinical and human studies have shown the influence of physical activity on several signalling pathways involved in tumour development, growth and progression, including the insulin signalling pathway (IGF-1, insulin), chronic inflammation (involving inflammatory cytokines such as IL-6, TNF α , CRP) and endocrine hormone regulation (estrogens, adipokines).^{47–49} By affecting the endogenous systemic milieu, physical activity is believed to influence cellular processes and tumour growth, and therefore reduce the risk of recurrence, increase treatment efficacy and improve survival.⁵⁰ Also, because vitamin D alters mechanisms implicated in cellular growth and proliferation, accumulating evidence suggests that normal-to-high ranges of serum vitamin D levels improve breast cancer prognosis and outcome.⁵¹ Based on the data in the literature, it is not possible to conclude a causal relationship between the metabolic effects of physical activity and the impact on breast cancer risk and survival. Biological effects of physical activity on these biomarkers of endogenous mechanisms interfering in cancer suppression or proliferation remain to be elucidated in order to better understand the benefit of physical activity during adjuvant treatment.⁴⁹

In this context, given the accumulating evidence for the benefits and safety of regular exercise during treatments of localized breast cancer, it is necessary to systematically encourage patients to remain or become physically active from the time of diagnosis and to implement and assess the most appropriate strategies of physical activity in clinical practice. The aim of the DISCO trial is to encourage engagement in exercise during breast cancer treatment through two innovative types of interventions, that is to say a web-based connected device and therapeutic patient education, which aim to develop patients' autonomy in their practice of physical activity. The primary objective of the DISCO trial is to evaluate the efficacy of two interventions, either single or combined, concomitant to adjuvant treatments, on the physical activity level of breast cancer patients at the end of the 6-month interventions, compared to usual care: one is an exercise program using a connected device (comprising an activity tracker linked to a smartphone application and a website and providing an individualized, semi-supervised, technology-based exercise program) and the other is a therapeutic

BMJ Open

patient education intervention. The research hypothesis is that patients participating in the 6-month exercise program using the connected device or therapeutic education intervention are more likely to achieve the international physical activity recommendations, compared to women receiving physical activity recommendations only (usual care). The WHO recommendations to maintain or improve health, which applied when the study protocol was developed, are to do at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic physical activity or an equivalent combination each week, and muscle-strengthening activities at least two days a week.¹¹ Secondary objectives are: (i) to evaluate the adherence to the interventions; the impact of the interventions on physical fitness, physical activity profile, anthropometrics, quality of life, fatigue, biological parameters, occupational status and lifestyle factors; the efficacy of the 6-month interventions on physical activity level at 12 months; the representations and acceptability of activity tracker and therapeutic patient education; and ii) to assess the cost-effectiveness of the interventions. If one of the interventions is individually effective, the efficacy of the combination of both interventions at 6 and 12 months will be evaluated.

Ne.

162 METHODS AND DESIGN

163 Trial design

The DISCO (an acronym for "dispositif connecté", i.e., connected device in English) trial is a 2x2 prospective, multicentre, factorial, randomised, controlled and open-label study (phase III), conducted by the Léon Bérard comprehensive cancer centre (Lyon, France) among women receiving treatment for localized breast cancer. The clinical protocol was designed and written according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines (see Supplementary file 1). The flowchart of the study is presented in Figure 1. Patients will be randomly assigned to one of the four arms of the study according to the 2×2 factorial design (1:1:1:1 ratio). They will all receive international recommendations on physical activity,¹¹ and: (i) women allocated to the "connected device" arm will benefit from a 6-month individualized, semi-supervised exercise program carried out autonomously. The program consists of an evolving goal of daily numbers of steps using an activity

tracker and two sessions of brisk walking and one session of muscle strengthening per week, using dedicated smartphone application and website; (ii) women allocated to the "therapeutic patient education" arm will benefit from four therapeutic education sessions on exercise; (iii) women allocated to the "combined" arm will benefit from both interventions in parallel; (iv) women allocated to the "control" arm will receive usual care.

180 Eligibility criteria for participants

Inclusion criteria include: being a female 18 to 75 years old; diagnosed with a first primary non-metastatic invasive breast carcinoma histologically confirmed; treated with curative surgery and requiring adjuvant treatment (chemotherapy, hormonotherapy and/or radiotherapy) that present at one of the investigating centres; providing a medical certificate of no contraindication to exercise; being available and willing to participate in the study for the duration of the interventions and follow-up; using a personal smartphone compatible with an application used for the intervention (iOS operating system from version 9.3, Android operating system from version 5.0, no Microsoft operating system) and having a computer with Internet access; being able to understand, read and write French; and being affiliated with a social security scheme.

Non-inclusion criteria include: recurrent, metastatic or inflammatory breast cancer; personal history or co-existence of other primary cancer (except for in situ cancer regardless of the site, basal cell skin cancer and non-mammary cancer in complete remission for more than 5 years); presenting a contraindication to exercise according to the investigator (such as cardiorespiratory or bone pathologies, non-stabilized chronic diseases such as diabetes, malnutrition, etc.); presenting severe malnutrition according to the criteria of the French National Health Authority (i.e., for women \leq 70 years: weight loss ≥15% in 6 months or ≥10% in 1 month; for women >70 years: weight loss ≥15% in 6 months or $\geq 10\%$ in 1 month, and body mass index (BMI) <18 kg/m²);⁵² being unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study; pregnant or breastfeeding or of childbearing age without effective contraception for the duration of the study.

3 4		
	200	
5 6 7 8 9 10 11 12 13	201	Recruitment
	202	Recruitment started in May 2018. Participants will be recruited at several national comprehensive
	203	cancer centres, clinics or hospitals located in France (see ClinicalTrials.gov NCT03529383), which will
	204	ensure adequate participant enrolment to reach the target sample size in a timely manner. Inclusion
14 15	205	of patients will be carried out after surgery and confirmation of the indication of adjuvant treatment.
16 17	206	The study will be proposed to patients at the postoperative, pre-chemotherapy or pre-radiotherapy
18 19	207	consultation (by the surgeon, oncologist or radiotherapist investigator, respectively) depending on the
20 21 22	208	patient's treatment plan. At this visit, the investigator will check all eligibility criteria and propose to
22 23 24	209	the eligible patients to participate in the study, explain the objectives and study process and give them
25 26	210	an information notice. After sufficient time for reflection, eligible patients who agree to participate will
27 28 29 30 31	211	date and sign an informed consent (see Supplementary file 2) and will be included prior to the onset
	212	of adjuvant therapy (or within one month thereafter). The number of eligible patients refusing to
32 33	213	participate in the study and the reason for non-participation will be recorded.
34 35	214	
36 37		
	215	Randomisation
38 39	215 216	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity
38 39 40 41		
38 39 40	216	Prior to randomisation, participants will be asked to complete the Recent Physical Activity
38 39 40 41 42 43 44 45 46	216 217	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed
38 39 40 41 42 43 44 45 46 47 48	216 217 218	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record.
 38 39 40 41 42 43 44 45 46 47 48 49 50 	216 217 218 219	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris,
38 39 40 41 42 43 44 45 46 47 48 49	216 217 218 219 220	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	216 217 218 219 220 221	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25 kg/m ² , ≥25 and <30 kg/m ² , ≥30 kg/m ²), baseline physical activity level from RPAQ (<150 min/week,
38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	216 217 218 219 220 221 222	Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25 kg/m², ≥25 and <30 kg/m², ≥30 kg/m²), baseline physical activity level from RPAQ (<150 min/week, ≥150 min/week of moderate-to-vigorous physical activity) and prescribed adjuvant treatments at

INTERVENTIONS

At baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population¹¹, which will be delivered orally by a certified exercise instructor with the help of a leaflet.

Intervention with a connected device

Participants randomised to the "connected device" arm will benefit from a 6-month exercise program. The connected device consists of an activity tracker (connected wristband, LS417-F model, CARE Fitness, Bobigny, France) that participants will wear daily, a dedicated smartphone application and a dedicated website proposing an individualized, semi-supervised exercise program adapted to cancer patients (developed by BIOMOUV, Paris, France). This automated web- and mobile-based exercise program will aim to support participants to enhance physical activity in two ways: doing structured exercise sessions and increasing daily physical activity (number of steps). Exercise sessions will be automatically generated by an algorithm based on the patient profile (described below). The participants will receive notifications informing them of a new structured exercise session available on the website or mobile application, or alerting them when a session was not carried out, and inviting them to execute it when possible. Participants will receive a free 6-month subscription to the program. -Setting up the connected device: At the end of the baseline assessment, the certified exercise instructor will introduce the customized exercise program to the participants and will give them the activity tracker and a user guide for the connected device. Then, the certified exercise instructor will explain the functioning of the activity tracker, the dedicated smartphone application and the dedicated website, as well as assist the participants to install the application on their smartphone. The participants will be registered in the customized exercise program by the certified exercise instructor. The registration will consist of completing a web-based questionnaire about personal and health data to determine the participant profile (age, weight, height, level of aerobic and muscular strength, treatment, symptoms, availabilities for exercise sessions and sports materials).

BMJ Open

-Baseline level of aerobic and muscular strength for the individualised exercise program: The physical fitness tests performed at baseline will be used to classify the participants at the start of the exercise program according to their aerobic level (for the walking sessions) and their muscular strength level (for the strengthening sessions). The aerobic level categories will be determined by the distance performed during the 6-minute walk test (6MWT): aerobic group 1 (<460 meters), aerobic group 2 (460 to 580 meters) and aerobic group 3 (>580 meters). The muscular strength level categories will be determined by the number of sit-ups performed on a chair in 30 seconds during the Sit-to-stand test: muscular strength group 1 (<10 repetitions), muscular strength group 2 (11 to 14 repetitions) and muscular strength group 3 (≥15 repetitions). Thresholds were based on average values reached by women receiving breast cancer treatments for the 6MWT (pooled mean value, 523 m) and the Sit-tostand test (pooled mean value, 13 repetitions) from a previous study;⁵⁶ these values were checked for consistency with percentile scores obtained at the 6MWT and Sit-to-stand test in community-dwelling older women,⁵⁷ then the interquartile range was used to determine the thresholds for the three groups of this study. The level categories assigned will be entered by the exercise instructor in the baseline patient profile and will be used by the automated algorithm to set up the level of the first walking and muscle strengthening sessions.

-Exercise program: The 6-month exercise program will be semi-supervised by the certified exercise instructor through an individual follow-up of participants (see 'Participant follow-up' part and 'Continuous monitoring' part). It will be carried out autonomously by the participants at home by using the smartphone application and the website. The program is based on three structured unsupervised sessions per week alternating two types of exercise: two walking sessions (by following oral instructions given via the smartphone application) and one muscle strengthening session (by using videos accessible on the website). The levels of the first walking and muscle strengthening sessions will be determined by the fitness tests performed at baseline (see 'Baseline level' part). Then, subsequent sessions will be planned according to the available days of the participant. Strengthening exercises will be adapted according to sports materials available at their home (e.g., Swiss ball, sports mat, stick,

> weight, etc.). Each session will include: 1) a warm-up period of 5 minutes; 2) a body session of 10 to 35 minutes of strengthening exercises, or 10 to 50 minutes of walking (mixing continuous and/or intermittent effort); 3) a 5-minute recovery period, consisting of stretching and relaxation during strengthening sessions or a cool down during walking sessions. Sessions will be of moderate-to-high intensity (\geq 3 and \leq 9 METs).

The three structured unsupervised exercise sessions per week are configured by a unique algorithm hosted by an accredited personal healthcare data host (Orange Business Services, Paris, France), to plan the exercise sessions and determine the exercise level in an adapted and progressive manner by increasing the duration and then intensity in accordance with principles of exercise training and progression.^{58,59} At the beginning of each session, the duration and intensity of the session will be determined according to the perceived difficulties (evaluated by a Borg scale) and emotional state (recorded by an emoji) of the participant in the previous session, and will be modified or postponed according to the level of fatigue (evaluated by a Borg scale), the level of dyspnea (evaluated by a Borg scale), the presence or absence of unusual muscle pain and the presence or absence of unusual nausea/diarrhea. In case of a severe adverse event related to disease or treatment (i.e., joint disability, osteoarthritis, cachexia, hand-foot syndrome, aplasia, diuretic, axillary node dissection, pace-maker, chemotherapy, targeted therapy, hormone therapy, radiotherapy, COPD, diabetes) or temporary contraindication to exercise, declared by the participant on her device, the program and sessions will be adapted or suspended until the participant's health improves.

In addition, participants will have the opportunity to perform additional exercise sessions according
 to their preferences and lifestyle, outside the program. Participants will be asked to record these
 sessions through the smartphone application or the website: type of activity (e.g., walking, hiking,
 cycling) from a list adapted from Ainsworth's Compendium,⁶⁰ and its duration and intensity.

301 —*Number of daily steps:* Participants will be advised to wear the activity tracker daily and to launch
 302 the application regularly (preferably daily), which will automatically synchronize with the activity
 303 tracker via Bluetooth connection and will collect the number of steps. The target number of steps will

BMJ Open

be 3,000 steps per day at the program onset, and then will be re-set based on the average number of daily steps during the first week after inclusion. The target number of daily steps will evolve automatically every three weeks based on the average number of daily steps achieved during the previous three weeks, and will be updated automatically in the application. Consistent with principles of exercise training and progression,^{58,59} after each 3-week cycle, if the goal of steps per day is reached by the participant, the target goal will increase by 15% during the following 3-week-cycle, within a maximum target of 10,000 daily steps. If the average number of daily steps does not meet the goal, the target will remain unchanged in the next cycle.

-Participant follow-up: Telephone follow-ups will be carried out by the certified exercise instructor at 10 days, 2 months and 4 months after the intervention onset to ensure the proper functioning of the connected device, review the use of the connected device, review the conduct of the sessions and answer the participants' questions if they may have. Participants will be orally encouraged to remain physically active on a daily basis (reminder of the benefits and recommendations of physical activity, success and satisfaction during the exercise sessions). During the 6-month intervention, the participants will have the opportunity to contact the certified exercise instructor or the clinical research assistant at any time, by e-mail (directly through the website) or by telephone for any question or assistance with the connected device.

-Continuous monitoring: The certified exercise instructor will monitor the use of the connected device by the participants and their progress in the program through a dedicated professional website that provides real-time access to the participants' data. On this website, an automatically generated daily event table will inform the certified exercise instructor of the occurrence of disabilities reported by the participants that may lead to modifying their program (e.g., severe fatigue, dyspnea, unusual muscle pain) or if participants have not performed their planned sessions or used their activity tracker for seven consecutive days. Upon these alerts, the certified exercise instructor will contact the participants to precisely analyse the reported disabilities, advise participants, identify the causes of non-use of the connected device, solve possible technical problems or reinforce participant's motivation if necessary.

—End of the intervention: At the end of the 6-month program, participants will keep their activity
 tracker to be encouraged to continue regularly exercising in autonomy. Upon their request, continued
 subscription to the dedicated application and website will be offered for another six months, with no
 individual follow-up anymore.

335 Intervention of therapeutic patient education

Participants randomised to the therapeutic patient education arm will benefit from a therapeutic patient education intervention, in addition to receiving the international physical activity recommendations. The intervention is part of the therapeutic patient education program set up at the Léon Bérard cancer centre and validated by the Regional Health Agency ("Agence Régionale de Santé Rhône-Alpes"). It will be disseminated in the investigating centres according to the criteria of the Regional Health Agency. The therapeutic patient education intervention consists of four sessions that will be scheduled according to participants' availability during their follow-up visits as part of their usual clinical management over a 6-month period.

First, participants will be invited to an initial 1-hour individual face-to-face session of educational diagnosis with a health professional trained in therapeutic patient education. This session will assess their needs and establish a contract of objectives to reach. Then, participants will be invited to participate in two collective educational sessions (1h30 each with a group of 10 patients maximum per session). These sessions will be composed of theoretical and practical workshops to help them understand their physical activity in their daily life and implement the necessary means to practice regular exercise in autonomy. Finally, participants will be invited to another 1-hour individual session, where an educational evaluation will be conducted to identify whether they achieve their individual objectives set at the time of the educational diagnosis.

359

1 2

2
3
4
5
6
7
, 8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
42
44
45
46
47
48
49
5 0
50
51
52
53
54
55
56
57
57
58 59

354 **Combined interventions**

Participants randomised to the 'combined intervention' arm will benefit from a combination of the connected device intervention and the therapeutic patient education intervention in parallel for 6 months.

EVALUATIONS 360 The initial assessment (T0) will be performed prior to randomisation for minimization purposes. 361 362 The other three evaluations will then be conducted at baseline (T1), 6 months (T2) and 12 months (T3). 363 All study participants will then be followed at 6 months ± 1 month post-randomisation (corresponding 364 to the end of participation in the interventions for women in the connected device, therapeutic patient 365 education and combined arms) and at 12 months ± 1 month post-randomisation (corresponding to a 366 follow-up period of 6 months post-interventions). Assessments will be carried out by a clinical research 367 assistant and a certified exercise instructor. The clinical research assistant will contact participants by 368 phone to invite them to follow-up visits and to promote participant retention and complete follow-up. 369 Participants will have no compensation for participation and all study visits will be scheduled on days 370 of their medical or health-related appointments.

All evaluations (baseline, 6 and 12 months) will include physical fitness tests, anthropometric measures, self-administered questionnaires and a non-fasting blood draw (baseline and 6 months only). Data will be recorded using an electronic case report form (eCRF).

374

⁰ 375 **DATA COLLECTION**

376 The study outcome measures and their schedule are summarised in Table 1.

377 Socio-demographic and clinical data

57 378 Socio-demographic and clinical data, including month/year of birth, age at diagnosis of breast
 58
 59 379 cancer, family status, level of education, hormonal status, tumour histology and personal history of

> breast cancer will be collected at baseline. Family status, potential cancer progression and all treatments received for cancer will be collected at 6 and 12 months. All data will be extracted from patients' electronic medical records, except family status and level of education that will be selfreported in a questionnaire.

> The occupational status will be assessed using a self-administered questionnaire asking employment status, occupation, size of the company, the perceived intensity of the physical effort at work, the evolution of employment status at return to work in case of sick leave.⁶¹

388 Anthropometrics and body composition

The standing height (cm), body weight (kg) and waist (cm) and hip (cm) circumferences will be measured using standardized procedures and BMI will be calculated as the body weight in kilograms divided by the square of the height in meters (kg/m²). The waist circumference will be measured midway between the last floating rib and the iliac crest. The hip circumference will be measured at the tip of the pubis. Body composition will be measured by a bioelectrical impedance meter (Biody XPert ZM II, eBiody, eBIODY SAS, La Ciotat, France) to assess fat mass (in kg), lean body mass (in kg), muscle mass (in kg), dry lean mass (in kg), total body water (in L), intracellular fluid (in L) and extracellular fluid (in L).

398 Physical fitness

Cardiorespiratory fitness will be evaluated by the walking endurance during the 6MWT (distance
covered in metres) with perceived difficulty using the Borg scale.⁶² During this test, participants will be
asked to perform the maximum walk shuttle distance on a 30-metre long flat corridor in 6 minutes.
The lower limb muscle strength will be measured using the sit-to-stand test (number of sit-ups on a
chair in 30 seconds). During this test, participants will be asked to sit down on a chair and get up as
many times as possible during 30 seconds.⁶³

BMJ Open

3 4	405
5 6	406
7 8	407
9 10 11	408
12 13	409
14 15	410
16 17	411
18 19 20	412
20 21 22	413
23 24	414
25 26	415
27 28 29	416
30 31	417
32 33	418
34 35	419
36 37 38	420
38 39 40	421
41 42	422
43 44	423
45 46	424
47 48 49	425
50 51	426
52 53	427
54 55	428
56 57 58	429
58 59 60	430

Hand prehensile strength will be measured by the handgrip test using hand dynamometry (Jamar Plus Digital Hand Dynamometer, Patterson Medical, Huthwaite, UK), which is a validated index of the isometric strength of the hand and forearm muscles.⁶⁴ During this hand-grip test, participants will be asked to squeeze the handgrip as strongly as possible to obtain the maximal force (in kg). Two measures will be performed on each hand and the best performance will be registered.

The flexibility of lower limbs will be measured using the sit-and-reach flexibility test (Deluxe Baseline flexibility test, 3B Scientific, Bartenheim, France).⁶⁵ In this test, participants will sit on the floor on a mat with their legs stretched out straight ahead. They will be asked to lean forward as far as possible and the distance between fingertips and toes will be measured (in cm) (i.e., by considering the level of the feet as recording zero, any measure that does not reach the toes is negative and any measure beyond the toes is positive).

The balance will be measured using the bilateral single-leg stance test.⁶⁶ The participants will stand and be asked to lift a foot and hold the position for a maximum of 60 seconds, then to do the same exercise on the other foot (duration held in equilibrium, 2 times 60 seconds).

20 Physical activity level, sitting time and achievement of physical activity recommendations

421 The validated self-administered questionnaire RPAQ will be used to measure the self-reported 422 physical activity.^{53,67} The RPAQ was designed to assess usual physical activity in the last four weeks, 423 covering three activity domains: domestic physical activity, including sitting time that is a good proxy 424 of sedentary behaviour; occupational physical activity, including transportation to and from work; and 425 recreational physical activity. The RPAQ gives specific scores in the metabolic equivalent of task (MET) 426 unit for activities of very low intensity (<1.5 METs, i.e., sedentary activities), low intensity (1.5 to 427 <3 METs), moderate intensity (3 to <6 METs) and high intensity (≥6 METs, i.e., vigorous activities) 428 within each domain during the past four weeks. Questions will be coded and converted in MET-minute 429 per four weeks according to the Compendium of Physical Activities⁶⁰ by multiplying the number of 430 METs by the duration and frequency of each activity. Then, the global score of physical activity will be

obtained by adding the number of MET-minutes per four weeks in each intensity and each domain.
The physical activity profile will be defined as the time spent in physical activities of low, moderate and
high intensities. The physical activity level will be defined by the overall weekly physical activity
(average expressed in MET-hour/week).

Achievement of international physical activity guidelines will be computed for each individual by
dividing the time spent in moderate-to-vigorous physical activity (i.e., ≥3 METs) into two categories:¹¹
<150 min/week of moderate-to-vigorous physical activity (i.e., under physical activity guidelines); ≥150
min/week of moderate-to-vigorous physical activity (i.e., reaching physical activity guidelines).

Patient-reported outcomes

The quality of life will be measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality-Of-Life Questionnaire (QLQ-C30) and its specific module for breast cancer (BR-23).68 The QLQ-C30 is a 30-item validated self-administered questionnaire that evaluates five functioning domains (i.e., physical, role, emotional, cognitive and social), a global quality-of-life domain, three symptom domains (i.e., pain, fatigue and nausea) and six single items (i.e., dyspnea, insomnia, anorexia, diarrhea, constipation and financial impact). Each item is associated with a score ranging from 0 to 100. For the functioning and global quality-of-life scales, a higher score corresponds to a better functioning level. For scales related to symptoms, a lower score corresponds to a better functioning level. The BR-23 module gathers data about perceived body image, sexual functioning, sex enjoyment, arm symptoms, breast symptoms and systemic therapy side effects.

The health-related quality of life will be assessed using the EQ-5D-5L questionnaire.⁶⁹ This standardized self-administered questionnaire describes five dimensions (i.e., mobility, self-care, usual activities, pain/discomfort and anxiety/depression) being rated using five levels (i.e., no, slight, moderate, severe and extreme problems), and comprises a 0-100 visual analogue scale recording the self-rated health (where the endpoints are labelled 'The best health you can imagine' and 'The worst health you can imagine'). Page 21 of 50

1 2 3

BMJ Open

4			
5			
6			
7			
, 8			
9			
	0		
	1		
1			
	2 3		
1			
1			
	5 6		
1	7		
	, 8		
	9		
	0		
2			
2 2			
2 2			
2			
	4 5		
2			
	7 8		
2 3	9		
3 3			
3 3			
3 3			
3			
3			
3	/		
3	8		
3	9		
4			
4			
4	_		
4			
-	4		
	5		
	6		
4			
4			
4			
5			
5			
5			
5			
5			
5			
5	6		
5	7		
5			
5	9		

474

Fatigue will be assessed using the Piper Fatigue Scale-12 (PFS-12), a 12-item self-reported questionnaire with four subscales (i.e., behavioural, affective, sensory and cognitive/mood aspects of fatigue):⁷⁰ the higher the score, the worse the fatigue. All items together will produce a total score for fatigue that will be used to define categories as follows: no fatigue (score=0), mild fatigue (score 1-3), moderate fatigue (score 4-6) and severe fatigue (score 7-10).

462 Social deprivation will be assessed using the EPICES (Evaluation of Deprivation and Inequalities in
463 Health Examination Centres) score.⁷¹ The score will be computed by adding each question coefficient
464 to the intercept whenever the answer is "yes." The score ranges from 0 to 100 (i.e., the higher the
465 score, the greater the deprivation level) with the threshold for deprivation at 30.

466 Lifestyle factors, assessed using a self-administered questionnaire, include tobacco status (i.e., 467 never, former, current smoker), lifetime and current tobacco use (expressed in pack-years) and alcohol 468 intake over the past 6 months (usual frequency of consumption [i.e., never, less than 1/month, 1-3 times/month, 1-6 times/week, daily] of different categories of alcoholic beverages [i.e., wine, beer, 469 470 cider, aperitif wine, cocktail/punch, aniseed alcohol, spirits] as well as the usual number of glasses). 471 The amount of alcohol will be computed by multiplying the frequency of consumption by the number 472 of glasses and alcohol content of each type of alcoholic beverage. The average daily alcohol intake over 473 the past 6 months (in g/day) will be computed by summing the amount of alcohol from each beverage.

475 **Determinants of Physical activity**

The 21-item self-administered questionnaire "Barriers to Being Active Quiz" will be used to qualitatively assess barriers to the regular practice of physical activity.⁷²

478 Uses, representations and motivation towards physical activity will be assessed within the study
 479 population using a self-administered questionnaire available online. Acceptability of connected
 480 devices and acceptability of therapeutic patient education will be assessed among participants
 481 randomised to the corresponding arms using a paper-based self-administered questionnaire. These
 482 questionnaires will be developed following the Unified Theory of Acceptance and Use of Technology

(UTAUT),⁷³ which is a specification of the Theory of Planned Behaviour⁷⁴ designed to explain and predict the probability of behaviour change among individuals faced with new technologies. The Theory of Planned Behaviour has been massively used during the last two decades to promote health behaviours such as physical activity. Besides, item wording will be based on the results of individual and collective interviews conducted for that purpose and designed to identify social representations⁷⁵ of health protection and physical activity incentive devices.

Compliance with interventions

Compliance with each intervention will be assessed at the 6-month evaluation only for patients randomized to the "connected device", "therapeutic patient education" and "combined" arms. Compliance will be assessed by the number of days of use of the activity tracker, the participation rate in scheduled exercise sessions, the participation rate in scheduled therapeutic education sessions and the proportion of compliant patients, depending on the intervention allocated, following the recommendations of the protocol. Patients' compliance and reasons for non-compliance during the intervention period (6 months) will be described for each arm.

499 Biological assessments

A non-fasting blood sample (one 10-ml EDTA tube and one 10-ml dry tube) will be collected at
baseline and 6 months. In particular, blood will be drawn at baseline before the onset of adjuvant
treatments, otherwise no blood samples will be collected. The following biological factors will be
assessed in the blood samples: circulating serum levels of endocrine factors (IGF-1, insulin, estradiol),
circulating plasma levels of inflammatory cytokines (IL-6, TNFα, CRP), circulating plasma levels of
adipokines (adiponectin, leptin) and vitamin D status.

5 506

507 STUDY OUTCOMES

Page 23 of 50

1

BMJ Open

2 3 4	508	The primary endpoint will be the proportion of women who achieve at 6 months the internationally
5 6	509	recommended level of physical activity (at least 150 min/week of moderate-to-vigorous physical
7 8	510	activity, i.e., intensity \geq 3 METs) assessed by the RPAQ self-administered questionnaire.
9 10 11 12 13 14 15 16 17 18 19	511	Secondary endpoints will be:
	512	1. Assessment of the efficacy of the programs at 12 months (i.e., the proportion of women who achieve
	513	the internationally recommended level of physical activity);
	514	2. Assessment of the adherence to the interventions at 6 months (the proportion of participants who
	515	are compliant to the program, participation rate in planned sessions);
20 21 22	516	3. Assessment of the impact between baseline and 6 months and between 6–12 months of the
23 24	517	interventions on physical activity profile (changes in time spent in different intensities of physical
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40	518	activity and time spent in sedentary activities), physical fitness (changes in results to the 6-minute walk
	519	test, hand-grip test, sit-to-stand test, sit-and-reach flexibility test and single-leg stance test),
	520	anthropometrics (changes in weight, waist and hip circumferences, BMI, fat mass, lean body mass,
	521	muscle mass, dry lean mass and body water), quality of life (changes in scores obtained from the EORTC
	522	QLQ-C30 questionnaire and its BR-23 module), fatigue condition (changes in scores obtained from the
	523	PFS-12 questionnaire), health-related quality of life (changes in scores obtained from the EQ-5D-5L
	524	questionnaire), social deprivation (changes in scores obtained from the EPICES self-administered
41 42	525	questionnaire), occupational status (the proportion of participants who changed their employment
43 44	526	status, with return to work and who perceived difficulty at work obtained from a self-administered
45 46	527	questionnaire) and lifestyle factors (the proportion of participants who change their tobacco use and
47 48 49	528	alcohol intake obtained from a self-administered questionnaire).
50 51	529	4. Assessment of the impact of the interventions on biological parameters between baseline and
52 53	530	6 months (changes in serum circulating levels of endocrine factors [insulin, IGF1, estradiol], changes in
54 55 56	531	plasma circulating levels of cytokines [inflammatory cytokines: IL-6, TNF, and CRP; adipokines:
57 58 59 60	532	adiponectin and leptin], the proportion of participants with a modification on vitamin D status).

> 5. Assessment of the representations and acceptability of activity tracker and therapeutic patient education, at baseline, 6 and 12 months (proportions of participants who accept the connected device and who accept the therapeutic program, according to scores obtained from a self-administered gualitative questionnaire used in social psychology science).

537 6. Assessment of refusal rate among eligible patients (the proportion of patients who refuse to538 participate).

539 7. Assessment of the cost-utility and the cost-effectiveness of implementing each intervention at
540 12 months, using clinical data (treatments received, patients' diary on medical consultations), hospital
541 costs (national data) and benefit in physical activity level.

543 STATISTICAL ANALYSIS

544 Sample size determination

The efficacy rate assumptions are μ =40 %, μ + μ A=55 % and μ + μ B=65 % for the "control", "therapeutic patient education" and "connected device" arm modalities, respectively. The expected benefit in the "therapeutic patient education" arm compared to the "control" arm is 15% (40% efficacy in the "control" arm versus 55% efficacy in the "therapeutic patient education" arm). The expected benefit in the "connected device" arm compared to the "control" arm is 25% (40% efficacy in the second device" arm versus 55% efficacy in the "control" arm is 25% (40% efficacy in the "control" arm versus 65% efficacy in the "connected device" arm).²³

The sample size is calculated to allow the two comparisons of interest to be tested bilaterally at the threshold of 0.025. Assuming that the "therapeutic patient education" intervention and the "connected device" intervention act independently (additive model), the sample size required to compare therapeutic patient education (i.e., participants assigned to the "therapeutic patient education" and "combined" arms) versus no therapeutic patient education (i.e., participants assigned to the "control" and "connected device" arms) is given by the following formula:

57 557 [μ + (μ+μΒ)] / 2, versus [(μ+μΑ) + (μ + μΑ + μΒ)/2]

⁵⁹ 558 that is, (40 % + 65 %) / 2 = 52,5 %, versus (55 % + 80 %) / 2 = 67,5 %

Page 25 of 50

564

1

BMJ Open

2	
3	
4	
5	
6	
7	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
19	
20	
21	
22	
23	
24	
25	
26	
27	
28	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
52	
54	
55	
56	
57	
58	
59	

559 With a first species risk α =0.025 and a power of 80% in the bilateral situation, the number of 560 patients to include per treatment arm to demonstrate the efficacy of the therapeutic patient education 561 will be 108 (or 432 for the four treatment arms) (nQuery V6.0, Chi-two test with continuity correction). 562 This number of patients will also allow a power greater than 95% to evaluate the efficacy of the 563 "connected device" intervention, always with a risk α = 0.025 in the bilateral situation.

565 Data analysis plan

The following populations will be defined for statistical analyses: i) the intent-to-treat (ITT) population, which includes all randomised participants in the study; ii) the per-protocol population, which consists of a subgroup of participants from the ITT population, who has no major protocol violations and who follows the procedure for the duration of the study. Analyses in the ITT population will be performed for all the study endpoints; analyses in the per-protocol population will be performed for exploratory purposes. The randomisation date will be considered as the reference date in all delay calculations, unless any other way is specified.

573 Baseline data will be described in the ITT population and presented by randomised arms. For the primary outcome, proportions will be estimated for the two targeted comparisons: (i) participants who 574 575 received the connected device vs. participants who did not; (ii) participants who benefited from the 576 therapeutic patient education intervention vs. participants who did not. Results will be presented with 577 their 95% confidence interval. The use of a 2x2 factorial design will allow to test, respectively: the 578 efficacy of the intervention with a connected device (compared to without a connected device); the 579 efficacy of the therapeutic patient education intervention (compared to no therapeutic patient 580 education); and the interest of two combined intervention modalities (i.e., connected device and 581 therapeutic patient education) compared to the single intervention with the connected device only or 582 with therapeutic patient education only. The analysis strategy will therefore be as follows:⁷⁶ 583 1) searching first for an interaction by a specific interaction test, performed at the significance level of 584 0.05 (Chi-square test or use of an interaction term in a logistic model); 2) in the absence of interaction, 60

> testing each of the two bilateral interest comparisons at the threshold of 0.025, namely the efficacy of the intervention with the connected device and the efficacy of the therapeutic patient education intervention; 3) in case of the efficacy of either one of the intervention modalities, evaluating the interest of the combination of the two interventions compared to the single intervention with the connected device only or with therapeutic patient education only.

For secondary outcome variables, the efficacy of the program at 12 months, as well as according to stratification criteria, will be analysed similarly to the primary outcome. The adherence to the interventions will be evaluated by the proportion of compliant participants and participation rate in planned sessions. Changes in physical activity profile, physical fitness, anthropometrics, quality of life, fatigue, social deprivation and biological parameters will be analysed by the absolute and/or relative variations in each of these endpoints; these variations will be compared between with and without each intervention, for each intervention, and between combined interventions and the single one, using a parametric test. Occupational status and lifestyle factors will be analysed by comparing the proportion of participants between interventions or their combination. Representations and acceptability of activity tracker and therapeutic patient education will be analysed by comparing the proportion of participants between randomisation and follow-up assessments. A method for imputing missing data will be considered if necessary.

602 Statistical analyses will be performed using SAS[®] software version 9.4 or later.

604 Medico-economic analysis

8605The cost-effectiveness analysis will be conducted alongside the trial using the French national0606health insurance perspective. Quantities of resources used [external consultations, hospital stays2607including Diagnosis-related groups, drugs with extra payments and other healthcare-related costs] will4608be collected on the eCRF and multiplied by the respective unit costs. The intervention with therapeutic609patient education and the intervention with connected device will be evaluated using a bottom-up9610micro-costing approach.^{77,78} Using the Diagnosis-related group, hospital stays will be evaluated based

Page 27 of 50

BMJ Open

on the French National hospital costs study database. External consultations and wider examinations, community care (general practitioner visits, nurse visits, etc.) will be valued on the basis of the General Nomenclature of Professional Treatments (NGAP, "Nomenclature Générale des Actes Professionnels"). The cost of biological treatments will be estimated using the Nomenclature of Biological Medical Treatments (NABM, "Nomenclature des Actes de Biologie Médicale"). The cost of technical treatments (e.g., imaging) will be estimated using the Common Classification of Medical Treatments (CCAM, "Classification Commune des Actes Médicaux"). Acquisition costs for the most expansive drugs will be based on the list of common units of dispensation for supplementary medicines ("liste des unités communes de dispensation prise en charge en sus"). Finally, costs of medical transport will be derived from the French Court of Audit's report on medical transport expenses covered by the French National Health insurance. The time horizon will be 12 months. Hence, neither costs nor effectiveness will be discounted. Mean costs and effectiveness will be derived for all four strategies under consideration: connected device, therapeutic patient education, combined and control arms. Incremental Cost-Effectiveness Ratios (ICERs) will be expressed in cost per quality-adjusted life year (QALY) gained using EQ-5D-5L to estimate utility, cost per life year gained, cost per BMI unit lost and cost per centimetre of waist-to-hip circumference lost. One-way sensitivity analyses will be conducted by varying resource consumption and unit cost parameters and graphically illustrated in a Tornado diagram. The uncertainty surrounding the ICERs will be also captured by a probabilistic analysis using non-parametric bootstrap methods as recommended by the French National Authority for Health.⁷⁹

8 631

⁾ 632 **ADVERSE EVENTS**

All participants will continuously report the occurrence of adverse events regarding neuropathies and joint pain in their patient's notebook, which will be collected at 6 and 12 months. Those equipped with the connected device will also report potential adverse events before and after each session of their exercise program (see *Connected device*). Due to the low risks associated with the interventions,¹⁶

637 this study is part of the so-called "intervention research with minimal risks and constraints" in the
638 French legislation and therefore only these adverse events arising within the framework of the study
639 will be reported.

640 In the occurrence of an adverse event regarding neuropathies and joint pain, the principal 641 investigator will report it to the health authorities responsible for vigilance without delay. The 642 promotor will also report the adverse events, as well as any safety measures to be proposed, to the 643 French Ethics Committee and the investigators without delay.

645 DATA MANAGEMENT

The database for clinical data and randomisation will be created using EnnovClinical® software. Its access will be secured (personal identification and password protection) for maintaining confidentiality at all times. Individual participants will not be identified in any reports of this trial. All data from the connected device will be merged to the clinical database at the end of the study. Investigators and data analysts will have access to the final dataset.

Data monitoring will be provided by the trial steering committee, including overall project supervision, progress monitoring, advice on scientific credibility, and ensuring the integrity and appropriate running of the project. The clinical research assistant will verify all consent forms, compliance with established protocol and procedures, and data quality in the eCRF. The research team will make biannual reports to the trial steering committee.

46 656

657 PATIENT AND PUBLIC INVOLVEMENT

An association of breast cancer patients' representatives (Europa Donna France, http://www.europadonna.fr/) was involved in preparing the conduct of interventions and evaluations, in particular by considering patients' expectations, experience and desire for global care. The association will be involved in plans to disseminate the study results to breast cancer patients, study participants and wider patient communities concerned.

1		
2 3 4	663	
5 6	664	ETHICS AND DISSEMINATION
7 8 9 10 11 12 13 14 15	665	The study protocol was approved by the French ethics committee (Comité de Protection des
	666	Personnes Est I, ID RCB 2017-A03360-53, 1^{st} February 2018) and its database was reported to the
	667	French National Commission for Data Protection and Liberties (CNIL, ref. MR-001 no. 2016177, 13^{th}
	668	December 2016). Substantial protocol modifications will be submitted to the ethics committee for
16 17	669	approval and protocol amendment. The trial has been prospectively registered on
18 19 20	670	http://www.ClinicalTrials.gov (NCT number: NCT03529383, 17 th May 2018).
20 21 22	671	The study findings will be widely disseminated through the clinical community by publications in
23 24	672	international, peer-reviewed journals and by presentations at national and international conferences.
25 26	673	They will also be communicated to patients through associations of patients' representatives and
27 28 29	674	science-based information websites. They will be useful for improving the clinical care of cancer
30 31	675	patients and providing useful information for implementing exercise programs for cancer patients to
32 33	676	health professionals, institutions and public authorities. The study sponsors will disseminate the study
34 35	677	findings to their stakeholders.
36 37 38	678	
39 40	679	DISCUSSION
41 42	680	This article presents the protocol for the DISCO trial, which aims to evaluate the efficacy of a web-
43 44	681	and mobile-based connected device intervention and of a therapeutic patient education intervention,
45 46 47	682	either single or combined, on the physical activity levels of breast cancer patients undergoing adjuvant
48 49	683	treatment, as well as to assess the cost-effectiveness of the interventions. This multicentre study
50 51	684	opened in May 2018 and recruitment is expected to end in Summer 2021. In the short term, the
52 53	685	expected results are to develop the autonomy of breast cancer patients in their practice of physical
54 55 56	686	activity, as well as to identify the best strategies of physical activity during breast cancer adjuvant
57 58	687	treatments to increase and sustain physical activity levels in patients, overall or in specific subgroups
59 60	688	according to BMI, baseline physical activity level and type of adjuvant treatment. In the medium term,

the goal of the DISCO trial is to disseminate innovative programs in supportive cancer care, based on
 scientific evidence, to systematically integrate exercise in breast cancer cares.

While an increasing number of studies have demonstrated the benefits of exercise in breast cancer patients, the routine implementation in the cancer care process lacks behind evidence and practice guidelines.^{80–82} While the prescription of physical activity in supervised programs has been shown superior compared to non-supervised programs,^{22,83} semi-supervised interventions seem to yield comparable or superior benefits to supervised programs.⁸⁴ Therefore, the semi-supervised exercise program of the DISCO trial through continuous follow-up has been designed according to the preferences of women with breast cancer so as not to leave patients in total autonomy.^{36,85} Connected devices are tools developed over the last 10 years that are very promising for promoting physical activity in the general population and in patients with chronic diseases such as cancer^{86,87} and for developing distance-based physical activity interventions.⁸⁸

The semi-supervised home-based physical activity program of the DISCO trial using the connected device provides flexibility to patients that may facilitate adherence and to overcome barriers due to distance of facilities from women's home and spatial inequalities of access.²⁷ Connected devices allow proposing a tailored physical activity program to patients regardless of their place of residence, and enable patients to practice physical activities of their choice, at any time that suits them. Therefore, they may reduce geographical and organisational barriers in the access of patients to exercise, a key issue to improve their engagement in regular and sustained physical activity.²⁷ Previous studies in oncology have reported that the use of mobile devices has benefits to overcome motivational barriers to physical activity, which can help patients staying physically active over the medium and long term.^{89,90} Moreover, some studies have shown that breast cancer patients achieved higher fitness levels during supervised training compared to unsupervised training, even low and medium levels of supervision have been effective, as less resource-intensive options for effective and longer-term behaviour change strategies based on exercises in cancer patients and survivors.^{84,91}

BMJ Open

Activity trackers have become increasingly popular in recent years. Patients have reported positive feedback on using activity trackers such as pleasant to wear, easy to use and a strong motivational role through the real-time display of daily number of steps.⁹² Also, walking is an inexpensive activity that can be performed anywhere and does not require specific skills. A study on preferences for technologysupported interventions in breast cancer survivors has reported that 63% would like to use a physical activity mobile application and 90% would find a physical activity tracker useful to monitor and increase physical activity.³⁵

Despite the potential benefits of connected devices in cancer care, their use may face several important issues. First, ethical challenges related to the security of sensitive data storage have been raised.⁹³ To ensure that data transfer and storage guarantee informational privacy and patient safety,⁹⁴ an activity tracker made in France (i.e., allowing storing health data only in France) and an accredited national health data host were chosen for the DISCO trial. Particularly, ensuring medical data security is a reassuring choice for patients to participate in this new kind of medical research. Second, technical challenges have been raised, related to technological robustness, reliability of data collection and processing, and ease of use. Therefore, an activity tracker with a step display on the screen, a user-friendly interface, good reliability and a good price-performance ratio was chosen in the DISCO trial. Third, connected devices may create or exacerbate access disparities related to technological literacy and economic means, as well as reliable access to the internet in rural or isolated areas.⁹³ Fourth, medical reasons are usually not easy to control in patients' adherence to exercise programs. Reliance upon self-assessment of the participant's fatigue, evaluation of the participant before and after each session on the remote monitoring, up as the source of information about the participant's health, can result in the ignorance of aspects of the participant's health that cannot easily be monitored.⁹³

52
53736Therapeutic patient education has been suggested to increase physical activity level in patients with54
55737chronic diseases⁴⁶ and to improve multiple health outcomes, together with behavioural interventions56
57738including physical activity.⁹⁵ Therapeutic patient education interventions might be promising for58
59739promoting a physically active lifestyle in cancer patients as it helps patients establish lifestyle changes

and reinforce self-management.⁹⁵ Therapeutic patient education differs from traditional patient education in its intrinsic structure. Traditional patient education is directed towards informing and teaching patients how to manage their condition or disease. In contrast, therapeutic patient education differs from traditional patient education in the self-management conferred on the patient.⁴⁰ Therefore, therapeutic patient education is more broadly directed towards how the patient accepts his/her condition and manages his/her problems on a daily basis and the impact of the disease on personal, family, professional and social life. Yet, in oncology, few therapeutic patient education studies targeting pain, fatigue, toxicities or treatment adherence are ongoing, and evaluations are rarely conducted.⁴¹ To our knowledge, only one program of therapeutic patient education specific to physical activity has been evaluated in cancer patients.⁴⁵ However, a recent qualitative study has shown the value of therapeutic patient education on the attitudes towards the physical activity of women with breast cancer to promote regular exercise, which is a guarantee of a better quality of life.96

In order to evaluate the efficacy of two interventions in the DISCO trial, the primary outcome measure will be based on the physical activity level of the participants with or without interventions compared to international recommendations. The RPAQ questionnaire will be used for the primary outcome measure on account of its easy implementation. The authors acknowledge that this declarative evaluation confers methodological limits to the study. But the RPAQ questionnaire has been validated against objective methods (i.e., combined accelerometry and heart rate monitoring)⁶⁷ to evaluate moderate-to-vigorous physical activities, which is relevant for the primary outcome. No objective measures of physical activity have been planned because of organisational and logistic difficulties to equip and follow participants for one week (i.e., the usual duration of monitoring with an accelerometer such as Actigraph[™]).⁹⁷ Such a test would even be particularly overwhelming for cancer patients during the demanding period of adjuvant treatment onset. Additionally, the number of daily steps reported by the activity tracker was not chosen as the primary outcome because the activity tracker used in the study was not validated for monitoring physical activity in research or for

BMJ Open

medical purposes when the study was designed, although its reliability was evaluated against other
 devices (data not shown). However, recently the performance and reliability of smart devices tend to
 be increasingly validated.⁹⁸

To understand the results of the DISCO clinical study, it is essential to study beliefs about connected devices and their appropriation by the patients, particularly to understand why behaviours of the patients tend to fade over time. In therapeutic education, beliefs and representations are essential to the success of the intervention. Moreover, with the connected devices, only technical dimensions are not sufficient to understand and highlight why individuals adopt or misuse the connected devices.^{73,74} There is still limited evidence or contrasting conclusions surrounding the cost-effectiveness of interventions promoting physical activity among women with breast cancer from studies conducted in France, the Netherland and Australia.^{99–104} In various chronic conditions other than cancer, there is now clear evidence in favour of exercise-based programs for the treatment of various chronic conditions such as musculoskeletal, rheumatologic disorders, and cardiovascular diseases.¹⁰⁵ As more research is needed to evaluate the cost-effectiveness of physical activity in the treatment of cancers, particularly breast cancer, the economic evaluation planned in the DISCO trial will fill in the gap by adding useful information.

In conclusion, the study findings will provide valuable information on the efficacy of exercise
 interventions during breast cancer treatments, overcoming current barriers of access to facilities. They
 will further guide the development of evidence-based innovative interventions, to systematically
 include physical activity in the breast cancer care process. Finally, the economic evaluation planned in
 the DISCO trial will provide useful information for decision-makers.

Supplementary file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol.
 Supplementary file 2: English language example of the patient consent

1 2		
3 4	791	Abbreviations
5 6	792	BMI: body mass index;
7 8	793	eCRF: electronic case report form;
9 10 11	794	EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality-Of-Life
12 13	795	Questionnaire;
14 15	796	EPICES: Evaluation of Deprivation and Inequalities in Health Examination Centres (questionnaire);
16 17	797	ITT: intent-to-treat;
18 19	798	MET: metabolic equivalent of task;
20 21 22	799	PFS-12: Piper Fatigue Scale-12;
23 24	800	RPAQ: Recent Physical Activity Questionnaire;
25 26 27 28 29 30 31 32 33 34 35 36 37	801	WHO: World Health Organization;
	802	6MWT: six-minute walk test.
	803	
	804	Acknowledgments
	805	The authors are thanksful to Romain Buono, Meyssane Djebali, Carmen Dupuis, Stephany Fiore, Emilie
	806	Rémir, Cécile Dalban, Antonin Poullet, Renaud Meyrand, Rodolf Mongondry, Magali Dubois, Solène
38 39 40	807	Poirey, Valentine Bertollin, Amélie Dupré, Apolline Michel, Axel Lion, Magalie Hureau and Morgane
40 41 42	808	Sejallon for their contribution to the conduct of the DISCO trial at the Léon Bérard cancer centre. The
43 44	809	authors are also grateful to Mrs Françoise Picard from Europa Donna France, association of breast
45 46	810	cancer patients' representatives, for her active participation, advice and support in the DISCO trial, and
47 48 49	811	to Dr Hwayoung Noh for English editing.
50 51	812	
52 53	813	Authors' contributions
54 55	814	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the
56 57 58	815	research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological
58 59 60	816	aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise
		32

BMJ Open

2				
3 4	817	training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and		
5 6	818	AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational		
7 8	819	status. All authors were involved in in planning the methods and measurement and a priori analysis		
9 10 11	820	planning. MT and BFo wrote the initial draft of the manuscript. All authors reviewed and provided		
12 13	821	comprehensive contribution to the manuscript, and approved the final manuscript.		
14 15	822			
16 17 18	823	Funding		
19 20	824	The DISCO trial is financially supported by the "Fondation ARC pour la Recherche sur le Cancer" and		
21 22	825	the French National Cancer Institute ("Institut National du Cancer") (grant no. PREV201601260), the		
23 24 25	826	Foundation for Medical Research ("Fondation pour la Recherche Médicale", grant no.		
25 26 27	827	DOC20161136212), "Métropole de Lyon / Cancéropôle Lyon Auvergne Rhône-Alpes" (CLARA) (grant		
28 29	828	no. 2016 Projet Structurant) and AG2R La Mondiale.		
30 31	829			
32 33	830	Competing interests		
34 35 36	831	None declared.		
37 38	832	Competing interests None declared. Ethics approval		
39 40	833	Ethics approval		
41 42	834	Ethics approval was provided by the French Ethics Committee (Comité de Protection des Personnes		
43				
44 45	835	Est I).		
45 46	835 836	Est I).		
45		Est I). References		
45 46 47 48	836 837	References		
45 46 47 48 49	836 837 838	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: 		
45 46 47 48 49 50 51 52 53	836 837	References		
45 46 47 48 49 50 51 52 53 54	836 837 838 839 840	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i>. 2018;68(6):394-424. doi:10.3322/caac.21492 		
45 46 47 48 49 50 51 52 53 54 55	836 837 838 839 840 841	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin.</i> 2018;68(6):394-424. doi:10.3322/caac.21492 2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. <i>Estimations nationales de l'incidence et de la</i> 		
45 46 47 48 49 50 51 52 53 54 55 56	836 837 838 839 840 841 841 842	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i>. 2018;68(6):394-424. doi:10.3322/caac.21492 2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. <i>Estimations nationales de l'incidence et de la</i> <i>mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres</i> 		
45 46 47 48 49 50 51 52 53 54 55 56 57	836 837 838 839 840 841 842 843	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i>. 2018;68(6):394-424. doi:10.3322/caac.21492 2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. <i>Estimations nationales de l'incidence et de la</i> <i>mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres</i> <i>des cancers du réseau Francim. Synthèse</i>. Santé publique France; 2019:20. https://www.e- 		
45 46 47 48 49 50 51 52 53 54 55 56 57 58	836 837 838 839 840 841 842 843 844	 References Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i>. 2018;68(6):394-424. doi:10.3322/caac.21492 Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. <i>Estimations nationales de l'incidence et de la mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres des cancers du réseau Francim. Synthèse</i>. Santé publique France; 2019:20. https://www.e-cancer.fr/content/download/266450/3759432/file/Synthese_Estimations%20nationales%20in 		
45 46 47 48 49 50 51 52 53 54 55 56 57	836 837 838 839 840 841 842 843	 References 1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. <i>CA Cancer J Clin</i>. 2018;68(6):394-424. doi:10.3322/caac.21492 2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. <i>Estimations nationales de l'incidence et de la</i> <i>mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres</i> <i>des cancers du réseau Francim. Synthèse.</i> Santé publique France; 2019:20. https://www.e- 		

1 2			
3 4 5 6	846 847 848	3.	Cowppli-Bony A, Uhry Z, Remontet L, et al. Survival of solid cancer patients in France, 1989-2013: a population-based study. <i>Eur J Cancer Prev</i> . 2017;26(6):461-468. doi:10.1097/CEJ.0000000000000372
7 8 9 10 11	849 850 851 852	4.	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000- 14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> . 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
12 13 14 15 16	853 854 855	5.	Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. <i>Int J Cancer</i> . 2013;132(10):2404-2412. doi:10.1002/ijc.27895
17 18 19	856 857	6.	Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. <i>Cancer</i> . 2012;118(8 Suppl):2261-2269. doi:10.1002/cncr.27475
20 21 22 23 24	858 859 860	7.	Makari-Judson G, Braun B, Jerry DJ, Mertens WC. Weight gain following breast cancer diagnosis: Implication and proposed mechanisms. <i>World J Clin Oncol</i> . 2014;5(3):272-282. doi:10.5306/wjco.v5.i3.272
25 26 27 28	861 862 863	8.	Galizia D, Milani A, Geuna E, et al. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Med</i> . 2018;7(9):4339-4344. doi:10.1002/cam4.1687
29 30 31 32	864 865 866	9.	Foucaut A-M, Berthouze SE, Touillaud M, et al. Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. <i>Cancer Nurs</i> . 2015;38(4):E1- 9. doi:10.1097/NCC.000000000000187
33 34 35 36 37	867 868 869	10.	Møller T, Andersen C, Lillelund C, et al. Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. <i>Sci Rep</i> . 2020;10(1):9710. doi:10.1038/s41598-020-66513-9
38 39 40 41	870 871 872	11.	World Health Organization. <i>Global Recommendations on Physical Activity for Health</i> . World Health Organization; 2011:60. http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf
42 43 44 45	873 874 875	12.	Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. <i>Ann Oncol</i> . 2014;25(10):1901-1914. doi:10.1093/annonc/mdu042
46 47 48 49 50	876 877 878	13.	Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. <i>J Natl Cancer</i> <i>Inst</i> . 2015;107(12):djv275. doi:10.1093/jnci/djv275
50 51 52 53 54	879 880 881	14.	McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. <i>Med Sci Sports Exerc</i> . 2019;51(6):1252-1261. doi:10.1249/MSS.0000000000001937
55 56 57 58 59 60	882 883 884	15.	WCRF/AICR. <i>Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. The Third Expert Report</i> . World Cancer Research Fund International/American Institute for Cancer Research; 2018. https://www.wcrf.org/dietandcancer

2			
3	885	16.	Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in
4	886		patients with advanced cancer: a systematic review. Support Care Cancer. 2017;25(10):3031-
5 6	887		3050. doi:10.1007/s00520-017-3827-0
7			
8	888	17.	Juvet LK, Thune I, Elvsaas IKØ, et al. The effect of exercise on fatigue and physical functioning
9	889		in breast cancer patients during and after treatment and at 6 months follow-up: A meta-
10	890		analysis. <i>Breast</i> . 2017;33:166-177. doi:10.1016/j.breast.2017.04.003
11			
12	891	18.	Lipsett A, Barrett S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant
13	892		radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-
14	893		analysis. Breast. 2017;32:144-155. doi:10.1016/j.breast.2017.02.002
15 16			
17	894	19.	Coughlin SS, Caplan LS, Williams V. Home-based physical activity interventions for breast
18	895		cancer patients receiving primary therapy: a systematic review. Breast Cancer Res Treat.
19	896		2019;178(3):513-522. doi:10.1007/s10549-019-05424-4
20	~~~	•	
21	897	20.	Kang D-W, Lee E-Y, An KY, Min J, Jeon JY, Courneya KS. Associations between physical activity
22	898		and comorbidities in Korean cancer survivors. <i>J Cancer Surviv</i> . 2018;12(4):441-449.
23	899		doi:10.1007/s11764-018-0683-y
24	000	24	Zene V. Husene M. Change ACK Zhan V. Ca MUKAI Master anglusis of the offerte of evention
25 26	900	21.	Zeng Y, Huang M, Cheng ASK, Zhou Y, So WKW. Meta-analysis of the effects of exercise
20 27	901		intervention on quality of life in breast cancer survivors. <i>Breast Cancer</i> . 2014;21(3):262-274.
28	902		doi:10.1007/s12282-014-0521-7
29	903	22.	Buffart LM, Kalter J, Sweegers MG, et al. Effects and moderators of exercise on quality of life
30	904	22.	and physical function in patients with cancer: An individual patient data meta-analysis of 34
31	905		RCTs. <i>Cancer Treat Rev.</i> 2017;52:91-104. doi:10.1016/j.ctrv.2016.11.010
32	903		KC13. Cuncer Treat Nev. 2017, 52.51-104. 001.10.1010/j.ctiv.2010.11.010
33 34	906	23.	Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and
54 35	907		recurrence in breast cancer survivors: A systematic review and meta-analysis of
36	908		epidemiological studies. <i>Acta Oncol</i> . 2015;54(5):635-654. doi:10.3109/0284186X.2014.998275
37	500		
38	909	24.	Friedenreich CM, Stone CR, Cheung WY, Hayes SC. Physical Activity and Mortality in Cancer
39	910		Survivors: A Systematic Review and Meta-Analysis. JNCI Cancer Spectr. 2020;4(1):pkz080.
40	911		doi:10.1093/jncics/pkz080
41			
42	912	25.	Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical Activity and Cancer Outcomes:
43 44	913		A Precision Medicine Approach. Clinical Cancer Research. 2016;22(19):4766-4775.
44 45	914		doi:10.1158/1078-0432.CCR-16-0067
46			
47	915	26.	Demark-Wahnefried W, Schmitz KH, Alfano CM, et al. Weight management and physical
48	916		activity throughout the cancer care continuum. CA Cancer J Clin. 2018;68(1):64-89.
49	917		doi:10.3322/caac.21441
50			
51	918	27.	Foucaut A-M, Morelle M, Kempf-Lépine A-S, et al. Feasibility of an exercise and nutritional
52	919		intervention for weight management during adjuvant treatment for localized breast cancer:
53	920		the PASAPAS randomized controlled trial. Support Care Cancer. 2019;27(9):3449-3461.
54 55	921		doi:10.1007/s00520-019-4658-y
55 56			
57	922	28.	Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people
58	923		living with and beyond cancer. Cochrane Database Syst Rev. 2018;9:CD010192.
59	924		doi:10.1002/14651858.CD010192.pub3
60			

3 4 5 6	925 926 927	29.	Lunde P, Nilsson BB, Bergland A, Kværner KJ, Bye A. The Effectiveness of Smartphone Apps for Lifestyle Improvement in Noncommunicable Diseases: Systematic Review and Meta-Analyses. <i>J Med Internet Res.</i> 2018;20(5):e162. doi:10.2196/jmir.9751
7 8 9 10 11	928 929 930	30.	Schaffer K, Panneerselvam N, Loh KP, et al. Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. <i>J Natl</i> <i>Compr Canc Netw</i> . 2019;17(1):57-63. doi:10.6004/jnccn.2018.7082
12 13 14 15	931 932 933	31.	Coughlin SS, Caplan LS, Stone R. Use of consumer wearable devices to promote physical activity among breast, prostate, and colorectal cancer survivors: a review of health intervention studies. <i>J Cancer Surviv</i> . 2020;14(3):386-392. doi:10.1007/s11764-020-00855-1
16 17 18 19	934 935 936	32.	Dorri S, Asadi F, Olfatbakhsh A, Kazemi A. A Systematic Review of Electronic Health (eHealth) interventions to improve physical activity in patients with breast cancer. <i>Breast Cancer</i> . 2020;27(1):25-46. doi:10.1007/s12282-019-00982-3
20 21 22 23	937 938	33.	Beg MS, Gupta A, Stewart T, Rethorst CD. Promise of Wearable Physical Activity Monitors in Oncology Practice. <i>J Oncol Pract</i> . 2017;13(2):82-89. doi:10.1200/JOP.2016.016857
23 24 25 26	939 940	34.	Schinköthe T. Individualized eHealth Support for Oncological Therapy Management. <i>Breast Care</i> . 2019;14(3):130-134. doi:10.1159/000500900
27 28 29 30	941 942 943	35.	Phillips SM, Conroy DE, Keadle SK, et al. Breast cancer survivors' preferences for technology- supported exercise interventions. <i>Support Care Cancer</i> . 2017;25(10):3243-3252. doi:10.1007/s00520-017-3735-3
31 32 33 34	944 945 946	36.	Phillips SM, Courneya KS, Welch WA, et al. Breast cancer survivors' preferences for mHealth physical activity interventions: findings from a mixed methods study. <i>J Cancer Surviv</i> . 2019;13(2):292-305. doi:10.1007/s11764-019-00751-3
35 36 37 38 39	947 948 949	37.	Nielsen AM, Welch WA, Gavin KL, et al. Preferences for mHealth physical activity interventions during chemotherapy for breast cancer: a qualitative evaluation. <i>Support Care Cancer</i> . 2020;28(4):1919-1928. doi:10.1007/s00520-019-05002-w
40 41 42	950 951	38.	Lacroix A, Assal J-P. L'éducation thérapeutique des patients: accompagner les patients avec une maladie chronique : nouvelles approches. 3rd ed.; 2011.
43 44 45	952 953	39.	Fabre S. Evaluating therapeutic patient education: Objectives and criteria. <i>Joint Bone Spine</i> . 2017;84(2):121-123. doi:10.1016/j.jbspin.2016.11.002
46 47 48 49 50 51	954 955 956 957	40.	World Health Organization. <i>Therapeutic Patient Education: Continuing Education Programmes</i> for Health Care Providers in the Field of Prevention of Chronic Diseases. Report of a WHO Working Group. World Health Organization, Regional Office for Europe; 1998:76. https://apps.who.int/iris/handle/10665/108151
52 53 54 55	958 959 960	41.	Buiret G, Chidiac F, Pujo K, Combe C. [How to reconcile therapeutic patient education and care pathology in oncology: Application in head and neck neoplams]. <i>Bull Cancer</i> . 2019;106(5):468-478. doi:10.1016/j.bulcan.2019.02.008
56 57 58 59 60	961 962 963	42.	Bourmaud A, Anota A, Moncharmont C, et al. Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study. <i>Br J Cancer</i> . 2017;116(7):849-858. doi:10.1038/bjc.2017.31

1 2			
3 4 5	964 965	43.	Pérol D, Toutenu P, Lefranc A, et al. [Therapeutic education in oncology: involving patient in the management of cancer]. <i>Bull Cancer</i> . 2007;94(3):267-274.
6 7 8 9 10 11	966 967 968 969	44.	Arthurs G, Simpson J, Brown A, Kyaw O, Shyrier S, Concert CM. The effectiveness of therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer patients in ambulatory care settings: a systematic review. <i>JBI Database System Rev Implement Rep</i> . 2015;13(5):244-292. doi:10.11124/jbisrir-2015-2057
12 13 14 15 16	970 971 972 973	45.	Carayol M, Delpierre C, Bernard P, Ninot G. Population-, intervention- and methodology- related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for breast cancer: a meta-regression analysis. <i>Psychooncology</i> . 2015;24(7):737-747. doi:10.1002/pon.3727
17 18 19 20	974 975 976	46.	Conn VS, Hafdahl AR, Brown SA, Brown LM. Meta-analysis of patient education interventions to increase physical activity among chronically ill adults. <i>Patient Educ Couns</i> . 2008;70(2):157-172. doi:10.1016/j.pec.2007.10.004
21 22 23 24 25 26	977 978 979 980	47.	Meneses-Echávez JF, Correa-Bautista JE, González-Jiménez E, et al. The Effect of Exercise Training on Mediators of Inflammation in Breast Cancer Survivors: A Systematic Review with Meta-analysis. <i>Cancer Epidemiol Biomarkers Prev</i> . 2016;25(7):1009-1017. doi:10.1158/1055- 9965.EPI-15-1061
27 28 29 30 31	981 982 983 984	48.	Kang D-W, Lee J, Suh S-H, Ligibel J, Courneya KS, Jeon JY. Effects of Exercise on Insulin, IGF Axis, Adipocytokines, and Inflammatory Markers in Breast Cancer Survivors: A Systematic Review and Meta-analysis. <i>Cancer Epidemiol Biomarkers Prev</i> . 2017;26(3):355-365. doi:10.1158/1055-9965.EPI-16-0602
32 33 34 35 36	985 986 987	49.	Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM. Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. <i>J</i> Natl Cancer Inst. 2012;104(11):815-840. doi:10.1093/jnci/djs207
37 38 39 40	988 989 990	50.	Patel AV, Friedenreich CM, Moore SC, et al. American College of Sports Medicine Roundtable Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. <i>Med Sci</i> <i>Sports Exerc</i> . 2019;51(11):2391-2402. doi:10.1249/MSS.000000000002117
41 42 43 44	991 992 993	51.	Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. <i>Nat Rev Cancer</i> . 2014;14(5):342-357. doi:10.1038/nrc3691
45 46 47 48 49 50 51 52	994 995 996 997 998 999	52.	Haute Autorité de Santé. <i>Recommandations professionnelles - Stratégie de prise en charge en cas de dénutrition protéino-énergétique chez la personne âgée [Professional recommendations - Management strategy in case of protein-energy malnutrition in the Elderly]</i> . Haute Autorité de Santé; 2007:25. https://www.has-sante.fr/upload/docs/application/pdf/denutrition_personne_agee_2007recommandations.pdf
53 54 55 56	1000 1001 1002	53.	Besson H, Brage S, Jakes RW, Ekelund U, Wareham NJ. Estimating physical activity energy expenditure, sedentary time, and physical activity intensity by self-report in adults. <i>Am J Clin Nutr</i> . 2010;91(1):106-114. doi:10.3945/ajcn.2009.28432
57 58 59 60	1003 1004	54.	Pocock SJ, Simon R. Sequential Treatment Assignment with Balancing for Prognostic Factors in the Controlled Clinical Trial. <i>Biometrics</i> . 1975;31(1):103-115. doi:10.2307/2529712

2			
3 4 5 6	1005 1006 1007	55.	Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials. a review. <i>Control Clin Trials</i> . 2002;23(6):662-674. doi:10.1016/s0197-2456(02)00242-8
7 8 9 10 11	1008 1009 1010	56.	Neil-Sztramko SE, Kirkham AA, Hung SH, Niksirat N, Nishikawa K, Campbell KL. Aerobic capacity and upper limb strength are reduced in women diagnosed with breast cancer: a systematic review. <i>J Physiother</i> . 2014;60(4):189-200. doi:10.1016/j.jphys.2014.09.005
11 12 13 14 15	1011 1012 1013	57.	Rikli RE, Jones CJ. Functional Fitness Normative Scores for Community-Residing Older Adults, Ages 60-94. <i>Journal of Aging and Physical Activity</i> . 1999;7(2):162-181. doi:10.1123/japa.7.2.162
16 17 18 19	1014 1015 1016	58.	Campbell KL, Neil SE, Winters-Stone KM. Review of exercise studies in breast cancer survivors: attention to principles of exercise training. <i>Br J Sports Med</i> . 2012;46(13):909-916. doi:10.1136/bjsports-2010-082719
20 21 22 23 24	1017 1018 1019	59.	Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. <i>J Cachexia Sarcopenia Muscle</i> . 2015;6(2):115-124. doi:10.1002/jcsm.12042
25 26 27 28	1020 1021 1022	60.	Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. <i>Med Sci Sports Exerc</i> . 2011;43(8):1575-1581. doi:10.1249/MSS.0b013e31821ece12
29 30 31 32	1023 1024 1025	61.	Fassier J-B, Durand M-J, Caillard J-F, Roquelaure Y, Loisel P. Results of a feasibility study: barriers and facilitators in implementing the Sherbrooke model in France. <i>Scand J Work</i> <i>Environ Health</i> . 2015;41(3):223-233. doi:10.5271/sjweh.3489
33 34 35 36	1026 1027	62.	Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. <i>Int J Sports Med</i> . 2013;34(7):631-636. doi:10.1055/s-0032-1323746
37 38 39 40	1028 1029 1030	63.	Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. <i>Res Q Exerc Sport</i> . 1999;70(2):113-119. doi:10.1080/02701367.1999.10608028
41 42 43 44 45	1031 1032 1033 1034	64.	Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodríguez L, Fernández-de-Las-Peñas C, Ruiz JR, Arroyo-Morales M. The handgrip strength test as a measure of function in breast cancer survivors: relationship to cancer-related symptoms and physical and physiologic parameters. <i>Am J Phys Med Rehabil</i> . 2012;91(9):774-782. doi:10.1097/PHM.0b013e31825f1538
46 47 48 49 50	1035 1036 1037	65.	Wells KF, Dillon EK. The Sit and Reach—A Test of Back and Leg Flexibility. <i>Research Quarterly American Association for Health, Physical Education and Recreation</i> . 1952;23(1):115-118. doi:10.1080/10671188.1952.10761965
50 51 52 53 54	1038 1039 1040	66.	Bohannon RW. Single Limb Stance Times: A Descriptive Meta-Analysis of Data From Individuals at Least 60 Years of Age. <i>Topics in Geriatric Rehabilitation</i> . 2006;22(1):70-77. doi:10.1097/00013614-200601000-00010
55 56 57 58 59 60	1041 1042 1043	67.	Golubic R, May AM, Benjaminsen Borch K, et al. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. <i>PLoS ONE</i> . 2014;9(3):e92829. doi:10.1371/journal.pone.0092829

1 2			
3 4 5 6	1044 1045 1046	68.	Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. <i>J Clin Oncol</i> . 1995;13(5):1249-1254. doi:10.1200/JCO.1995.13.5.1249
7 8 9 10	1047 1048 1049	69.	Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Qual Life Res</i> . 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4
11 12 13 14 15	1050 1051 1052	70.	Reeve BB, Stover AM, Alfano CM, et al. The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2012;136(1):9-20. doi:10.1007/s10549-012-2212-4
16 17 18	1053 1054	71.	Labbe E, Blanquet M, Gerbaud L, et al. A new reliable index to measure individual deprivation: the EPICES score. <i>Eur J Public Health</i> . 2015;25(4):604-609. doi:10.1093/eurpub/cku231
19 20 21 22 23	1055 1056 1057	72.	Centers for Disease Control and Prevention. Overcoming Barriers to Physical Activity: Barriers to Being Active Quiz-What keeps you from being more active? Published online 2007. https://www.cdc.gov/diabetes/ndep/pdfs/8-road-to-health-barriers-quiz-508.pdf
23 24 25 26	1058 1059	73.	Venkatesh, Morris, Davis, Davis. User Acceptance of Information Technology: Toward a Unified View. <i>MIS Quarterly</i> . 2003;27(3):425. doi:10.2307/30036540
27 28 29	1060 1061	74.	Ajzen I. The theory of planned behavior. <i>Organizational Behavior and Human Decision Processes</i> . 1991;50(2):179-211. doi:10.1016/0749-5978(91)90020-T
30 31 32 33 34	1062 1063 1064 1065	75.	Jodelet, D. Interconnections between social representations and intervention. In: <i>Social Representations in the "Social Arena."</i> A. De Rosa. Routledge; 2012:77-88. https://www.academia.edu/36160041/Jodelet_D2012Interconnections_between_social _representations_and_intervention
35 36 37 38	1066 1067	76.	Green S, Liu P-Y, O'Sullivan J. Factorial design considerations. <i>J Clin Oncol</i> . 2002;20(16):3424- 3430. doi:10.1200/JCO.2002.03.003
39 40 41	1068 1069	77.	Frick KD. Microcosting quantity data collection methods. <i>Med Care</i> . 2009;47(7 Suppl 1):S76-81. doi:10.1097/MLR.0b013e31819bc064
42 43 44 45	1070 1071 1072	78.	El Khal M, Perrier L, Carretier J, et al. [The cost of the therapeutic education program "Eat better, move more through nutrition education" in patients with breast cancer]. <i>Bull Cancer</i> . 2020;107(12):1252-1259. doi:10.1016/j.bulcan.2020.07.003
46 47 48 49 50 51	1073 1074 1075 1076	79.	Haute Autorité de Santé. <i>Guide méthodologique - Choix méthodologique pour l'évaluation économique à la HAS [Methodological guide - Methodological choices for economic evaluation at the National Health Authority</i>]. Haute Autorité de Santé; 2011:83. https://www.has-sante.fr/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
52 53 54	1077 1078	80.	Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. <i>CA Cancer J Clin</i> . 2012;62(4):243-274. doi:10.3322/caac.21142
55 56 57 58 59 60	1079 1080 1081	81.	Institut National du Cancer. <i>Plan cancer 2014-2019 : priorités et objectifs</i> . Institut National du Cancer; 2015:210. http://www.e-cancer.fr/Plan-cancer/Plan-cancer-2014-2019-priorites-et-objectifs

3 4 5	1082 1083	82.	Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. <i>Clin Nutr</i> . 2017;36(1):11-48. doi:10.1016/j.clnu.2016.07.015
6 7 8 9 10 11	1084 1085 1086 1087	83.	Sweegers MG, Altenburg TM, Chinapaw MJ, et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. <i>Br J Sports Med</i> . 2018;52(8):505-513. doi:10.1136/bjsports-2017-097891
12 13 14 15 16	1088 1089 1090 1091	84.	Bluethmann SM, Vernon SW, Gabriel KP, Murphy CC, Bartholomew LK. Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2015;149(2):331-342. doi:10.1007/s10549-014-3255-5
17 18 19 20	1092 1093 1094	85.	Delrieu L, Vallance JK, Morelle M, et al. Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>Eur J Cancer Care (Engl)</i> . 2020;29(1):e13169. doi:10.1111/ecc.13169
21 22 23 24 25	1095 1096 1097	86.	Quintiliani LM, Mann DM, Puputti M, Quinn E, Bowen DJ. Pilot and Feasibility Test of a Mobile Health-Supported Behavioral Counseling Intervention for Weight Management Among Breast Cancer Survivors. <i>JMIR Cancer</i> . 2016;2(1):e4. doi:10.2196/cancer.5305
26 27 28 29	1098 1099 1100	87.	Delrieu L, Pialoux V, Pérol O, et al. Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR Mhealth Uhealth</i> . 2020;8(1):e12306. doi:10.2196/12306
30 31 32 33 34	1101 1102 1103	88.	Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of distance- based physical activity interventions for cancer survivors (2013-2018): We still haven't found what we're looking for. <i>Cancer Treat Rev.</i> 2018;69:188-203. doi:10.1016/j.ctrv.2018.07.012
35 36 37 38	1104 1105 1106	89.	Cadmus-Bertram LA, Marcus BH, Patterson RE, Parker BA, Morey BL. Randomized Trial of a Fitbit-Based Physical Activity Intervention for Women. <i>Am J Prev Med</i> . 2015;49(3):414-418. doi:10.1016/j.amepre.2015.01.020
39 40 41 42	1107 1108 1109	90.	Lavallée JF, Abdin S, Faulkner J, Husted M. Barriers and facilitators to participating in physical activity for adults with breast cancer receiving adjuvant treatment: A qualitative metasynthesis. <i>Psychooncology</i> . 2019;28(3):468-476. doi:10.1002/pon.4980
43 44 45 46 47	1110 1111 1112	91.	Westphal T, Rinnerthaler G, Gampenrieder SP, et al. Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. <i>Cancer Med</i> . 2018;7(12):5962-5972. doi:10.1002/cam4.1851
48 49 50 51	1113 1114 1115	92.	O'Brien T, Troutman-Jordan M, Hathaway D, Armstrong S, Moore M. Acceptability of wristband activity trackers among community dwelling older adults. <i>Geriatr Nurs</i> . 2015;36(2 Suppl):S21-25. doi:10.1016/j.gerinurse.2015.02.019
52 53 54	1116 1117	93.	Ho A, Quick O. Leaving patients to their own devices? Smart technology, safety and therapeutic relationships. <i>BMC Med Ethics</i> . 2018;19(1):18. doi:10.1186/s12910-018-0255-8
55 56 57 58 59 60	1118 1119 1120	94.	European Union (EU), European Economic Area (EEA). General Data Protection Regulation (EU). Published online May 4, 2016. https://ec.europa.eu/info/law/law-topic/data-protection-rules_en

1			
2 3 4 5	1121 1122	95.	Lagger G, Pataky Z, Golay A. Efficacy of therapeutic patient education in chronic diseases and obesity. <i>Patient Educ Couns</i> . 2010;79(3):283-286. doi:10.1016/j.pec.2010.03.015
6 7 8 9 10 11	1123 1124 1125 1126	96.	Mino J-C, Lefève C. Improved understanding of the experience of physical activity after a cancer from a philosophy of health perspective [Mieux comprendre l'expérience de l'activité physique après un cancer grâce à la philosophie de la santé]. <i>Santé Publique</i> . 2016;28 Suppl 1:S101-107.
11 12 13 14 15	1127 1128 1129	97.	Peddle-McIntyre CJ, Cavalheri V, Boyle T, et al. A Review of Accelerometer-based Activity Monitoring in Cancer Survivorship Research. <i>Med Sci Sports Exerc</i> . 2018;50(9):1790-1801. doi:10.1249/MSS.0000000000001644
16 17 18 19	1130 1131 1132	98.	Degroote L, De Bourdeaudhuij I, Verloigne M, Poppe L, Crombez G. The Accuracy of Smart Devices for Measuring Physical Activity in Daily Life: Validation Study. <i>JMIR Mhealth Uhealth</i> . 2018;6(12):e10972. doi:10.2196/10972
20 21 22 23 24 25	1133 1134 1135 1136	99.	Mourgues C, Gerbaud L, Leger S, et al. Positive and cost-effectiveness effect of spa therapy on the resumption of occupational and non-occupational activities in women in breast cancer remission: a French multicentre randomised controlled trial. <i>Eur J Oncol Nurs</i> . 2014;18(5):505-511. doi:10.1016/j.ejon.2014.04.008
26 27 28 29	1137 1138 1139	100.	Mewes JC, Steuten LMG, Duijts SFA, et al. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. <i>J Cancer Surviv</i> . 2015;9(1):126-135. doi:10.1007/s11764-014-0396-9
30 31 32 33	1140 1141 1142	101.	Gordon LG, DiSipio T, Battistutta D, et al. Cost-effectiveness of a pragmatic exercise intervention for women with breast cancer: results from a randomized controlled trial. <i>Psychooncology</i> . 2017;26(5):649-655. doi:10.1002/pon.4201
34 35 36 37 38	1143 1144 1145	102.	van Waart H, van Dongen JM, van Harten WH, et al. Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>Eur J Health Econ</i> . 2018;19(6):893-904. doi:10.1007/s10198-017-0936-0
39 40 41 42 43	1146 1147 1148 1149	103.	Perrier L, Foucaut A-M, Morelle M, et al. Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Support Care Cancer</i> . 2020;28(6):2829-2842. doi:10.1007/s00520-019-05078-4
44 45 46 47 48	1150 1151 1152	104.	Khan KA, Mazuquin B, Canaway A, Petrou S, Bruce J. Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer. <i>Breast Cancer Res Treat</i> . 2019;176(1):37-52. doi:10.1007/s10549-019-05235-7
48 49 50 51 52 53 54 55 56 57 58 59 60	1153 1154 1155 1156 1157	105.	Guillon M, Rochaix L, Dupont J-CK. COST-EFFECTIVENESS OF INTERVENTIONS BASED ON PHYSICAL ACTIVITY IN THE TREATMENT OF CHRONIC CONDITIONS: A SYSTEMATIC LITERATURE REVIEW. <i>Int J Technol Assess Health Care</i> . 2018;34(5):481-497. doi:10.1017/S0266462318000533


ŀ	Assessments	Tools	Baseline +1month	6 months ±1month	12 month ±1month
Demographic an	d clinical data	Patient's medical record	·Inonth	THIOHU	±11101111
	ear of birth	Fatient's medical record	х		
A			X		
-	nent status		X	Х	х
	history of breast cancer			^	^
	treatment		X X	х	х
				^	Λ
	al receptor status		X		
	histology		Х	V	V
	progression			Х	Х
Anthropometric	s				
- Height		Gauge	Х		
- Weight		Scale	Х	Х	Х
	-hip circumference	Measuring tape	Х	Х	Х
•	nposition: fat mass, lean	Bioelectrical impedance	Х	Х	Х
mass, dr	y lean mass, body water	analysis			
Physical fitness			Х	Х	Х
•	endurance with perceived	6MWT and Borg scale			
difficulty	-				
	nb muscle strength	Sit-to-stand test			
	ehensile strength	Hand-grip test			
•	y of lower limbs	Sit-and-reach flexibility test			
- Balance		Single-leg stance test			
	level, sitting time and	RPAQ Questionnaire	Х	Х	Х
achievement of	_	NI AQ Questionnaire	Λ	Λ	Λ
recommendation					
Patient-reported					
- Quality c		EORTC QLQ-C30 questionnaire	х	Х	х
- Quality C	n me	and BR-23 module	^	~	Λ
Lloolth -	alated quality of life		v	v	v
	elated quality of life	EQ-5D-5L Questionnaire	X	X	X
- Fatigue		PFS-12 questionnaire	X	Х	X
	Inerability	EPICES questionnaire	Х		Х
	physical activity			.,	
	to regular physical activity;	Self-administered questionnaire	X	Х	Х
lifestyle					
	presentations and	Online self-administered	Х	Х	Х
	on of physical activity;	questionnaire			
•	oility of activity trackers				
	patients in the "connected				
device" a	and "combined" arms);				
acceptab	oility of therapeutic patient				
educatio	n (only for patients in the				
"therane	utic patient education" and				
therape	-				
"combin	eu annsj				
	eu anns,	Blood sample	Х	Х	
"combin Biological data	ndocrine factors (IGF-1,	Blood sample	Х	Х	

Table 1 Summary of outcome measures and data collection schedule for the DISCO trial

1 2						
3 4		Assessments	Tools	Baseline	6 months ±1month	12 months ±1month
5 6 7 8 9 10	1	 Plasmatic inflammatory cytokines (IL-6, TNFα, CRP) Plasmatic adipokines (adiponectin, leptin) Vitamin D status 		· inonci		
11 12 13 14	_	Compliance with each intervention (only for patients in the "connected device", "therapeutic patient education" and "combined" arms)	Connected device and/or patient's record		Х	
15 16	-	Adverse events (neuropathies, joint pain)	Patient's diary		Х	X
17	1159					
18 19 20 21 22 23	1160					
24 25 26 27						
28 29 30						
31 32 33 34						
35 36 37 38						
39 40 41 42						
43 44 45						
46 47 48 49						
50 51 52 53 54 55 56 57 58 59						
60						

1 2		
3	1161	Figure 1: Flow chart of participants through the DISCO trial.
4 5		
6 7		
8		
9 10		
11 12		
13		
14 15		
16		
17 18		
19 20		
21		
22 23		
24 25		
26		
27 28		
29 30		
31		
32 33		
34 35		
36		
37 38		
39		
40 41		
42 43		
44		
45 46		
47 48		
49		
50 51		
52 53		
54		
55 56		
57		
58 59		
60		

Page 47 of 50



	SP	IR	Т	$\overline{\mathbf{V}}$
Standard Protocol Items: Re	COMMENDA	TIONS FOR IN	TERVENTIO	NAL TRIALS

SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative info	ormation	O_r	
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2, 26
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	8, ethics copy
Funding	4	Sources and types of financial, material, and other support	30, funding copy
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 31-32
responsibilities	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	31
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	31

BMJ Open

1				
2 3 4 5	Introduction Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	7
6 7		6b	Explanation for choice of comparators	7
8 9	Objectives	7	Specific objectives or hypotheses	7
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8
14 15	Methods: Participa	nts, inte	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8-9
22 23 24	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9-15
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	12-13
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	13-14
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34 35 36 37 38	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	17, Table 1
39 40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9, 16-17, Figure1, Table1
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	22						
	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8						
5 7 8 9	Methods: Assignment of interventions (for controlled trials)									
	Allocation:									
) 1 2 3 4 5	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10						
5 7 3)	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10						
	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9-10						
	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A						
		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A						
	Methods: Data coll	ection,	management, and analysis							
	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	17-21						
;))		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17						
1 2 3 4 5			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	3						

Page 51 of 50

BMJ Open

1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	17, 24
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	23-24
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	10, 23-24
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	23-24
14 15	Methods: Monitorin	g		
16 17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	25
21 22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14, 24-25
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	25
31 32	Ethics and dissemi	nation		
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	2, 25-26, 32
37 38 39 40 41	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	26
42 43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	4

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	25
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	32
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	25
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	25-26
	31b	Authorship eligibility guidelines and any intended use of professional writers	31
	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
Appendices			
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	9, Suppl file 2
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	21
Amendments to the p	rotoco	I that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarifica I should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Co -NoDerivs 3.0 Unported" license.	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

Connected device and therapeutic patient education to promote physical activity among women with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised controlled trial

Journal:	BMJ Open
Manuscript ID	bmjopen-2020-045448.R2
Article Type:	Protocol
Date Submitted by the Author:	15-Jul-2021
Complete List of Authors:	Touillaud, Marina; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment" Fournier, Baptiste; Centre Léon Bérard, Department of Prevention Cancer Environment Pérol, Olivia; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment" Delrieu, Lidia; Centre Léon Bérard, Department of Prevention Cancer Environment; Université Claude Bernard Lyon 1, Inter-University Laboratory of Human Movement Biology EA7424 Maire, Aurélia; Centre Léon Bérard, Department of Prevention Cancer Environment Belladame, Elodie; Centre Léon Bérard, Department of Prevention Cancer Environment Pérol, David; Centre Léon Bérard, Department of Of Clinical Research and Innovation Perrier, Lionel; Centre Léon Bérard, Direction of Clinical Research and Innovation; GATE, UMR-CNRS 5824, University of Lyon Preau, Marie; Lumière University Lyon 2, GRePS EA4163 Institute of Psychology LEROY, Tanguy; Lumière University Lyon 2, GRePS EA4163 Institute of Psychology LEROY, Tanguy; Lumière University Lyon 2, GRePS EA4163 Institute of Psychology Pascal, Sébastien; Biomouv Durand, Thierry; Centre Léon Bérard, Department of Hospital Information Fervers, Béatrice; Centre Léon Bérard, Department of Prevention Cancer Environment; UMR1296, INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and Environment"
Primary Subject Heading :	Oncology
Secondary Subject Heading:	Sports and exercise medicine, Nutrition and metabolism, Health economics, Sociology

	1
Keywords:	Breast tumours < ONCOLOGY, SPORTS MEDICINE, MEDICAL EDUCATION & TRAINING
	SCHOLARONE [™]
	Manuscripts
For peer review	/ only - http://bmjopen.bmj.com/site/about/guidelines.xhtml



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our <u>licence</u>.

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which <u>Creative Commons</u> licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

review only

2		
3 4	1	Connected device and therapeutic patient education to promote physical activity among women
5 6	2	with localized breast cancer (DISCO trial): Protocol for a multicentre 2x2 factorial randomised
7 8	3	controlled trial
9 10 11	4	
12 13	5	Marina Touillaud ^{1,2} , Baptiste Fournier ¹ , Olivia Pérol ^{1,2} , Lidia Delrieu ^{1,3} , Aurélia Maire ¹ , Elodie
14 15	6	Belladame ¹ , David Pérol ⁴ , Lionel Perrier ^{4,5} , Marie Préau ⁶ , Tanguy Leroy ⁶ , Jean-Baptiste Fassier ⁷ , Florie
16 17 18	7	Fillol ⁸ , Sébastien Pascal ⁸ , Thierry Durand ⁹ , Béatrice Fervers ^{1,2}
19 20	8	
21 22	9	¹ Department of Prevention Cancer Environment, Léon Bérard Cancer Centre, Lyon, France
23 24	10	² UMR 1296 INSERM-Centre Léon Bérard-Ministère des Armées "Radiations: Defense, Health and
25 26 27	11	Environment", Léon Bérard Cancer Centre, Lyon, France
28 29	12	³ Inter-University Laboratory of Human Movement Biology EA7424, Claude Bernard Lyon 1 University,
30 31	13	University of Lyon, Villeurbanne, France
32 33	14	⁴ Direction of Clinical Research and Innovation, Léon Bérard Cancer Centre, Lyon, France
34 35 36	15	⁵ GATE Lyon Saint-Etienne, UMR-CNRS 5824, University of Lyon, Ecully, France
37 38	16	⁶ GRePS EA4163 Institute of Psychology, Lyon 2 University, Bron, France
39 40	17	⁷ Hospices Civils de Lyon, Claude Bernard Lyon 1 University, UMRESTTE UMR T 9405, Lyon, France
41 42 42	18	⁸ Biomouv, Paris, France
43 44 45	19	⁹ Department of Hospital Information, Léon Bérard Cancer Centre, Lyon, France
46 47	20	
48 49	21	Correspondence to:
50 51	22	Dr Béatrice Fervers; beatrice.fervers@lyon.unicancer.fr
52 53 54 55 56 57 58 59 60	23	

24 ABSTRACT

> Introduction: Despite safety and benefits of physical activity during treatment of localized breast cancer, successful exercise strategies remain to be determined. The primary objective of the DISCO trial is to evaluate the efficacy of two 6-month exercise interventions, either single or combined, concomitant to adjuvant treatments, on the physical activity level of breast cancer patients, compared to usual care: an exercise program using a connected device (activity tracker, smartphone application, website) and a therapeutic patient education intervention. Secondary objectives are to evaluate adherence to interventions, their impact at 6 and 12 months, representations and acceptability of interventions, and to assess the cost-effectiveness of the interventions using quality-adjusted life years. Methods and analysis: This is a 2x2 factorial, multicentre, phase III randomised controlled trial. The study population (with written informed consent) will consist of 432 women diagnosed with primary localized invasive breast carcinoma and eligible for adjuvant chemotherapy, hormonotherapy and/or radiotherapy. They will be randomly allocated between one of four arms: (i) web-based connected device (evolving target number of daily steps and an individualized, semi-supervised, adaptive program of two walking and one muscle strengthening sessions per week in autonomy), (ii) therapeutic patient education (one educational diagnosis, two collective educational sessions, one evaluation), (iii) combination of both interventions, (iv) control. All participants will receive the international physical activity recommendations. Assessments (baseline, 6 and 12 months) will include physical fitness tests, anthropometrics measures, body composition (CT-scan, bioelectrical impedance), self-administered questionnaires [physical activity profile (RPAQ), quality of life (EORTC QLQ-C30, EQ-5D-5L), fatigue (PFS-12), social deprivation (EPICES), lifestyle, physical activity barriers, occupational status] and biological parameters (blood draw).

46 Ethics and dissemination: This study was reviewed and approved by the French Ethics Committee. The
47 findings will be disseminated to the scientific and medical community via publications in peer-reviewed
48 journals and conference presentations.

Registration: ClinicalTrials.gov NCT03529383; 05/17/2018.
 60

BMJ Open

1		
2		
3	50	
4		
5	51	Keywords: Breast cancer, Physical activity, Sitting time, Activity tracker, Connected device, Web-
6	51	Reymonds: Breast current, Thysical activity, Sitting time, Activity flacker, connected acvice, web
7		
8	52	based, eHealth, Therapeutic patient education, Randomised controlled trial
9		
10	53	
11		
12	54	Word count: 8445
13	54	WOID COUNT. 6445
14		
15	55	
16	56	Strengths and limitations of this study
17		
18		This wands wind a limited with four same has the adventees to surplusts the officers, of two
19	57	- This randomized clinical trial with four arms has the advantage to evaluate the efficacy of two
20		
21	58	interventions, either single or their combination, using a 2x2 factorial design, ensuring a higher
22		
23	59	statistical power than a classic trial with three arms, for a similar sample size.
24	00	
25	60	While the compared doubted in the second compared the compared to be a
26	60	- While the connected device intervention is semi-supervised, the exercise program has been
27		
28	61	designed according to the preferences of women with breast cancer so as not to leave patients
29		
30	62	in total autonomy and to provide organisational flexibility to patients to facilitate adherence.
31	02	
32	62	Despite the netential herefite of concerted devices in severe and their use may free
33	63	- Despite the potential benefits of connected devices in cancer care, their use may face
34		
35	64	important issues, such as ethical challenges related to the security of sensitive data storage,
36		
37	65	technical challenges related to technological robustness and reliability, exacerbating access
	00	
38	<i>cc</i>	discoution and calf account of the participant's fations or health condition
39	66	disparities, and self-assessment of the participant's fatigue or health condition.
40		
41	67	- The primary outcome measure is based on a declarative evaluation of physical activity that
42		
43	68	confers methodological limits to the study, but the validated questionnaire was chosen
44	00	conters methodological minto to the stady, but the validated questionnaire was chosen
45	60	
46	69	according for its easy implementation for cancer patients compared to accelerometer
47		
48	70	monitoring and its relevance for the primary outcome.
49		
50		
51		
52		
53		
54		
55		
56		

71 INTRODUCTION

Breast cancer is the leading cause of cancer in women worldwide with 1.6 million new cases diagnosed each year,¹ representing more than a third of all new cancer cases in women. In France, breast cancer also represents the leading cause of cancer incidence and mortality among women, with approximately 58,000 new cases and 12,000 breast cancer deaths estimated in 2018.² Despite a very good prognosis worldwide with overall survival of 85% at 5 years (87% in France) and 71% at 10 years (78% in France) for all stages combined, $^{3-5}$ a large number of patients with breast cancer experience adverse effects of cancer and its treatments such as fatigue, impaired quality of life, anxiety or weight gain.6-8

In women with breast cancer, deteriorations of physical activity level and cardiorespiratory fitness are frequent.^{9,10} Physical activity is defined as any bodily movement produced by skeletal muscles that requires energy expenditure, including any daily life activity of household, occupation, recreation (e.g., sports) or transportation. Exercise is a subset of physical activity that is planned, structured and repetitive, in the purpose of improving or maintaining physical fitness.¹¹ After a breast cancer diagnosis, lack of physical activity, obesity and weight gain have been shown to increase the risk of cancer-related comorbidities and treatment adverse effects, to worsen long-term health and to cause poor prognosis.^{12–14} The benefits of physical activity have been well recognized in primary cancer prevention.¹⁵ Numerous studies have shown the safety¹⁶ and benefits of physical activity performed concomitantly with breast cancer treatments. These benefits include reduced fatigue^{17–19} and comorbidities²⁰, improved quality of life^{21,22} and physical functioning,^{10,17,19,22} as well as possibly reduced risk of recurrence²³ and improved overall and specific survival with a positive dose-response relationship.^{14,23,24} Despite these benefits and international evidence-based guidelines of physical activity prescription for clinicians and their patients, accessibility to exercise programs and implementing the guidelines in the cancer care process remain a challenge for patients and health care providers.^{25–27} While a growing number of facilities offer exercise programs to cancer patients, distance

BMJ Open

3 4	
5	
6	
7	
8 9	
10	
11	
12	1
13 14	
14 15	1
16	
17	1
18	1
19 20	1
21	1
22	-
23	1
24 25	
25 26	1
27	
28	1
29 30	
30 31	_
32	1
33	-
34	1
35 36	
37	1
38	
39	1
40 41	
42	1
43	1
44	1
45 46	1
40 47	_
48	1
49	
50 51	1
51 52	
53	1
54	1
55	_
56 57	1
57 58	1
59	1

96 from home constitutes a barrier to regular exercise during cancer treatments.²⁶ Successful exercise
97 strategies during and beyond cancer treatment remain to be determined in clinical trials.²⁸

98 The recent development of connected devices such as activity trackers offers a real opportunity in oncology to promote and monitor patients' physical activity.²⁹ While adherence to lifestyle 99 100 interventions is a major challenge, connected activity trackers and smartphone applications enable L01 structured monitoring of health parameters and provide feedback to patients. A systematic review of L02 randomised controlled trials of physical activity interventions using new technologies such as activity trackers in cancer patients (including five studies in breast cancer) has shown that patients significantly L03 L04 increased their number of steps per day in the majority of the studies.³⁰ Recent reviews of intervention L05 studies conducted among breast cancer patients have also shown that patients increased their physical activity when they used activity trackers.^{31,32} Overall, connected activity trackers receive increasing 106 L07 interest for being systematically integrated into clinical oncology practice.^{33,34} Yet, more research is needed, especially clinical trials, to demonstrate the effectiveness of these tools and to respond to the L08 L09 preferences of breast cancer patients.^{35–37}

Therapeutic patient education has emerged in the 1990s in response to the recognition of the need L10 to support patients in the self-management of their chronic diseases, such as diabetes and asthma.^{38,39} 111 L12 According to the World Health Organization (WHO), therapeutic patient education aims to "help patients acquire or maintain the skills they need to best manage their lives with a chronic disease".⁴⁰ L13 L14 In the cancer field, several cancer-specific programs of therapeutic patient education have been set up L15 to manage pain, fatigue, side effects of treatment (chemotherapy, surgery) or compliance to treatment.^{41–44} By enhancing relevant knowledge and skills, therapeutic patient education may greatly L16 contribute to increasing patients' autonomy in their disease management. Despite the performance in L17 modifying long-term individual behaviours and adherence to cancer treatments,44 the benefits of L18 L19 therapeutic patient education on physical activity levels in cancer patients early after diagnosis has been poorly investigated.^{45,46} The research on therapeutic patient education in the breast cancer and L20 121 exercise context is limited to date and warrants further research. 60

Several biological mechanisms have been proposed to explain the effects of physical activity on breast cancer risk and outcome. Preclinical and human studies have shown the influence of physical activity on several signalling pathways involved in tumour development, growth and progression, including the insulin signalling pathway (IGF-1, insulin), chronic inflammation (involving inflammatory cytokines such as IL-6, TNF α , CRP) and endocrine hormone regulation (estrogens, adipokines).^{47–49} By affecting the endogenous systemic milieu, physical activity is believed to influence cellular processes and tumour growth, and therefore reduce the risk of recurrence, increase treatment efficacy and improve survival.⁵⁰ Also, because vitamin D alters mechanisms implicated in cellular growth and proliferation, accumulating evidence suggests that normal-to-high ranges of serum vitamin D levels improve breast cancer prognosis and outcome.⁵¹ Based on the data in the literature, it is not possible to conclude a causal relationship between the metabolic effects of physical activity and the impact on breast cancer risk and survival. Biological effects of physical activity on these biomarkers of endogenous mechanisms interfering in cancer suppression or proliferation remain to be elucidated in order to better understand the benefit of physical activity during adjuvant treatment.⁴⁹

In this context, given the accumulating evidence for the benefits and safety of regular exercise during treatments of localized breast cancer, it is necessary to systematically encourage patients to remain or become physically active from the time of diagnosis and to implement and assess the most appropriate strategies of physical activity in clinical practice. The aim of the DISCO trial is to encourage engagement in exercise during breast cancer treatment through two innovative types of interventions, that is to say a web-based connected device and therapeutic patient education, which aim to develop patients' autonomy in their practice of physical activity. The primary objective of the DISCO trial is to evaluate the efficacy of two interventions, either single or combined, concomitant to adjuvant treatments, on the physical activity level of breast cancer patients at the end of the 6-month interventions, compared to usual care: one is an exercise program using a connected device (comprising an activity tracker linked to a smartphone application and a website and providing an individualized, semi-supervised, technology-based exercise program) and the other is a therapeutic

BMJ Open

patient education intervention. The research hypothesis is that patients participating in the 6-month exercise program using the connected device or therapeutic education intervention are more likely to achieve the international physical activity recommendations, compared to women receiving physical activity recommendations only (usual care). The WHO recommendations to maintain or improve health, which applied when the study protocol was developed, are to do at least 150 min of moderate-intensity or 75 min of vigorous-intensity aerobic physical activity or an equivalent combination each week, and muscle-strengthening activities at least two days a week.¹¹ Secondary objectives are: (i) to evaluate the adherence to the interventions; the impact of the interventions on physical fitness, physical activity profile, anthropometrics, quality of life, fatigue, biological parameters, occupational status and lifestyle factors; the efficacy of the 6-month interventions on physical activity level at 12 months; the representations and acceptability of activity tracker and therapeutic patient education; and ii) to assess the cost-effectiveness of the interventions. If one of the interventions is individually effective, the efficacy of the combination of both interventions at 6 and 12 months will be evaluated.

162 METHODS AND DESIGN

163 Trial design

The DISCO (an acronym for "dispositif connecté", i.e., connected device in English) trial is a 2x2 prospective, multicentre, factorial, randomised, controlled and open-label study (phase III), conducted by the Léon Bérard comprehensive cancer centre (Lyon, France) among women receiving treatment for localized breast cancer. The clinical protocol was designed and written according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) guidelines (see Supplementary file 1). The flowchart of the study is presented in Figure 1. Patients will be randomly assigned to one of the four arms of the study according to the 2×2 factorial design (1:1:1:1 ratio). They will all receive international recommendations on physical activity,¹¹ and: (i) women allocated to the "connected device" arm will benefit from a 6-month individualized, semi-supervised exercise program carried out autonomously. The program consists of an evolving goal of daily numbers of steps using an activity

Ne.

tracker and two sessions of brisk walking and one session of muscle strengthening per week, using dedicated smartphone application and website; (ii) women allocated to the "therapeutic patient education" arm will benefit from four therapeutic education sessions on exercise; (iii) women allocated to the "combined" arm will benefit from both interventions in parallel; (iv) women allocated to the "control" arm will receive usual care.

180 Eligibility criteria for participants

Inclusion criteria include: being a female 18 to 75 years old; diagnosed with a first primary non-metastatic invasive breast carcinoma histologically confirmed; treated with curative surgery and requiring adjuvant treatment (chemotherapy, hormonotherapy and/or radiotherapy) that present at one of the investigating centres; providing a medical certificate of no contraindication to exercise; being available and willing to participate in the study for the duration of the interventions and follow-up; using a personal smartphone compatible with an application used for the intervention (iOS operating system from version 9.3, Android operating system from version 5.0, no Microsoft operating system) and having a computer with Internet access; being able to understand, read and write French; and being affiliated with a social security scheme.

Non-inclusion criteria include: recurrent, metastatic or inflammatory breast cancer; personal history or co-existence of other primary cancer (except for in situ cancer regardless of the site, basal cell skin cancer and non-mammary cancer in complete remission for more than 5 years); presenting a contraindication to exercise according to the investigator (such as cardiorespiratory or bone pathologies, non-stabilized chronic diseases such as diabetes, malnutrition, etc.); presenting severe malnutrition according to the criteria of the French National Health Authority (i.e., for women \leq 70 years: weight loss ≥15% in 6 months or ≥10% in 1 month; for women >70 years: weight loss ≥15% in 6 months or $\geq 10\%$ in 1 month, and body mass index (BMI) <18 kg/m²);⁵² being unable to be followed for medical, social, family, geographic or psychological reasons for the duration of the study; pregnant or breastfeeding or of childbearing age without effective contraception for the duration of the study.

2		
2 3 4	200	
5 6	201	Recruitment
7 8	202	Recruitment started in May 2018. Participants will be recruited at several national comprehensive
9 10 11	203	cancer centres, clinics or hospitals located in France (see ClinicalTrials.gov NCT03529383), which will
12 13	204	ensure adequate participant enrolment to reach the target sample size in a timely manner. Inclusion
14 15	205	of patients will be carried out after surgery and confirmation of the indication of adjuvant treatment.
16 17	206	The study will be proposed to patients at the postoperative, pre-chemotherapy or pre-radiotherapy
18 19 20	207	consultation (by the surgeon, oncologist or radiotherapist investigator, respectively) depending on the
20 21 22	208	patient's treatment plan. At this visit, the investigator will check all eligibility criteria and propose to
23 24	209	the eligible patients to participate in the study, explain the objectives and study process and give them
25 26	210	an information notice. After sufficient time for reflection, eligible patients who agree to participate will
27 28 29	211	date and sign an informed consent (see Supplementary file 2) and will be included prior to the onset
29 30 31	212	of adjuvant therapy (or within one month thereafter). The number of eligible patients refusing to
32 33	213	participate in the study and the reason for non-participation will be recorded.
32 33 34 35	213 214	participate in the study and the reason for non-participation will be recorded.
32 33 34 35 36 37		participate in the study and the reason for non-participation will be recorded. Randomisation
32 33 34 35 36 37 38 39	214	
32 33 34 35 36 37 38	214 215	Randomisation
32 33 34 35 36 37 38 39 40 41 42 43 44	214 215 216	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46	214 215 216 217	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48	214 215 216 217 218	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record.
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47	214 215 216 217 218 219	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris,
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53	214 215 216 217 218 219 220	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55	214 215 216 217 218 219 220 221	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25 kg/m ² , ≥25 and <30 kg/m ² , ≥30 kg/m ²), baseline physical activity level from RPAQ (<150 min/week,
32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54	214 215 216 217 218 219 220 221 222	Randomisation Prior to randomisation, participants will be asked to complete the Recent Physical Activity Questionnaire (RPAQ) to assess their level of physical activity. ⁵³ Their weight, body size and prescribed adjuvant treatments will be collected from the patient's medical record. Participants will be randomised using EnnovClinical® software (version 7.5.710.4, Ennov, Paris, France) into one of the four arms of the trial, by using the following minimization criteria: ^{54,55} BMI (<25 kg/m ² , ≥25 and <30 kg/m ² , ≥30 kg/m ²), baseline physical activity level from RPAQ (<150 min/week, ≥150 min/week of moderate-to-vigorous physical activity) and prescribed adjuvant treatments at

INTERVENTIONS

At baseline, all participants will receive the international recommendations in terms of physical activity for promoting health in the general population¹¹, which will be delivered orally by a certified exercise instructor with the help of a leaflet.

Intervention with a connected device

Participants randomised to the "connected device" arm will benefit from a 6-month exercise program. The connected device consists of an activity tracker (connected wristband, LS417-F model, CARE Fitness, Bobigny, France) that participants will wear daily, a dedicated smartphone application and a dedicated website proposing an individualized, semi-supervised exercise program adapted to cancer patients (developed by BIOMOUV, Paris, France). This automated web- and mobile-based exercise program will aim to support participants to enhance physical activity in two ways: doing structured exercise sessions and increasing daily physical activity (number of steps). Exercise sessions will be automatically generated by an algorithm based on the patient profile (described below). The participants will receive notifications informing them of a new structured exercise session available on the website or mobile application, or alerting them when a session was not carried out, and inviting them to execute it when possible. Participants will receive a free 6-month subscription to the program. -Setting up the connected device: At the end of the baseline assessment, the certified exercise instructor will introduce the customized exercise program to the participants and will give them the activity tracker and a user guide for the connected device. Then, the certified exercise instructor will explain the functioning of the activity tracker, the dedicated smartphone application and the dedicated website, as well as assist the participants to install the application on their smartphone. The participants will be registered in the customized exercise program by the certified exercise instructor. The registration will consist of completing a web-based questionnaire about personal and health data to determine the participant profile (age, weight, height, level of aerobic and muscular strength, treatment, symptoms, availabilities for exercise sessions and sports materials).

BMJ Open

-Baseline level of aerobic and muscular strength for the individualised exercise program: The physical fitness tests performed at baseline will be used to classify the participants at the start of the exercise program according to their aerobic level (for the walking sessions) and their muscular strength level (for the strengthening sessions). The aerobic level categories will be determined by the distance performed during the 6-minute walk test (6MWT): aerobic group 1 (<460 meters), aerobic group 2 (460 to 580 meters) and aerobic group 3 (>580 meters). The muscular strength level categories will be determined by the number of sit-ups performed on a chair in 30 seconds during the Sit-to-stand test: muscular strength group 1 (<10 repetitions), muscular strength group 2 (11 to 14 repetitions) and muscular strength group 3 (≥15 repetitions). Thresholds were based on average values reached by women receiving breast cancer treatments for the 6MWT (pooled mean value, 523 m) and the Sit-to-stand test (pooled mean value, 13 repetitions) from a previous study;⁵⁶ these values were checked for consistency with percentile scores obtained at the 6MWT and Sit-to-stand test in community-dwelling older women,⁵⁷ then the interquartile range was used to determine the thresholds for the three groups of this study. The level categories assigned will be entered by the exercise instructor in the baseline patient profile and will be used by the automated algorithm to set up the level of the first walking and muscle strengthening sessions.

-Exercise program: The 6-month exercise program will be semi-supervised by the certified exercise instructor through an individual follow-up of participants (see 'Participant follow-up' part and 'Continuous monitoring' part). It will be carried out autonomously by the participants at home by using the smartphone application and the website. The program is based on three structured unsupervised sessions per week alternating two types of exercise: two walking sessions (by following oral instructions given via the smartphone application) and one muscle strengthening session (by using videos accessible on the website). The levels of the first walking and muscle strengthening sessions will be determined by the fitness tests performed at baseline (see 'Baseline level' part). Then, subsequent sessions will be planned according to the available days of the participant. Strengthening exercises will be adapted according to sports materials available at their home (e.g., Swiss ball, sports mat, stick,

> 278 weight, etc.). Each session will include: 1) a warm-up period of 5 minutes; 2) a body session of 10 to 35 279 minutes of strengthening exercises, or 10 to 50 minutes of walking (mixing continuous and/or 280 intermittent effort); 3) a 5-minute recovery period, consisting of stretching and relaxation during 281 strengthening sessions or a cool down during walking sessions. Sessions will be of moderate-to-high 282 intensity (\geq 3 and \leq 9 METs).

The three structured unsupervised exercise sessions per week are configured by a unique algorithm hosted by an accredited personal healthcare data host (Orange Business Services, Paris, France), to plan the exercise sessions and determine the exercise level in an adapted and progressive manner by increasing the duration and then intensity in accordance with principles of exercise training and progression.^{58,59} At the beginning of each session, the duration and intensity of the session will be determined according to the perceived difficulties (evaluated by a Borg scale) and emotional state (recorded by an emoji) of the participant in the previous session, and will be modified or postponed according to the level of fatigue (evaluated by a Borg scale), the level of dyspnea (evaluated by a Borg scale), the presence or absence of unusual muscle pain and the presence or absence of unusual nausea/diarrhea. In case of a severe adverse event related to disease or treatment (i.e., joint disability, osteoarthritis, cachexia, hand-foot syndrome, aplasia, diuretic, axillary node dissection, pace-maker, chemotherapy, targeted therapy, hormone therapy, radiotherapy, COPD, diabetes) or temporary contraindication to exercise, declared by the participant on her device, the program and sessions will be adapted or suspended until the participant's health improves.

In addition, participants will have the opportunity to perform additional exercise sessions according
 to their preferences and lifestyle, outside the program. Participants will be asked to record these
 sessions through the smartphone application or the website: type of activity (e.g., walking, hiking,
 cycling) from a list adapted from Ainsworth's Compendium,⁶⁰ and its duration and intensity.

301 —Number of daily steps: Participants will be advised to wear the activity tracker daily and to launch
 302 the application regularly (preferably daily), which will automatically synchronize with the activity
 303 tracker via Bluetooth connection and will collect the number of steps. The target number of steps will

BMJ Open

be 3,000 steps per day at the program onset, and then will be re-set based on the average number of daily steps during the first week after inclusion. The target number of daily steps will evolve automatically every three weeks based on the average number of daily steps achieved during the previous three weeks, and will be updated automatically in the application. Consistent with principles of exercise training and progression,^{58,59} after each 3-week cycle, if the goal of steps per day is reached by the participant, the target goal will increase by 15% during the following 3-week-cycle, within a maximum target of 10,000 daily steps. If the average number of daily steps does not meet the goal, the target will remain unchanged in the next cycle.

-Participant follow-up: Telephone follow-ups will be carried out by the certified exercise instructor at 10 days, 2 months and 4 months after the intervention onset to ensure the proper functioning of the connected device, review the use of the connected device, review the conduct of the sessions and answer the participants' questions if they may have. Participants will be orally encouraged to remain physically active on a daily basis (reminder of the benefits and recommendations of physical activity, success and satisfaction during the exercise sessions). During the 6-month intervention, the participants will have the opportunity to contact the certified exercise instructor or the clinical research assistant at any time, by e-mail (directly through the website) or by telephone for any question or assistance with the connected device.

-Continuous monitoring: The certified exercise instructor will monitor the use of the connected device by the participants and their progress in the program through a dedicated professional website that provides real-time access to the participants' data. On this website, an automatically generated daily event table will inform the certified exercise instructor of the occurrence of disabilities reported by the participants that may lead to modifying their program (e.g., severe fatigue, dyspnea, unusual muscle pain) or if participants have not performed their planned sessions or used their activity tracker for seven consecutive days. Upon these alerts, the certified exercise instructor will contact the participants to precisely analyse the reported disabilities, advise participants, identify the causes of non-use of the connected device, solve possible technical problems or reinforce participant's motivation if necessary.

-End of the intervention: At the end of the 6-month program, participants will keep their activity tracker to be encouraged to continue regularly exercising in autonomy. Upon their request, continued subscription to the dedicated application and website will be offered for another six months, with no individual follow-up anymore.

Intervention of therapeutic patient education

Participants randomised to the therapeutic patient education arm will benefit from a therapeutic patient education intervention, in addition to receiving the international physical activity recommendations. The intervention is part of the therapeutic patient education program set up at the Léon Bérard cancer centre and validated by the Regional Health Agency ("Agence Régionale de Santé Rhône-Alpes"). It will be disseminated in the investigating centres according to the criteria of the Regional Health Agency. The therapeutic patient education intervention consists of four sessions that will be scheduled according to participants' availability during their follow-up visits as part of their usual clinical management over a 6-month period.

First, participants will be invited to an initial 1-hour individual face-to-face session of educational diagnosis with a health professional trained in therapeutic patient education. This session will assess their needs and establish a contract of objectives to reach. Then, participants will be invited to participate in two collective educational sessions (1h30 each with a group of 10 patients maximum per session). These sessions will be composed of theoretical and practical workshops to help them understand their physical activity in their daily life and implement the necessary means to practice regular exercise in autonomy. Finally, participants will be invited to another 1-hour individual session, where an educational evaluation will be conducted to identify whether they achieve their individual objectives set at the time of the educational diagnosis.

359

360

1 2

2
3
4
5
6
7
8
9
10
11
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
53
54
55
56
57
58
59

354 **Combined interventions**

EVALUATIONS

Participants randomised to the 'combined intervention' arm will benefit from a combination of the connected device intervention and the therapeutic patient education intervention in parallel for 6 months.

The initial assessment (T0) will be performed prior to randomisation for minimization purposes. 361 362 The other three evaluations will then be conducted at baseline (T1), 6 months (T2) and 12 months (T3). 363 All study participants will then be followed at 6 months ± 1 month post-randomisation (corresponding 364 to the end of participation in the interventions for women in the connected device, therapeutic patient 365 education and combined arms) and at 12 months ± 1 month post-randomisation (corresponding to a 366 follow-up period of 6 months post-interventions). Assessments will be carried out by a clinical research 367 assistant and a certified exercise instructor. The clinical research assistant will contact participants by 368 phone to invite them to follow-up visits and to promote participant retention and complete follow-up. 369 Participants will have no compensation for participation and all study visits will be scheduled on days 370 of their medical or health-related appointments.

All evaluations (baseline, 6 and 12 months) will include physical fitness tests, anthropometric measures, self-administered questionnaires and a non-fasting blood draw (baseline and 6 months only). Data will be recorded using an electronic case report form (eCRF).

374

⁰ 375 **DATA COLLECTION**

376 The study outcome measures and their schedule are summarised in Table 1.

377 Socio-demographic and clinical data

57 378 Socio-demographic and clinical data, including month/year of birth, age at diagnosis of breast
 58
 59 379 cancer, family status, level of education, hormonal status, tumour histology and personal history of

> breast cancer will be collected at baseline. Family status, potential cancer progression and all treatments received for cancer will be collected at 6 and 12 months. All data will be extracted from patients' electronic medical records, except family status and level of education that will be selfreported in a questionnaire.

> 384 The occupational status will be assessed using a self-administered questionnaire asking 385 employment status, occupation, size of the company, the perceived intensity of the physical effort at 386 work, the evolution of employment status at return to work in case of sick leave.⁶¹

388 Anthropometrics and body composition

The standing height (cm), body weight (kg) and waist (cm) and hip (cm) circumferences will be measured using standardized procedures and BMI will be calculated as the body weight in kilograms divided by the square of the height in meters (kg/m²). The waist circumference will be measured midway between the last floating rib and the iliac crest. The hip circumference will be measured at the tip of the pubis. Body composition will be measured by a bioelectrical impedance meter (Biody XPert ZM II, eBiody, eBIODY SAS, La Ciotat, France) to assess fat mass (in kg), lean body mass (in kg), muscle mass (in kg), dry lean mass (in kg), total body water (in L), intracellular fluid (in L) and extracellular fluid (in L).

398 Physical fitness

Cardiorespiratory fitness will be evaluated by the walking endurance during the 6MWT (distance
covered in metres) with perceived difficulty using the Borg scale.⁶² During this test, participants will be
asked to perform the maximum walk shuttle distance on a 30-metre long flat corridor in 6 minutes.
The lower limb muscle strength will be measured using the sit-to-stand test (number of sit-ups on a
chair in 30 seconds). During this test, participants will be asked to sit down on a chair and get up as
many times as possible during 30 seconds.⁶³

BMJ Open

3 4	405
5 6	406
7 8	407
9 10	408
11 12	409
13 14	410
15 16 17	411
17 18 19	412
20 21	413
22 23	
24 25	414
26 27	415
28 29	416
30 31	417
32 33	418
34 35	419
36 37	420
38 39	421
40 41 42	422
43 44	423
45 46	424
47 48	425
49 50	426
51 52	427
53 54	428
55 56 57	429
57 58 59	
59 60	430

Hand prehensile strength will be measured by the handgrip test using hand dynamometry (Jamar Plus Digital Hand Dynamometer, Patterson Medical, Huthwaite, UK), which is a validated index of the isometric strength of the hand and forearm muscles.⁶⁴ During this hand-grip test, participants will be asked to squeeze the handgrip as strongly as possible to obtain the maximal force (in kg). Two measures will be performed on each hand and the best performance will be registered.

The flexibility of lower limbs will be measured using the sit-and-reach flexibility test (Deluxe Baseline flexibility test, 3B Scientific, Bartenheim, France).⁶⁵ In this test, participants will sit on the floor on a mat with their legs stretched out straight ahead. They will be asked to lean forward as far as possible and the distance between fingertips and toes will be measured (in cm) (i.e., by considering the level of the feet as recording zero, any measure that does not reach the toes is negative and any measure beyond the toes is positive).

The balance will be measured using the bilateral single-leg stance test.⁶⁶ The participants will stand and be asked to lift a foot and hold the position for a maximum of 60 seconds, then to do the same exercise on the other foot (duration held in equilibrium, 2 times 60 seconds).

20 Physical activity level, sitting time and achievement of physical activity recommendations

The validated self-administered questionnaire RPAQ will be used to measure the self-reported physical activity.^{53,67} The RPAQ was designed to assess usual physical activity in the last four weeks, covering three activity domains: domestic physical activity, including sitting time that is a good proxy of sedentary behaviour; occupational physical activity, including transportation to and from work; and recreational physical activity. The RPAQ gives specific scores in the metabolic equivalent of task (MET) unit for activities of very low intensity (<1.5 METs, i.e., sedentary activities), low intensity (1.5 to <3 METs), moderate intensity (3 to <6 METs) and high intensity (≥6 METs, i.e., vigorous activities) within each domain during the past four weeks. Questions will be coded and converted in MET-minute per four weeks according to the Compendium of Physical Activities⁶⁰ by multiplying the number of METs by the duration and frequency of each activity. Then, the global score of physical activity will be

obtained by adding the number of MET-minutes per four weeks in each intensity and each domain.
The physical activity profile will be defined as the time spent in physical activities of low, moderate and
high intensities. The physical activity level will be defined by the overall weekly physical activity
(average expressed in MET-hour/week).

Achievement of international physical activity guidelines will be computed for each individual by
dividing the time spent in moderate-to-vigorous physical activity (i.e., ≥3 METs) into two categories:¹¹
<150 min/week of moderate-to-vigorous physical activity (i.e., under physical activity guidelines); ≥150
min/week of moderate-to-vigorous physical activity (i.e., reaching physical activity guidelines).

440 Patient-reported outcomes

The quality of life will be measured using the European Organization for Research and Treatment of Cancer (EORTC) Quality-Of-Life Questionnaire (QLQ-C30) and its specific module for breast cancer (BR-23).68 The QLQ-C30 is a 30-item validated self-administered questionnaire that evaluates five functioning domains (i.e., physical, role, emotional, cognitive and social), a global quality-of-life domain, three symptom domains (i.e., pain, fatigue and nausea) and six single items (i.e., dyspnea, insomnia, anorexia, diarrhea, constipation and financial impact). Each item is associated with a score ranging from 0 to 100. For the functioning and global quality-of-life scales, a higher score corresponds to a better functioning level. For scales related to symptoms, a lower score corresponds to a better functioning level. The BR-23 module gathers data about perceived body image, sexual functioning, sex enjoyment, arm symptoms, breast symptoms and systemic therapy side effects.

48 451 The health-related quality of life will be assessed using the EQ-5D-5L questionnaire.⁶⁹ This
452 standardized self-administered questionnaire describes five dimensions (i.e., mobility, self-care, usual
453 activities, pain/discomfort and anxiety/depression) being rated using five levels (i.e., no, slight,
454 moderate, severe and extreme problems), and comprises a 0-100 visual analogue scale recording the
455 self-rated health (where the endpoints are labelled 'The best health you can imagine' and 'The worst
456 health you can imagine').

Page 21 of 51

1 2 3

BMJ Open

4			
5			
6			
7			
, 8			
9			
1	0		
1	1		
	2		
1			
1	כ ∧		
1	5		
1	5 6		
1			
1			
1	~		
1 2	9 0		
2 ว	1		
2 ว	ו ר		
2 ว	2		
2 ว	3 ⊿		
2 ว	4 7		
2	2 2		
222222222	6 7		
2	/		
2	8		
2	9		
л.	U		
3	1		
3	2		
3	3		
3	4		
3	5		
3	6		
3	7		
3	8		
3			
4			
4			
4			
4			
4			
4	5		
4	-		
4			
4			
4			
5			
5			
5			
5			
5			
5			
5			
5			
5			
5			

474

Fatigue will be assessed using the Piper Fatigue Scale-12 (PFS-12), a 12-item self-reported questionnaire with four subscales (i.e., behavioural, affective, sensory and cognitive/mood aspects of fatigue):⁷⁰ the higher the score, the worse the fatigue. All items together will produce a total score for fatigue that will be used to define categories as follows: no fatigue (score=0), mild fatigue (score 1-3), moderate fatigue (score 4-6) and severe fatigue (score 7-10).

462 Social deprivation will be assessed using the EPICES (Evaluation of Deprivation and Inequalities in
463 Health Examination Centres) score.⁷¹ The score will be computed by adding each question coefficient
464 to the intercept whenever the answer is "yes." The score ranges from 0 to 100 (i.e., the higher the
465 score, the greater the deprivation level) with the threshold for deprivation at 30.

466 Lifestyle factors, assessed using a self-administered questionnaire, include tobacco status (i.e., 467 never, former, current smoker), lifetime and current tobacco use (expressed in pack-years) and alcohol 468 intake over the past 6 months (usual frequency of consumption [i.e., never, less than 1/month, 1-3 times/month, 1-6 times/week, daily] of different categories of alcoholic beverages [i.e., wine, beer, 469 470 cider, aperitif wine, cocktail/punch, aniseed alcohol, spirits] as well as the usual number of glasses). 471 The amount of alcohol will be computed by multiplying the frequency of consumption by the number 472 of glasses and alcohol content of each type of alcoholic beverage. The average daily alcohol intake over 473 the past 6 months (in g/day) will be computed by summing the amount of alcohol from each beverage.

475 Determinants of Physical activity

The 21-item self-administered questionnaire "Barriers to Being Active Quiz" will be used to qualitatively assess barriers to the regular practice of physical activity.⁷²

478 Uses, representations and motivation towards physical activity will be assessed within the study
 479 population using a self-administered questionnaire available online. Acceptability of connected
 480 devices and acceptability of therapeutic patient education will be assessed among participants
 481 randomised to the corresponding arms using a paper-based self-administered questionnaire. These
 482 questionnaires will be developed following the Unified Theory of Acceptance and Use of Technology

(UTAUT),⁷³ which is a specification of the Theory of Planned Behaviour⁷⁴ designed to explain and predict the probability of behaviour change among individuals faced with new technologies. The Theory of Planned Behaviour has been massively used during the last two decades to promote health behaviours such as physical activity. Besides, item wording will be based on the results of individual and collective interviews conducted for that purpose and designed to identify social representations⁷⁵ of health protection and physical activity incentive devices.

490 Compliance with interventions

Compliance with each intervention will be assessed at the 6-month evaluation only for patients randomized to the "connected device", "therapeutic patient education" and "combined" arms. Compliance will be assessed by the number of days of use of the activity tracker, the participation rate in scheduled exercise sessions, the participation rate in scheduled therapeutic education sessions and the proportion of compliant patients, depending on the intervention allocated, following the recommendations of the protocol. Patients' compliance and reasons for non-compliance during the intervention period (6 months) will be described for each arm.

499 Biological assessments

A non-fasting blood sample (one 10-ml EDTA tube and one 10-ml dry tube) will be collected at
baseline and 6 months. In particular, blood will be drawn at baseline before the onset of adjuvant
treatments, otherwise no blood samples will be collected. The following biological factors will be
assessed in the blood samples: circulating serum levels of endocrine factors (IGF-1, insulin, estradiol),
circulating plasma levels of inflammatory cytokines (IL-6, TNFα, CRP), circulating plasma levels of
adipokines (adiponectin, leptin) and vitamin D status.

5 506

507 STUDY OUTCOMES

BMJ Open

2 3 4	508	The primary endpoint will be the proportion of women who achieve at 6 months the internationally
5 6	509	recommended level of physical activity (at least 150 min/week of moderate-to-vigorous physical
7 8	510	activity, i.e., intensity ≥3 METs) assessed by the RPAQ self-administered questionnaire.
9 10 11	511	Secondary endpoints will be:
11 12 13	512	1. Assessment of the efficacy of the programs at 12 months (i.e., the proportion of women who achieve
14 15 16 17 18 19 20	513	the internationally recommended level of physical activity);
	514	2. Assessment of the adherence to the interventions at 6 months (the proportion of participants who
	515	are compliant to the program, participation rate in planned sessions);
20 21 22	516	3. Assessment of the impact between baseline and 6 months and between 6–12 months of the
23 24	517	interventions on physical activity profile (changes in time spent in different intensities of physical
25 26	518	activity and time spent in sedentary activities), physical fitness (changes in results to the 6-minute walk
27 28 29 30 31 32 33	519	test, hand-grip test, sit-to-stand test, sit-and-reach flexibility test and single-leg stance test),
	520	anthropometrics (changes in weight, waist and hip circumferences, BMI, fat mass, lean body mass,
	521	muscle mass, dry lean mass and body water), quality of life (changes in scores obtained from the EORTC
34 35	522	QLQ-C30 questionnaire and its BR-23 module), fatigue condition (changes in scores obtained from the
36 37 20	523	PFS-12 questionnaire), health-related quality of life (changes in scores obtained from the EQ-5D-5L
38 39 40 41 42	524	questionnaire), social deprivation (changes in scores obtained from the EPICES self-administered
	525	questionnaire), occupational status (the proportion of participants who changed their employment
43 44	526	status, with return to work and who perceived difficulty at work obtained from a self-administered
45 46 47	527	questionnaire) and lifestyle factors (the proportion of participants who change their tobacco use and
47 48 49	528	alcohol intake obtained from a self-administered questionnaire).
50 51	529	4. Assessment of the impact of the interventions on biological parameters between baseline and
52 53	530	6 months (changes in serum circulating levels of endocrine factors [insulin, IGF1, estradiol], changes in
54 55 56	531	plasma circulating levels of cytokines [inflammatory cytokines: IL-6, TNF, and CRP; adipokines:
56 57 58 59 60	532	adiponectin and leptin], the proportion of participants with a modification on vitamin D status).

> 5. Assessment of the representations and acceptability of activity tracker and therapeutic patient education, at baseline, 6 and 12 months (proportions of participants who accept the connected device and who accept the therapeutic program, according to scores obtained from a self-administered gualitative questionnaire used in social psychology science).

537 6. Assessment of refusal rate among eligible patients (the proportion of patients who refuse to538 participate).

539 7. Assessment of the cost-utility and the cost-effectiveness of implementing each intervention at
540 12 months, using clinical data (treatments received, patients' diary on medical consultations), hospital
541 costs (national data) and benefit in physical activity level.

543 STATISTICAL ANALYSIS

544 Sample size determination

The efficacy rate assumptions are μ =40 %, μ + μ A=55 % and μ + μ B=65 % for the "control", "therapeutic patient education" and "connected device" arm modalities, respectively. The expected benefit in the "therapeutic patient education" arm compared to the "control" arm is 15% (40% efficacy in the "control" arm versus 55% efficacy in the "therapeutic patient education" arm). The expected benefit in the "connected device" arm compared to the "control" arm is 25% (40% efficacy in the second device" arm versus 55% efficacy in the "control" arm is 25% (40% efficacy in the "control" arm versus 65% efficacy in the "connected device" arm).²³

The sample size is calculated to allow the two comparisons of interest to be tested bilaterally at the threshold of 0.025. Assuming that the "therapeutic patient education" intervention and the "connected device" intervention act independently (additive model), the sample size required to compare therapeutic patient education (i.e., participants assigned to the "therapeutic patient education" and "combined" arms) versus no therapeutic patient education (i.e., participants assigned to the "control" and "connected device" arms) is given by the following formula:

57 557 [μ + (μ+μΒ)] / 2, versus [(μ+μΑ) + (μ + μΑ + μΒ)/2]

⁵⁹ 558 that is, (40 % + 65 %) / 2 = 52,5 %, versus (55 % + 80 %) / 2 = 67,5 %

Page 25 of 51

564

1

BMJ Open

2	
3	
4	
5	
6	
7	
/ 0	
8	
9	
10	
11	
12	
13	
14	
15	
16	
17	
18	
10	
20	
20	
21	
22	
23	
24	
25	
26	
20 27	
19 20 21 22 23 24 25 26 27 28 29	
28 29	
29	
30	
31	
32	
33	
34	
35	
36	
37	
38	
39	
40	
41	
42	
43	
44	
45	
46	
47	
48	
49	
50	
51	
52	
53	
54	
55	
56	
57	
58	
59	
60	

559 With a first species risk α =0.025 and a power of 80% in the bilateral situation, the number of 560 patients to include per treatment arm to demonstrate the efficacy of the therapeutic patient education 561 will be 108 (or 432 for the four treatment arms) (nQuery V6.0, Chi-two test with continuity correction). 562 This number of patients will also allow a power greater than 95% to evaluate the efficacy of the 563 "connected device" intervention, always with a risk α = 0.025 in the bilateral situation.

565 Data analysis plan

The following populations will be defined for statistical analyses: i) the intent-to-treat (ITT) population, which includes all randomised participants in the study; ii) the per-protocol population, which consists of a subgroup of participants from the ITT population, who has no major protocol violations and who follows the procedure for the duration of the study. Analyses in the ITT population will be performed for all the study endpoints; analyses in the per-protocol population will be performed for exploratory purposes. The randomisation date will be considered as the reference date in all delay calculations, unless any other way is specified.

573 Baseline data will be described in the ITT population and presented by randomised arms. For the primary outcome, proportions will be estimated for the two targeted comparisons: (i) participants who 574 575 received the connected device vs. participants who did not; (ii) participants who benefited from the 576 therapeutic patient education intervention vs. participants who did not. Results will be presented with 577 their 95% confidence interval. The use of a 2x2 factorial design will allow to test, respectively: the 578 efficacy of the intervention with a connected device (compared to without a connected device); the 579 efficacy of the therapeutic patient education intervention (compared to no therapeutic patient 580 education); and the interest of two combined intervention modalities (i.e., connected device and 581 therapeutic patient education) compared to the single intervention with the connected device only or 582 with therapeutic patient education only. The analysis strategy will therefore be as follows:⁷⁶ 583 1) searching first for an interaction by a specific interaction test, performed at the significance level of 584 0.05 (Chi-square test or use of an interaction term in a logistic model); 2) in the absence of interaction,

23

testing each of the two bilateral interest comparisons at the threshold of 0.025, namely the efficacy of
the intervention with the connected device and the efficacy of the therapeutic patient education
intervention; 3) in case of the efficacy of either one of the intervention modalities, evaluating the
interest of the combination of the two interventions compared to the single intervention with the
connected device only or with therapeutic patient education only.

For secondary outcome variables, the efficacy of the program at 12 months, as well as according to stratification criteria, will be analysed similarly to the primary outcome. The adherence to the interventions will be evaluated by the proportion of compliant participants and participation rate in planned sessions. Changes in physical activity profile, physical fitness, anthropometrics, quality of life, fatigue, social deprivation and biological parameters will be analysed by the absolute and/or relative variations in each of these endpoints; these variations will be compared between with and without each intervention, for each intervention, and between combined interventions and the single one, using a parametric test. Occupational status and lifestyle factors will be analysed by comparing the proportion of participants between interventions or their combination. Representations and acceptability of activity tracker and therapeutic patient education will be analysed by comparing the proportion of participants between randomisation and follow-up assessments. A method for imputing missing data will be considered if necessary.

602 Statistical analyses will be performed using SAS[®] software version 9.4 or later.

604 Medico-economic analysis

The cost-effectiveness analysis will be conducted alongside the trial using the French national health insurance perspective. Quantities of resources used [external consultations, hospital stays including Diagnosis-related groups, drugs with extra payments and other healthcare-related costs] will be collected on the eCRF and multiplied by the respective unit costs. The intervention with therapeutic patient education and the intervention with connected device will be evaluated using a bottom-up micro-costing approach.^{77,78} Using the Diagnosis-related group, hospital stays will be evaluated based Page 27 of 51

BMJ Open

on the French National hospital costs study database. External consultations and wider examinations, community care (general practitioner visits, nurse visits, etc.) will be valued on the basis of the General Nomenclature of Professional Treatments (NGAP, "Nomenclature Générale des Actes Professionnels"). The cost of biological treatments will be estimated using the Nomenclature of Biological Medical Treatments (NABM, "Nomenclature des Actes de Biologie Médicale"). The cost of technical treatments (e.g., imaging) will be estimated using the Common Classification of Medical Treatments (CCAM, "Classification Commune des Actes Médicaux"). Acquisition costs for the most expansive drugs will be based on the list of common units of dispensation for supplementary medicines ("liste des unités communes de dispensation prise en charge en sus"). Finally, costs of medical transport will be derived from the French Court of Audit's report on medical transport expenses covered by the French National Health insurance. The time horizon will be 12 months. Hence, neither costs nor effectiveness will be discounted. Mean costs and effectiveness will be derived for all four strategies under consideration: connected device, therapeutic patient education, combined and control arms. Incremental Cost-Effectiveness Ratios (ICERs) will be expressed in cost per quality-adjusted life year (QALY) gained using EQ-5D-5L to estimate utility, cost per life year gained, cost per BMI unit lost and cost per centimetre of waist-to-hip circumference lost. One-way sensitivity analyses will be conducted by varying resource consumption and unit cost parameters and graphically illustrated in a Tornado diagram. The uncertainty surrounding the ICERs will be also captured by a probabilistic analysis using non-parametric bootstrap methods as recommended by the French National Authority for Health.⁷⁹

8 631

632 ADVERSE EVENTS

All participants will continuously report the occurrence of adverse events regarding neuropathies and joint pain in their patient's notebook, which will be collected at 6 and 12 months. Those equipped with the connected device will also report potential adverse events before and after each session of their exercise program (see *Connected device*). The reported adverse events will then be graduated

637 <u>according the CTCAE v5.</u> Due to the low risks associated with the interventions,¹⁶ this study is part of
 638 the so-called "intervention research with minimal risks and constraints" in the French legislation and
 639 therefore only these adverse events arising within the framework of the study will be reported.

640 In the occurrence of an adverse event regarding neuropathies and joint pain, the principal 641 investigator will report it to the health authorities responsible for vigilance without delay. The 642 promotor will also report the adverse events, as well as any safety measures to be proposed, to the 643 French Ethics Committee and the investigators without delay.

645 DATA MANAGEMENT

The database for clinical data and randomisation will be created using EnnovClinical[®] software. Its access will be secured (personal identification and password protection) for maintaining confidentiality at all times. Individual participants will not be identified in any reports of this trial. All data from the connected device will be merged to the clinical database at the end of the study. Investigators and data analysts will have access to the final dataset.

Data monitoring will be provided by the trial steering committee, including overall project supervision, progress monitoring, advice on scientific credibility, and ensuring the integrity and appropriate running of the project. The clinical research assistant will verify all consent forms, compliance with established protocol and procedures, and data quality in the eCRF. The research team will make biannual reports to the trial steering committee.

657 PATIENT AND PUBLIC INVOLVEMENT

An association of breast cancer patients' representatives (Europa Donna France, http://www.europadonna.fr/) was involved in preparing the conduct of interventions and evaluations, in particular by considering patients' expectations, experience and desire for global care. The association will be involved in plans to disseminate the study results to breast cancer patients, study participants and wider patient communities concerned.

1		
2 3 4	663	
5 6	664	ETHICS AND DISSEMINATION
7 8	665	The study protocol was approved by the French ethics committee (Comité de Protection des
9 10 11	666	Personnes Est I, ID RCB 2017-A03360-53, 1^{st} February 2018) and its database was reported to the
12 13	667	French National Commission for Data Protection and Liberties (CNIL, ref. MR-001 no. 2016177, 13^{th}
14 15	668	December 2016). Substantial protocol modifications will be submitted to the ethics committee for
16 17 18	669	approval and protocol amendment. The trial has been prospectively registered on
19 20	670	http://www.ClinicalTrials.gov (NCT number: NCT03529383, 17 th May 2018).
21 22	671	The study findings will be widely disseminated through the clinical community by publications in
23 24	672	international, peer-reviewed journals and by presentations at national and international conferences.
25 26 27	673	They will also be communicated to patients through associations of patients' representatives and
27 28 29	674	science-based information websites. They will be useful for improving the clinical care of cancer
29 30 31	675	patients and providing useful information for implementing exercise programs for cancer patients to
32 33	676	health professionals, institutions and public authorities. The study sponsors will disseminate the study
34 35 36	677	findings to their stakeholders.
30 37 38	678	
39 40	679	DISCUSSION
41 42	680	This article presents the protocol for the DISCO trial, which aims to evaluate the efficacy of a web-
43 44 45	681	and mobile-based connected device intervention and of a therapeutic patient education intervention,
46 47	682	either single or combined, on the physical activity levels of breast cancer patients undergoing adjuvant
47 48 49	683	treatment, as well as to assess the cost-effectiveness of the interventions. This multicentre study
50 51	684	opened in May 2018 and recruitment is expected to end in Summer 2021. In the short term, the
52 53 54	685	expected results are to develop the autonomy of breast cancer patients in their practice of physical
54 55 56	686	activity, as well as to identify the best strategies of physical activity during breast cancer adjuvant
57 58	687	treatments to increase and sustain physical activity levels in patients, overall or in specific subgroups
59 60	688	according to BMI, baseline physical activity level and type of adjuvant treatment. In the medium term,

the goal of the DISCO trial is to disseminate innovative programs in supportive cancer care, based on
 scientific evidence, to systematically integrate exercise in breast cancer cares.

While an increasing number of studies have demonstrated the benefits of exercise in breast cancer patients, the routine implementation in the cancer care process lacks behind evidence and practice guidelines.^{80–82} While the prescription of physical activity in supervised programs has been shown superior compared to non-supervised programs,^{22,83} semi-supervised interventions seem to yield comparable or superior benefits to supervised programs.⁸⁴ Therefore, the semi-supervised exercise program of the DISCO trial through continuous follow-up has been designed according to the preferences of women with breast cancer so as not to leave patients in total autonomy.^{36,85} Connected devices are tools developed over the last 10 years that are very promising for promoting physical activity in the general population and in patients with chronic diseases such as cancer^{86,87} and for developing distance-based physical activity interventions.⁸⁸

The semi-supervised home-based physical activity program of the DISCO trial using the connected device provides flexibility to patients that may facilitate adherence and to overcome barriers due to distance of facilities from women's home and spatial inequalities of access.²⁷ Connected devices allow proposing a tailored physical activity program to patients regardless of their place of residence, and enable patients to practice physical activities of their choice, at any time that suits them. Therefore, they may reduce geographical and organisational barriers in the access of patients to exercise, a key issue to improve their engagement in regular and sustained physical activity.²⁷ Previous studies in oncology have reported that the use of mobile devices has benefits to overcome motivational barriers to physical activity, which can help patients staying physically active over the medium and long term.^{89,90} Moreover, some studies have shown that breast cancer patients achieved higher fitness levels during supervised training compared to unsupervised training, even low and medium levels of supervision have been effective, as less resource-intensive options for effective and longer-term behaviour change strategies based on exercises in cancer patients and survivors.^{84,91}

Activity trackers have become increasingly popular in recent years. Patients have reported positive feedback on using activity trackers such as pleasant to wear, easy to use and a strong motivational role through the real-time display of daily number of steps.⁹² Also, walking is an inexpensive activity that can be performed anywhere and does not require specific skills. A study on preferences for technologysupported interventions in breast cancer survivors has reported that 63% would like to use a physical activity mobile application and 90% would find a physical activity tracker useful to monitor and increase physical activity.³⁵

Despite the potential benefits of connected devices in cancer care, their use may face several important issues. First, ethical challenges related to the security of sensitive data storage have been raised.⁹³ To ensure that data transfer and storage guarantee informational privacy and patient safety,⁹⁴ an activity tracker made in France (i.e., allowing storing health data only in France) and an accredited national health data host were chosen for the DISCO trial. Particularly, ensuring medical data security is a reassuring choice for patients to participate in this new kind of medical research. Second, technical challenges have been raised, related to technological robustness, reliability of data collection and processing, and ease of use. Therefore, an activity tracker with a step display on the screen, a user-friendly interface, good reliability and a good price-performance ratio was chosen in the DISCO trial. Third, connected devices may create or exacerbate access disparities related to technological literacy and economic means, as well as reliable access to the internet in rural or isolated areas.⁹³ Fourth, medical reasons are usually not easy to control in patients' adherence to exercise programs. Reliance upon self-assessment of the participant's fatigue, evaluation of the participant before and after each session on the remote monitoring, up as the source of information about the participant's health, can result in the ignorance of aspects of the participant's health that cannot easily be monitored.⁹³

52
53736Therapeutic patient education has been suggested to increase physical activity level in patients with54
55737chronic diseases⁴⁶ and to improve multiple health outcomes, together with behavioural interventions56
57738including physical activity.⁹⁵ Therapeutic patient education interventions might be promising for58
59739promoting a physically active lifestyle in cancer patients as it helps patients establish lifestyle changes

and reinforce self-management.⁹⁵ Therapeutic patient education differs from traditional patient education in its intrinsic structure. Traditional patient education is directed towards informing and teaching patients how to manage their condition or disease. In contrast, therapeutic patient education differs from traditional patient education in the self-management conferred on the patient.⁴⁰ Therefore, therapeutic patient education is more broadly directed towards how the patient accepts his/her condition and manages his/her problems on a daily basis and the impact of the disease on personal, family, professional and social life. Yet, in oncology, few therapeutic patient education studies targeting pain, fatigue, toxicities or treatment adherence are ongoing, and evaluations are rarely conducted.⁴¹ To our knowledge, only one program of therapeutic patient education specific to physical activity has been evaluated in cancer patients.⁴⁵ However, a recent qualitative study has shown the value of therapeutic patient education on the attitudes towards the physical activity of women with breast cancer to promote regular exercise, which is a guarantee of a better quality of life.96

In order to evaluate the efficacy of two interventions in the DISCO trial, the primary outcome measure will be based on the physical activity level of the participants with or without interventions compared to international recommendations. The RPAQ questionnaire will be used for the primary outcome measure on account of its easy implementation. The authors acknowledge that this declarative evaluation confers methodological limits to the study. But the RPAQ questionnaire has been validated against objective methods (i.e., combined accelerometry and heart rate monitoring)⁶⁷ to evaluate moderate-to-vigorous physical activities, which is relevant for the primary outcome. No objective measures of physical activity have been planned because of organisational and logistic difficulties to equip and follow participants for one week (i.e., the usual duration of monitoring with an accelerometer such as Actigraph[™]).⁹⁷ Such a test would even be particularly overwhelming for cancer patients during the demanding period of adjuvant treatment onset. Additionally, the number of daily steps reported by the activity tracker was not chosen as the primary outcome because the activity tracker used in the study was not validated for monitoring physical activity in research or for

BMJ Open

medical purposes when the study was designed, although its reliability was evaluated against other
 devices (data not shown). However, recently the performance and reliability of smart devices tend to
 be increasingly validated.⁹⁸

To understand the results of the DISCO clinical study, it is essential to study beliefs about connected devices and their appropriation by the patients, particularly to understand why behaviours of the patients tend to fade over time. In therapeutic education, beliefs and representations are essential to the success of the intervention. Moreover, with the connected devices, only technical dimensions are not sufficient to understand and highlight why individuals adopt or misuse the connected devices.^{73,74} There is still limited evidence or contrasting conclusions surrounding the cost-effectiveness of interventions promoting physical activity among women with breast cancer from studies conducted in France, the Netherland and Australia.^{99–104} In various chronic conditions other than cancer, there is now clear evidence in favour of exercise-based programs for the treatment of various chronic conditions such as musculoskeletal, rheumatologic disorders, and cardiovascular diseases.¹⁰⁵ As more research is needed to evaluate the cost-effectiveness of physical activity in the treatment of cancers, particularly breast cancer, the economic evaluation planned in the DISCO trial will fill in the gap by adding useful information.

In conclusion, the study findings will provide valuable information on the efficacy of exercise
 interventions during breast cancer treatments, overcoming current barriers of access to facilities. They
 will further guide the development of evidence-based innovative interventions, to systematically
 include physical activity in the breast cancer care process. Finally, the economic evaluation planned in
 the DISCO trial will provide useful information for decision-makers.

Supplementary file 1: SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol.
 Supplementary file 2: English language example of the patient consent

1 2		
3 4	791	Abbreviations
5 6	792	BMI: body mass index;
7 8	793	eCRF: electronic case report form;
9 10 11	794	EORTC QLQ-C30: European Organization for Research and Treatment of Cancer Quality-Of-Life
12 13	795	Questionnaire;
14 15	796	EPICES: Evaluation of Deprivation and Inequalities in Health Examination Centres (questionnaire);
16 17	797	ITT: intent-to-treat;
18 19 20 21 22	798	MET: metabolic equivalent of task;
	799	PFS-12: Piper Fatigue Scale-12;
23 24	800	RPAQ: Recent Physical Activity Questionnaire;
25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44	801	WHO: World Health Organization;
	802	6MWT: six-minute walk test.
	803	
	804	Acknowledgments
	805	The authors are thanksful to Romain Buono, Meyssane Djebali, Carmen Dupuis, Stephany Fiore, Emilie
	806	Rémir, Cécile Dalban, Antonin Poullet, Renaud Meyrand, Rodolf Mongondry, Magali Dubois, Solène
	807	Poirey, Valentine Bertollin, Amélie Dupré, Apolline Michel, Axel Lion, Magalie Hureau and Morgane
	808	Sejallon for their contribution to the conduct of the DISCO trial at the Léon Bérard cancer centre. The
	809	authors are also grateful to Mrs Françoise Picard from Europa Donna France, association of breast
45 46	810	cancer patients' representatives, for her active participation, advice and support in the DISCO trial, and
47 48 49	811	to Dr Hwayoung Noh for English editing.
50 51	812	
52 53	813	Authors' contributions
54 55	814	BFe (principal investigator), MT, LD and TD conceived the study. BFe and MT obtained funding for the
56 57 58	815	research. BFe, MT, BFo and OP designed the protocol. DP and OP conceived the methodological
58 59 60	816	aspects of the trial. BFe, MT, BFo, LD, FF, SP and TD conceived the connected device and exercise
		32

BMJ Open

2		
2 3 4	817	training. LP, MT, OP, AM and EB designed the medico-economic study and eCRF. MP, TL, MT, OP and
5 6	818	AM designed the part on uses and representations. J-BF, MT and OP designed the part on occupational
7 8	819	status. All authors were involved in in planning the methods and measurement and a priori analysis
9 10 11	820	planning. MT and BFo wrote the initial draft of the manuscript. All authors reviewed and provided
11 12 13	821	comprehensive contribution to the manuscript, and approved the final manuscript.
14 15	822	
16 17	823	Funding
18 19 20	824	The DISCO trial is financially supported by the "Fondation ARC pour la Recherche sur le Cancer" and
20 21 22	825	the French National Cancer Institute ("Institut National du Cancer") (grant no. PREV201601260), the
23 24	826	Foundation for Medical Research ("Fondation pour la Recherche Médicale", grant no.
25 26	827	DOC20161136212), "Métropole de Lyon / Cancéropôle Lyon Auvergne Rhône-Alpes" (CLARA) (grant
27 28 29	828	no. 2016 Projet Structurant) and AG2R La Mondiale.
30 31	829	Competing interests None declared. Ethics approval
32 33	830	Competing interests
34 35	831	None declared.
36 37 38	832	
39 40	833	Ethics approval
41 42	834	Ethics approval was provided by the French Ethics Committee (Comité de Protection des Personnes
43 44	835	Est I).
45 46 47	836	
48 49	837	References
50	838	1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018:
51	839	GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.
52 53	840	CA Cancer J Clin. 2018;68(6):394-424. doi:10.3322/caac.21492
54 55	841	2. Defossez G, Le Guyader-Peyrou S, Uhry Z, et al. Estimations nationales de l'incidence et de la
55 56	842	mortalité par cancer en France métropolitaine entre 1990 et 2018. Étude à partir des registres
57	843	des cancers du réseau Francim. Synthèse. Santé publique France; 2019:20. https://www.e-
58	844	cancer.fr/content/download/266450/3759432/file/Synthese_Estimations%20nationales%20in
59	845	cidence%20et%20mortalite%20par%20cancer_juillet_2019.pdf
60		

1 2			
3 4 5 6	846 847 848	3.	Cowppli-Bony A, Uhry Z, Remontet L, et al. Survival of solid cancer patients in France, 1989-2013: a population-based study. <i>Eur J Cancer Prev</i> . 2017;26(6):461-468. doi:10.1097/CEJ.0000000000000372
7 8 9 10 11	849 850 851 852	4.	Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000- 14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. <i>Lancet</i> . 2018;391(10125):1023-1075. doi:10.1016/S0140-6736(17)33326-3
12 13 14 15 16	853 854 855	5.	Allemani C, Minicozzi P, Berrino F, et al. Predictions of survival up to 10 years after diagnosis for European women with breast cancer in 2000-2002. <i>Int J Cancer</i> . 2013;132(10):2404-2412. doi:10.1002/ijc.27895
17 18 19	856 857	6.	Berger AM, Gerber LH, Mayer DK. Cancer-related fatigue: implications for breast cancer survivors. <i>Cancer</i> . 2012;118(8 Suppl):2261-2269. doi:10.1002/cncr.27475
20 21 22 23 24	858 859 860	7.	Makari-Judson G, Braun B, Jerry DJ, Mertens WC. Weight gain following breast cancer diagnosis: Implication and proposed mechanisms. <i>World J Clin Oncol</i> . 2014;5(3):272-282. doi:10.5306/wjco.v5.i3.272
25 26 27 28	861 862 863	8.	Galizia D, Milani A, Geuna E, et al. Self-evaluation of duration of adjuvant chemotherapy side effects in breast cancer patients: A prospective study. <i>Cancer Med</i> . 2018;7(9):4339-4344. doi:10.1002/cam4.1687
29 30 31 32	864 865 866	9.	Foucaut A-M, Berthouze SE, Touillaud M, et al. Deterioration of Physical Activity Level and Metabolic Risk Factors After Early-Stage Breast Cancer Diagnosis. <i>Cancer Nurs</i> . 2015;38(4):E1- 9. doi:10.1097/NCC.000000000000187
33 34 35 36 37	867 868 869	10.	Møller T, Andersen C, Lillelund C, et al. Physical deterioration and adaptive recovery in physically inactive breast cancer patients during adjuvant chemotherapy: a randomised controlled trial. <i>Sci Rep</i> . 2020;10(1):9710. doi:10.1038/s41598-020-66513-9
38 39 40 41	870 871 872	11.	World Health Organization. <i>Global Recommendations on Physical Activity for Health</i> . World Health Organization; 2011:60. http://apps.who.int/iris/bitstream/10665/44399/1/9789241599979_eng.pdf
42 43 44 45	873 874 875	12.	Chan DSM, Vieira AR, Aune D, et al. Body mass index and survival in women with breast cancer-systematic literature review and meta-analysis of 82 follow-up studies. <i>Ann Oncol</i> . 2014;25(10):1901-1914. doi:10.1093/annonc/mdu042
46 47 48 49 50	876 877 878	13.	Playdon MC, Bracken MB, Sanft TB, Ligibel JA, Harrigan M, Irwin ML. Weight Gain After Breast Cancer Diagnosis and All-Cause Mortality: Systematic Review and Meta-Analysis. <i>J Natl Cancer</i> <i>Inst</i> . 2015;107(12):djv275. doi:10.1093/jnci/djv275
50 51 52 53 54	879 880 881	14.	McTiernan A, Friedenreich CM, Katzmarzyk PT, et al. Physical Activity in Cancer Prevention and Survival: A Systematic Review. <i>Med Sci Sports Exerc</i> . 2019;51(6):1252-1261. doi:10.1249/MSS.0000000000001937
55 56 57 58 59 60	882 883 884	15.	WCRF/AICR. <i>Diet, Nutrition, Physical Activity and Cancer: A Global Perspective. The Third Expert Report.</i> World Cancer Research Fund International/American Institute for Cancer Research; 2018. https://www.wcrf.org/dietandcancer

2			
3 4 5 6	885 886 887	16.	Heywood R, McCarthy AL, Skinner TL. Safety and feasibility of exercise interventions in patients with advanced cancer: a systematic review. <i>Support Care Cancer</i> . 2017;25(10):3031-3050. doi:10.1007/s00520-017-3827-0
7 8 9 10 11	888 889 890	17.	Juvet LK, Thune I, Elvsaas IKØ, et al. The effect of exercise on fatigue and physical functioning in breast cancer patients during and after treatment and at 6 months follow-up: A meta- analysis. <i>Breast</i> . 2017;33:166-177. doi:10.1016/j.breast.2017.04.003
12 13 14 15	891 892 893	18.	Lipsett A, Barrett S, Haruna F, Mustian K, O'Donovan A. The impact of exercise during adjuvant radiotherapy for breast cancer on fatigue and quality of life: A systematic review and meta-analysis. <i>Breast</i> . 2017;32:144-155. doi:10.1016/j.breast.2017.02.002
16 17 18 19	894 895 896	19.	Coughlin SS, Caplan LS, Williams V. Home-based physical activity interventions for breast cancer patients receiving primary therapy: a systematic review. <i>Breast Cancer Res Treat</i> . 2019;178(3):513-522. doi:10.1007/s10549-019-05424-4
20 21 22 23 24	897 898 899	20.	Kang D-W, Lee E-Y, An KY, Min J, Jeon JY, Courneya KS. Associations between physical activity and comorbidities in Korean cancer survivors. <i>J Cancer Surviv</i> . 2018;12(4):441-449. doi:10.1007/s11764-018-0683-y
25 26 27 28	900 901 902	21.	Zeng Y, Huang M, Cheng ASK, Zhou Y, So WKW. Meta-analysis of the effects of exercise intervention on quality of life in breast cancer survivors. <i>Breast Cancer</i> . 2014;21(3):262-274. doi:10.1007/s12282-014-0521-7
29 30 31 32	903 904 905	22.	Buffart LM, Kalter J, Sweegers MG, et al. Effects and moderators of exercise on quality of life and physical function in patients with cancer: An individual patient data meta-analysis of 34 RCTs. <i>Cancer Treat Rev.</i> 2017;52:91-104. doi:10.1016/j.ctrv.2016.11.010
33 34 35 36 37	906 907 908	23.	Lahart IM, Metsios GS, Nevill AM, Carmichael AR. Physical activity, risk of death and recurrence in breast cancer survivors: A systematic review and meta-analysis of epidemiological studies. <i>Acta Oncol</i> . 2015;54(5):635-654. doi:10.3109/0284186X.2014.998275
38 39 40 41	909 910 911	24.	Friedenreich CM, Stone CR, Cheung WY, Hayes SC. Physical Activity and Mortality in Cancer Survivors: A Systematic Review and Meta-Analysis. <i>JNCI Cancer Spectr</i> . 2020;4(1):pkz080. doi:10.1093/jncics/pkz080
42 43 44 45	912 913 914	25.	Friedenreich CM, Neilson HK, Farris MS, Courneya KS. Physical Activity and Cancer Outcomes: A Precision Medicine Approach. <i>Clinical Cancer Research</i> . 2016;22(19):4766-4775. doi:10.1158/1078-0432.CCR-16-0067
46 47 48 49 50 51 52 53 54 55	915 916 917	26.	Demark-Wahnefried W, Schmitz KH, Alfano CM, et al. Weight management and physical activity throughout the cancer care continuum. <i>CA Cancer J Clin</i> . 2018;68(1):64-89. doi:10.3322/caac.21441
	918 919 920 921	27.	Foucaut A-M, Morelle M, Kempf-Lépine A-S, et al. Feasibility of an exercise and nutritional intervention for weight management during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Support Care Cancer</i> . 2019;27(9):3449-3461. doi:10.1007/s00520-019-4658-y
56 57 58 59 60	922 923 924	28.	Turner RR, Steed L, Quirk H, et al. Interventions for promoting habitual exercise in people living with and beyond cancer. <i>Cochrane Database Syst Rev</i> . 2018;9:CD010192. doi:10.1002/14651858.CD010192.pub3

3 4 5 6	925 926 927	29.	Lunde P, Nilsson BB, Bergland A, Kværner KJ, Bye A. The Effectiveness of Smartphone Apps for Lifestyle Improvement in Noncommunicable Diseases: Systematic Review and Meta-Analyses. <i>J Med Internet Res.</i> 2018;20(5):e162. doi:10.2196/jmir.9751
7 8 9 10 11	928 929 930	30.	Schaffer K, Panneerselvam N, Loh KP, et al. Systematic Review of Randomized Controlled Trials of Exercise Interventions Using Digital Activity Trackers in Patients With Cancer. <i>J Natl</i> <i>Compr Canc Netw</i> . 2019;17(1):57-63. doi:10.6004/jnccn.2018.7082
12 13 14 15	931 932 933	31.	Coughlin SS, Caplan LS, Stone R. Use of consumer wearable devices to promote physical activity among breast, prostate, and colorectal cancer survivors: a review of health intervention studies. <i>J Cancer Surviv</i> . 2020;14(3):386-392. doi:10.1007/s11764-020-00855-1
16 17 18 19	934 935 936	32.	Dorri S, Asadi F, Olfatbakhsh A, Kazemi A. A Systematic Review of Electronic Health (eHealth) interventions to improve physical activity in patients with breast cancer. <i>Breast Cancer</i> . 2020;27(1):25-46. doi:10.1007/s12282-019-00982-3
20 21 22 23	937 938	33.	Beg MS, Gupta A, Stewart T, Rethorst CD. Promise of Wearable Physical Activity Monitors in Oncology Practice. <i>J Oncol Pract</i> . 2017;13(2):82-89. doi:10.1200/JOP.2016.016857
23 24 25 26	939 940	34.	Schinköthe T. Individualized eHealth Support for Oncological Therapy Management. <i>Breast Care</i> . 2019;14(3):130-134. doi:10.1159/000500900
27 28 29 30	941 942 943	35.	Phillips SM, Conroy DE, Keadle SK, et al. Breast cancer survivors' preferences for technology- supported exercise interventions. <i>Support Care Cancer</i> . 2017;25(10):3243-3252. doi:10.1007/s00520-017-3735-3
31 32 33 34	944 945 946	36.	Phillips SM, Courneya KS, Welch WA, et al. Breast cancer survivors' preferences for mHealth physical activity interventions: findings from a mixed methods study. <i>J Cancer Surviv</i> . 2019;13(2):292-305. doi:10.1007/s11764-019-00751-3
35 36 37 38 39	947 948 949	37.	Nielsen AM, Welch WA, Gavin KL, et al. Preferences for mHealth physical activity interventions during chemotherapy for breast cancer: a qualitative evaluation. <i>Support Care Cancer</i> . 2020;28(4):1919-1928. doi:10.1007/s00520-019-05002-w
40 41 42	950 951	38.	Lacroix A, Assal J-P. L'éducation thérapeutique des patients: accompagner les patients avec une maladie chronique : nouvelles approches. 3rd ed.; 2011.
43 44 45	952 953	39.	Fabre S. Evaluating therapeutic patient education: Objectives and criteria. <i>Joint Bone Spine</i> . 2017;84(2):121-123. doi:10.1016/j.jbspin.2016.11.002
46 47 48 49 50 51	954 955 956 957	40.	World Health Organization. <i>Therapeutic Patient Education: Continuing Education Programmes</i> for Health Care Providers in the Field of Prevention of Chronic Diseases. Report of a WHO Working Group. World Health Organization, Regional Office for Europe; 1998:76. https://apps.who.int/iris/handle/10665/108151
52 53 54 55	958 959 960	41.	Buiret G, Chidiac F, Pujo K, Combe C. [How to reconcile therapeutic patient education and care pathology in oncology: Application in head and neck neoplams]. <i>Bull Cancer</i> . 2019;106(5):468-478. doi:10.1016/j.bulcan.2019.02.008
56 57 58 59 60	961 962 963	42.	Bourmaud A, Anota A, Moncharmont C, et al. Cancer-related fatigue management: evaluation of a patient education program with a large-scale randomised controlled trial, the PEPs fatigue study. <i>Br J Cancer</i> . 2017;116(7):849-858. doi:10.1038/bjc.2017.31

2			
3	964	43.	Pérol D, Toutenu P, Lefranc A, et al. [Therapeutic education in oncology: involving patient in
4 5	965		the management of cancer]. Bull Cancer. 2007;94(3):267-274.
6	966	44.	Arthurs G, Simpson J, Brown A, Kyaw O, Shyrier S, Concert CM. The effectiveness of
7 8	967		therapeutic patient education on adherence to oral anti-cancer medicines in adult cancer
9	968		patients in ambulatory care settings: a systematic review. JBI Database System Rev Implement
10	969		<i>Rep</i> . 2015;13(5):244-292. doi:10.11124/jbisrir-2015-2057
11			
12	970	45.	Carayol M, Delpierre C, Bernard P, Ninot G. Population-, intervention- and methodology-
13 14	971		related characteristics of clinical trials impact exercise efficacy during adjuvant therapy for
15	972 973		breast cancer: a meta-regression analysis. <i>Psychooncology</i> . 2015;24(7):737-747.
16	973		doi:10.1002/pon.3727
17	974	46.	Conn VS, Hafdahl AR, Brown SA, Brown LM. Meta-analysis of patient education interventions
18	975		to increase physical activity among chronically ill adults. <i>Patient Educ Couns</i> . 2008;70(2):157-
19 20	976		172. doi:10.1016/j.pec.2007.10.004
20			
22	977	47.	Meneses-Echávez JF, Correa-Bautista JE, González-Jiménez E, et al. The Effect of Exercise
23	978		Training on Mediators of Inflammation in Breast Cancer Survivors: A Systematic Review with
24	979		Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2016;25(7):1009-1017. doi:10.1158/1055-
25 26	980		9965.EPI-15-1061
27	981	48.	Kang D-W, Lee J, Suh S-H, Ligibel J, Courneya KS, Jeon JY. Effects of Exercise on Insulin, IGF
28	982	40.	Axis, Adipocytokines, and Inflammatory Markers in Breast Cancer Survivors: A Systematic
29	983		Review and Meta-analysis. <i>Cancer Epidemiol Biomarkers Prev.</i> 2017;26(3):355-365.
30 31	984		doi:10.1158/1055-9965.EPI-16-0602
32			
33	985	49.	Ballard-Barbash R, Friedenreich CM, Courneya KS, Siddiqi SM, McTiernan A, Alfano CM.
34	986		Physical activity, biomarkers, and disease outcomes in cancer survivors: a systematic review. J
35	987		Natl Cancer Inst. 2012;104(11):815-840. doi:10.1093/jnci/djs207
36 37	988	50.	Patel AV, Friedenreich CM, Moore SC, et al. American College of Sports Medicine Roundtable
38	989	50.	Report on Physical Activity, Sedentary Behavior, and Cancer Prevention and Control. <i>Med Sci</i>
39	990		Sports Exerc. 2019;51(11):2391-2402. doi:10.1249/MSS.000000000002117
40			
41 42	991	51.	Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in
43	992		reducing cancer risk and progression. Nat Rev Cancer. 2014;14(5):342-357.
44	993		doi:10.1038/nrc3691
45	994	52.	Haute Autorité de Santé. Recommandations professionnelles - Stratégie de prise en charge en
46 47	994 995	52.	cas de dénutrition protéino-énergétique chez la personne âgée [Professional recommendations
47	996		- Management strategy in case of protein-energy malnutrition in the Elderly]. Haute Autorité
49	997		de Santé; 2007:25. https://www.has-
50	998		sante.fr/upload/docs/application/pdf/denutrition_personne_agee_2007
51 52	999		_recommandations.pdf
52 53			
54	1000	53.	Besson H, Brage S, Jakes RW, Ekelund U, Wareham NJ. Estimating physical activity energy
55	1001		expenditure, sedentary time, and physical activity intensity by self-report in adults. Am J Clin
56	1002		<i>Nutr</i> . 2010;91(1):106-114. doi:10.3945/ajcn.2009.28432
57 58	1003	54.	Pocock SJ, Simon R. Sequential Treatment Assignment with Balancing for Prognostic Factors in
58 59	1003		the Controlled Clinical Trial. <i>Biometrics</i> . 1975;31(1):103-115. doi:10.2307/2529712
60			

1 2			
3 4 5 6	1005 1006 1007	55.	Scott NW, McPherson GC, Ramsay CR, Campbell MK. The method of minimization for allocation to clinical trials. a review. <i>Control Clin Trials</i> . 2002;23(6):662-674. doi:10.1016/s0197-2456(02)00242-8
7 8 9 10	1008 1009 1010	56.	Neil-Sztramko SE, Kirkham AA, Hung SH, Niksirat N, Nishikawa K, Campbell KL. Aerobic capacity and upper limb strength are reduced in women diagnosed with breast cancer: a systematic review. <i>J Physiother</i> . 2014;60(4):189-200. doi:10.1016/j.jphys.2014.09.005
11 12 13 14 15	1011 1012 1013	57.	Rikli RE, Jones CJ. Functional Fitness Normative Scores for Community-Residing Older Adults, Ages 60-94. <i>Journal of Aging and Physical Activity</i> . 1999;7(2):162-181. doi:10.1123/japa.7.2.162
16 17 18 19	1014 1015 1016	58.	Campbell KL, Neil SE, Winters-Stone KM. Review of exercise studies in breast cancer survivors: attention to principles of exercise training. <i>Br J Sports Med</i> . 2012;46(13):909-916. doi:10.1136/bjsports-2010-082719
20 21 22 23 24	1017 1018 1019	59.	Sasso JP, Eves ND, Christensen JF, Koelwyn GJ, Scott J, Jones LW. A framework for prescription in exercise-oncology research. <i>J Cachexia Sarcopenia Muscle</i> . 2015;6(2):115-124. doi:10.1002/jcsm.12042
25 26 27 28	1020 1021 1022	60.	Ainsworth BE, Haskell WL, Herrmann SD, et al. 2011 Compendium of Physical Activities: a second update of codes and MET values. <i>Med Sci Sports Exerc</i> . 2011;43(8):1575-1581. doi:10.1249/MSS.0b013e31821ece12
29 30 31 32	1023 1024 1025	61.	Fassier J-B, Durand M-J, Caillard J-F, Roquelaure Y, Loisel P. Results of a feasibility study: barriers and facilitators in implementing the Sherbrooke model in France. <i>Scand J Work Environ Health</i> . 2015;41(3):223-233. doi:10.5271/sjweh.3489
33 34 35 36	1026 1027	62.	Schmidt K, Vogt L, Thiel C, Jäger E, Banzer W. Validity of the six-minute walk test in cancer patients. <i>Int J Sports Med</i> . 2013;34(7):631-636. doi:10.1055/s-0032-1323746
37 38 39 40	1028 1029 1030	63.	Jones CJ, Rikli RE, Beam WC. A 30-s chair-stand test as a measure of lower body strength in community-residing older adults. <i>Res Q Exerc Sport</i> . 1999;70(2):113-119. doi:10.1080/02701367.1999.10608028
41 42 43 44 45	1031 1032 1033 1034	64.	Cantarero-Villanueva I, Fernández-Lao C, Díaz-Rodríguez L, Fernández-de-Las-Peñas C, Ruiz JR, Arroyo-Morales M. The handgrip strength test as a measure of function in breast cancer survivors: relationship to cancer-related symptoms and physical and physiologic parameters. <i>Am J Phys Med Rehabil</i> . 2012;91(9):774-782. doi:10.1097/PHM.0b013e31825f1538
46 47 48 49 50	1035 1036 1037	65.	Wells KF, Dillon EK. The Sit and Reach—A Test of Back and Leg Flexibility. <i>Research Quarterly American Association for Health, Physical Education and Recreation</i> . 1952;23(1):115-118. doi:10.1080/10671188.1952.10761965
51 52 53 54	1038 1039 1040	66.	Bohannon RW. Single Limb Stance Times: A Descriptive Meta-Analysis of Data From Individuals at Least 60 Years of Age. <i>Topics in Geriatric Rehabilitation</i> . 2006;22(1):70-77. doi:10.1097/00013614-200601000-00010
55 56 57 58 59 60	1041 1042 1043	67.	Golubic R, May AM, Benjaminsen Borch K, et al. Validity of electronically administered Recent Physical Activity Questionnaire (RPAQ) in ten European countries. <i>PLoS ONE</i> . 2014;9(3):e92829. doi:10.1371/journal.pone.0092829

1 2			
3 4 5 6	1044 1045 1046	68.	Hjermstad MJ, Fossa SD, Bjordal K, Kaasa S. Test/retest study of the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire. <i>J Clin Oncol</i> . 1995;13(5):1249-1254. doi:10.1200/JCO.1995.13.5.1249
7 8 9 10 11	1047 1048 1049	69.	Janssen MF, Pickard AS, Golicki D, et al. Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: a multi-country study. <i>Qual Life Res</i> . 2013;22(7):1717-1727. doi:10.1007/s11136-012-0322-4
12 13 14 15	1050 1051 1052	70.	Reeve BB, Stover AM, Alfano CM, et al. The Piper Fatigue Scale-12 (PFS-12): psychometric findings and item reduction in a cohort of breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2012;136(1):9-20. doi:10.1007/s10549-012-2212-4
16 17 18	1053 1054	71.	Labbe E, Blanquet M, Gerbaud L, et al. A new reliable index to measure individual deprivation: the EPICES score. <i>Eur J Public Health</i> . 2015;25(4):604-609. doi:10.1093/eurpub/cku231
19 20 21 22 23	1055 1056 1057	72.	Centers for Disease Control and Prevention. Overcoming Barriers to Physical Activity: Barriers to Being Active Quiz-What keeps you from being more active? Published online 2007. https://www.cdc.gov/diabetes/ndep/pdfs/8-road-to-health-barriers-quiz-508.pdf
23 24 25 26	1058 1059	73.	Venkatesh, Morris, Davis, Davis. User Acceptance of Information Technology: Toward a Unified View. <i>MIS Quarterly</i> . 2003;27(3):425. doi:10.2307/30036540
27 28 29	1060 1061	74.	Ajzen I. The theory of planned behavior. <i>Organizational Behavior and Human Decision Processes</i> . 1991;50(2):179-211. doi:10.1016/0749-5978(91)90020-T
30 31 32 33 34	1062 1063 1064 1065	75.	Jodelet, D. Interconnections between social representations and intervention. In: <i>Social Representations in the "Social Arena."</i> A. De Rosa. Routledge; 2012:77-88. https://www.academia.edu/36160041/Jodelet_D2012Interconnections_between_social _representations_and_intervention
35 36 37 38	1066 1067	76.	Green S, Liu P-Y, O'Sullivan J. Factorial design considerations. <i>J Clin Oncol</i> . 2002;20(16):3424- 3430. doi:10.1200/JCO.2002.03.003
39 40 41	1068 1069	77.	Frick KD. Microcosting quantity data collection methods. <i>Med Care</i> . 2009;47(7 Suppl 1):S76-81. doi:10.1097/MLR.0b013e31819bc064
42 43 44 45	1070 1071 1072	78.	El Khal M, Perrier L, Carretier J, et al. [The cost of the therapeutic education program "Eat better, move more through nutrition education" in patients with breast cancer]. <i>Bull Cancer</i> . 2020;107(12):1252-1259. doi:10.1016/j.bulcan.2020.07.003
46 47 48 49 50 51	1073 1074 1075 1076	79.	Haute Autorité de Santé. <i>Guide méthodologique - Choix méthodologique pour l'évaluation économique à la HAS [Methodological guide - Methodological choices for economic evaluation at the National Health Authority</i>]. Haute Autorité de Santé; 2011:83. https://www.has-sante.fr/upload/docs/application/pdf/2011-11/guide_methodo_vf.pdf
52 53 54	1077 1078	80.	Rock CL, Doyle C, Demark-Wahnefried W, et al. Nutrition and physical activity guidelines for cancer survivors. <i>CA Cancer J Clin</i> . 2012;62(4):243-274. doi:10.3322/caac.21142
55 56 57 58 59 60	1079 1080 1081	81.	Institut National du Cancer. <i>Plan cancer 2014-2019 : priorités et objectifs</i> . Institut National du Cancer; 2015:210. http://www.e-cancer.fr/Plan-cancer/Plan-cancer-2014-2019-priorites-et-objectifs

3 4 5	1082 1083	82.	Arends J, Bachmann P, Baracos V, et al. ESPEN guidelines on nutrition in cancer patients. <i>Clin Nutr</i> . 2017;36(1):11-48. doi:10.1016/j.clnu.2016.07.015
6 7 8 9 10 11	1084 1085 1086 1087	83.	Sweegers MG, Altenburg TM, Chinapaw MJ, et al. Which exercise prescriptions improve quality of life and physical function in patients with cancer during and following treatment? A systematic review and meta-analysis of randomised controlled trials. <i>Br J Sports Med</i> . 2018;52(8):505-513. doi:10.1136/bjsports-2017-097891
12 13 14 15 16	1088 1089 1090 1091	84.	Bluethmann SM, Vernon SW, Gabriel KP, Murphy CC, Bartholomew LK. Taking the next step: a systematic review and meta-analysis of physical activity and behavior change interventions in recent post-treatment breast cancer survivors. <i>Breast Cancer Res Treat</i> . 2015;149(2):331-342. doi:10.1007/s10549-014-3255-5
17 18 19 20 21	1092 1093 1094	85.	Delrieu L, Vallance JK, Morelle M, et al. Physical activity preferences before and after participation in a 6-month physical activity intervention among women with metastatic breast cancer. <i>Eur J Cancer Care (Engl)</i> . 2020;29(1):e13169. doi:10.1111/ecc.13169
22 23 24 25	1095 1096 1097	86.	Quintiliani LM, Mann DM, Puputti M, Quinn E, Bowen DJ. Pilot and Feasibility Test of a Mobile Health-Supported Behavioral Counseling Intervention for Weight Management Among Breast Cancer Survivors. <i>JMIR Cancer</i> . 2016;2(1):e4. doi:10.2196/cancer.5305
26 27 28 29	1098 1099 1100	87.	Delrieu L, Pialoux V, Pérol O, et al. Feasibility and Health Benefits of an Individualized Physical Activity Intervention in Women With Metastatic Breast Cancer: Intervention Study. <i>JMIR Mhealth Uhealth</i> . 2020;8(1):e12306. doi:10.2196/12306
30 31 32 33 34	1101 1102 1103	88.	Groen WG, van Harten WH, Vallance JK. Systematic review and meta-analysis of distance- based physical activity interventions for cancer survivors (2013-2018): We still haven't found what we're looking for. <i>Cancer Treat Rev.</i> 2018;69:188-203. doi:10.1016/j.ctrv.2018.07.012
35 36 37 38	1104 1105 1106	89.	Cadmus-Bertram LA, Marcus BH, Patterson RE, Parker BA, Morey BL. Randomized Trial of a Fitbit-Based Physical Activity Intervention for Women. <i>Am J Prev Med</i> . 2015;49(3):414-418. doi:10.1016/j.amepre.2015.01.020
39 40 41 42	1107 1108 1109	90.	Lavallée JF, Abdin S, Faulkner J, Husted M. Barriers and facilitators to participating in physical activity for adults with breast cancer receiving adjuvant treatment: A qualitative metasynthesis. <i>Psychooncology</i> . 2019;28(3):468-476. doi:10.1002/pon.4980
43 44 45 46 47	1110 1111 1112	91.	Westphal T, Rinnerthaler G, Gampenrieder SP, et al. Supervised versus autonomous exercise training in breast cancer patients: A multicenter randomized clinical trial. <i>Cancer Med</i> . 2018;7(12):5962-5972. doi:10.1002/cam4.1851
48 49 50 51	1113 1114 1115	92.	O'Brien T, Troutman-Jordan M, Hathaway D, Armstrong S, Moore M. Acceptability of wristband activity trackers among community dwelling older adults. <i>Geriatr Nurs</i> . 2015;36(2 Suppl):S21-25. doi:10.1016/j.gerinurse.2015.02.019
52 53 54	1116 1117	93.	Ho A, Quick O. Leaving patients to their own devices? Smart technology, safety and therapeutic relationships. <i>BMC Med Ethics</i> . 2018;19(1):18. doi:10.1186/s12910-018-0255-8
55 56 57 58 59 60	1118 1119 1120	94.	European Union (EU), European Economic Area (EEA). General Data Protection Regulation (EU). Published online May 4, 2016. https://ec.europa.eu/info/law/law-topic/data-protection-rules_en

2			
3 4 5	1121 1122	95.	Lagger G, Pataky Z, Golay A. Efficacy of therapeutic patient education in chronic diseases and obesity. <i>Patient Educ Couns</i> . 2010;79(3):283-286. doi:10.1016/j.pec.2010.03.015
6 7 8 9 10 11	1123 1124 1125 1126	96.	Mino J-C, Lefève C. Improved understanding of the experience of physical activity after a cancer from a philosophy of health perspective [Mieux comprendre l'expérience de l'activité physique après un cancer grâce à la philosophie de la santé]. <i>Santé Publique</i> . 2016;28 Suppl 1:S101-107.
12 13 14 15	1127 1128 1129	97.	Peddle-McIntyre CJ, Cavalheri V, Boyle T, et al. A Review of Accelerometer-based Activity Monitoring in Cancer Survivorship Research. <i>Med Sci Sports Exerc</i> . 2018;50(9):1790-1801. doi:10.1249/MSS.000000000001644
16 17 18 19	1130 1131 1132	98.	Degroote L, De Bourdeaudhuij I, Verloigne M, Poppe L, Crombez G. The Accuracy of Smart Devices for Measuring Physical Activity in Daily Life: Validation Study. <i>JMIR Mhealth Uhealth</i> . 2018;6(12):e10972. doi:10.2196/10972
20 21 22 23 24 25	1133 1134 1135 1136	99.	Mourgues C, Gerbaud L, Leger S, et al. Positive and cost-effectiveness effect of spa therapy on the resumption of occupational and non-occupational activities in women in breast cancer remission: a French multicentre randomised controlled trial. <i>Eur J Oncol Nurs</i> . 2014;18(5):505-511. doi:10.1016/j.ejon.2014.04.008
26 27 28 29	1137 1138 1139	100.	Mewes JC, Steuten LMG, Duijts SFA, et al. Cost-effectiveness of cognitive behavioral therapy and physical exercise for alleviating treatment-induced menopausal symptoms in breast cancer patients. <i>J Cancer Surviv</i> . 2015;9(1):126-135. doi:10.1007/s11764-014-0396-9
30 31 32 33 34	1140 1141 1142	101.	Gordon LG, DiSipio T, Battistutta D, et al. Cost-effectiveness of a pragmatic exercise intervention for women with breast cancer: results from a randomized controlled trial. <i>Psychooncology</i> . 2017;26(5):649-655. doi:10.1002/pon.4201
35 36 37 38	1143 1144 1145	102.	van Waart H, van Dongen JM, van Harten WH, et al. Cost-utility and cost-effectiveness of physical exercise during adjuvant chemotherapy. <i>Eur J Health Econ</i> . 2018;19(6):893-904. doi:10.1007/s10198-017-0936-0
39 40 41 42 43	1146 1147 1148 1149	103.	Perrier L, Foucaut A-M, Morelle M, et al. Cost-effectiveness of an exercise and nutritional intervention versus usual nutritional care during adjuvant treatment for localized breast cancer: the PASAPAS randomized controlled trial. <i>Support Care Cancer</i> . 2020;28(6):2829-2842. doi:10.1007/s00520-019-05078-4
44 45 46 47 48	1150 1151 1152	104.	Khan KA, Mazuquin B, Canaway A, Petrou S, Bruce J. Systematic review of economic evaluations of exercise and physiotherapy for patients treated for breast cancer. <i>Breast Cancer Res Treat</i> . 2019;176(1):37-52. doi:10.1007/s10549-019-05235-7
48 49 50 51 52 53 54 55 56 57 58 59 60	1153 1154 1155 1156 1157	105.	Guillon M, Rochaix L, Dupont J-CK. COST-EFFECTIVENESS OF INTERVENTIONS BASED ON PHYSICAL ACTIVITY IN THE TREATMENT OF CHRONIC CONDITIONS: A SYSTEMATIC LITERATURE REVIEW. <i>Int J Technol Assess Health Care</i> . 2018;34(5):481-497. doi:10.1017/S0266462318000533

Table 1 Summary of outcome measures and data collection schedule for the DISCO trial

Assessments Tools Baseline 6 months 12 months +1month ±1month ±1month Patient's medical record Demographic and clinical data Month/year of birth Х 10 Age at diagnosis Х 11 **Employment status** Х Х Х 12 Personal history of breast cancer Х -13 Х Х Х Current treatment 14 Hormonal receptor status Х 15 Tumour histology Х _ 16 Disease progression Х Х 17 Anthropometrics 18 19 Х Height Gauge 20 Weight Scale Х Х Х 21 Waist-to-hip circumference Measuring tape Х Х Х 22 Х Body composition: fat mass, lean **Bioelectrical impedance** Х Х 23 mass, dry lean mass, body water analysis 24 25 **Physical fitness** Х Х Х 26 Walking endurance with perceived 6MWT and Borg scale 27 difficulty 28 Lower limb muscle strength Sit-to-stand test 29 Hand prehensile strength Hand-grip test 30 -Flexibility of lower limbs Sit-and-reach flexibility test 31 Single-leg stance test Balance 32 Х 33 Physical activity level, sitting time and **RPAQ Questionnaire** Х Х 34 achievement of physical activity 35 recommendations 36 **Patient-reported outcomes** 37 Quality of life EORTC QLQ-C30 questionnaire Х Х Х 38 and BR-23 module 39 Х Х Х Health-related quality of life EQ-5D-5L Questionnaire 40 PFS-12 questionnaire Х Х Х -Fatigue 41 Х -Social vulnerability **EPICES** questionnaire Х 42 43 **Determinants of physical activity** 44 Barriers to regular physical activity; Self-administered questionnaire Х Х Х 45 lifestyle 46 Uses, representations and Online self-administered Х Х Х 47 motivation of physical activity; questionnaire 48 acceptability of activity trackers 49 (only for patients in the "connected 50 device" and "combined" arms); 51 52 acceptability of therapeutic patient 53 education (only for patients in the 54 "therapeutic patient education" and 55 "combined" arms) 56 Х **Biological data Blood** sample Х 57 Serum endocrine factors (IGF-1, 58 insulin, estradiol) 59

60

1 2 3

4 5

6

7


8

9

1 2						
3 4	Ī	Assessments	Tools	Baseline +1month	6 months ±1month	12 months ±1month
5 6 7 8 9 10		 Plasmatic inflammatory cytokines (IL-6, TNFα, CRP) Plasmatic adipokines (adiponectin, leptin) Vitamin D status 				
11 12 13 14 15		Compliance with each intervention (only for patients in the "connected device", "therapeutic patient education" and "combined" arms)	Connected device and/or patient's record		Х	
16		Adverse events (neuropathies, joint pain)	Patient's diary <u>, CTCAE v5</u>		Х	Х
17	1159	Notes. 6MWT: six-minute walk test	i			
18 19 20 21 22	1160					
23 24 25						
26						
27						
28 29						
30						
31						
32						
33						
34						
35 36						
30 37						
38						
39						
40						
41						
42						
43 44						
44						
46						
47						
48						
49 50						
50						
52						
53						
54						
55 56						
50 57						
58						
59						
60						

1 2		
- 3 4	1161	Figure 1 Flow chart of participants through the DISCO trial.
5 6	1162	
7		
8 9		
10 11		
12		
13 14		
15 16		
17		
18 19		
20 21		
22		
23 24		
25 26		
27 28		
29		
30 31		
32 33		
34 35		
36		
37 38		
39 40		
41 42		
43		
44 45		
46 47		
48		
49 50		
51 52		
53		
54 55		
56 57		
58		
59 60		

Page 47 of 51





SPIRIT 2013 Checklist: Recommended items to address in a clinical trial protocol and related documents*

Section/item	ltem No	Description	Addressed on page number
Administrative inf	ormation		
Title	1	Descriptive title identifying the study design, population, interventions, and, if applicable, trial acronym	1
Trial registration	2a	Trial identifier and registry name. If not yet registered, name of intended registry	2, 26
	2b	All items from the World Health Organization Trial Registration Data Set	N/A
Protocol version	3	Date and version identifier	8, ethics copy
Funding	4	Sources and types of financial, material, and other support	30, funding copy
Roles and	5a	Names, affiliations, and roles of protocol contributors	1, 31-32
responsibilities	5b	Name and contact information for the trial sponsor	1
	5c	Role of study sponsor and funders, if any, in study design; collection, management, analysis, and interpretation of data; writing of the report; and the decision to submit the report for publication, including whether they will have ultimate authority over any of these activities	31
	5d	Composition, roles, and responsibilities of the coordinating centre, steering committee, endpoint adjudication committee, data management team, and other individuals or groups overseeing the trial, if applicable (see Item 21a for data monitoring committee)	31
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

BMJ Open

1				
1 2	Introduction			
3 4 5	Background and rationale	6a	Description of research question and justification for undertaking the trial, including summary of relevant studies (published and unpublished) examining benefits and harms for each intervention	7
6 7		6b	Explanation for choice of comparators	7
8 9	Objectives	7	Specific objectives or hypotheses	7
10 11 12 13	Trial design	8	Description of trial design including type of trial (eg, parallel group, crossover, factorial, single group), allocation ratio, and framework (eg, superiority, equivalence, noninferiority, exploratory)	8
14 15	Methods: Participa	nts, inte	erventions, and outcomes	
16 17 18	Study setting	9	Description of study settings (eg, community clinic, academic hospital) and list of countries where data will be collected. Reference to where list of study sites can be obtained	8
19 20 21	Eligibility criteria	10	Inclusion and exclusion criteria for participants. If applicable, eligibility criteria for study centres and individuals who will perform the interventions (eg, surgeons, psychotherapists)	8-9
22 23 24 25	Interventions	11a	Interventions for each group with sufficient detail to allow replication, including how and when they will be administered	9-15
25 26 27 28		11b	Criteria for discontinuing or modifying allocated interventions for a given trial participant (eg, drug dose change in response to harms, participant request, or improving/worsening disease)	12-13
29 30 31		11c	Strategies to improve adherence to intervention protocols, and any procedures for monitoring adherence (eg, drug tablet return, laboratory tests)	13-14
32 33		11d	Relevant concomitant care and interventions that are permitted or prohibited during the trial	N/A
34 35 36 37 38 39	Outcomes	12	Primary, secondary, and other outcomes, including the specific measurement variable (eg, systolic blood pressure), analysis metric (eg, change from baseline, final value, time to event), method of aggregation (eg, median, proportion), and time point for each outcome. Explanation of the clinical relevance of chosen efficacy and harm outcomes is strongly recommended	17, Table 1
39 40 41 42	Participant timeline	13	Time schedule of enrolment, interventions (including any run-ins and washouts), assessments, and visits for participants. A schematic diagram is highly recommended (see Figure)	9, 16-17, Figure1, Table1
43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	2

BMJ Open

1 2	Sample size	14	Estimated number of participants needed to achieve study objectives and how it was determined, including clinical and statistical assumptions supporting any sample size calculations	22	
3 4 5	Recruitment	15	Strategies for achieving adequate participant enrolment to reach target sample size	8	
6 7	Methods: Assignme	ent of ir	nterventions (for controlled trials)		
8 9	Allocation:				
10 11 12 13 14 15	Sequence generation	16a	Method of generating the allocation sequence (eg, computer-generated random numbers), and list of any factors for stratification. To reduce predictability of a random sequence, details of any planned restriction (eg, blocking) should be provided in a separate document that is unavailable to those who enrol participants or assign interventions	10	
16 17 18 19	Allocation concealment mechanism	16b	Mechanism of implementing the allocation sequence (eg, central telephone; sequentially numbered, opaque, sealed envelopes), describing any steps to conceal the sequence until interventions are assigned	10	
20 21 22 23	Implementation	16c	Who will generate the allocation sequence, who will enrol participants, and who will assign participants to interventions	9-10	
23 24 25 26	Blinding (masking)	17a	Who will be blinded after assignment to interventions (eg, trial participants, care providers, outcome assessors, data analysts), and how	N/A	
27 28 29		17b	If blinded, circumstances under which unblinding is permissible, and procedure for revealing a participant's allocated intervention during the trial	N/A	
30 31	Methods: Data colle	ection,	management, and analysis		
32 33 34 35 36 37	Data collection methods	18a	Plans for assessment and collection of outcome, baseline, and other trial data, including any related processes to promote data quality (eg, duplicate measurements, training of assessors) and a description of study instruments (eg, questionnaires, laboratory tests) along with their reliability and validity, if known. Reference to where data collection forms can be found, if not in the protocol	17-21	
38 39 40 41		18b	Plans to promote participant retention and complete follow-up, including list of any outcome data to be collected for participants who discontinue or deviate from intervention protocols	17	
42 43 44 45			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml		3

Page 51 of 51

BMJ Open

1 2 3 4	Data management	19	Plans for data entry, coding, security, and storage, including any related processes to promote data quality (eg, double data entry; range checks for data values). Reference to where details of data management procedures can be found, if not in the protocol	17, 24
5 6 7	Statistical methods	20a	Statistical methods for analysing primary and secondary outcomes. Reference to where other details of the statistical analysis plan can be found, if not in the protocol	23-24
8 9		20b	Methods for any additional analyses (eg, subgroup and adjusted analyses)	10, 23-24
10 11 12 13		20c	Definition of analysis population relating to protocol non-adherence (eg, as randomised analysis), and any statistical methods to handle missing data (eg, multiple imputation)	23-24
14 15	Methods: Monitorin	g		
16 17 18 19 20 21	Data monitoring	21a	Composition of data monitoring committee (DMC); summary of its role and reporting structure; statement of whether it is independent from the sponsor and competing interests; and reference to where further details about its charter can be found, if not in the protocol. Alternatively, an explanation of why a DMC is not needed	25
22 23 24		21b	Description of any interim analyses and stopping guidelines, including who will have access to these interim results and make the final decision to terminate the trial	N/A
25 26 27	Harms	22	Plans for collecting, assessing, reporting, and managing solicited and spontaneously reported adverse events and other unintended effects of trial interventions or trial conduct	14, 24-25
28 29 30	Auditing	23	Frequency and procedures for auditing trial conduct, if any, and whether the process will be independent from investigators and the sponsor	25
31 32	Ethics and dissemine	nation		
33 34 35 36	Research ethics approval	24	Plans for seeking research ethics committee/institutional review board (REC/IRB) approval	2, 25-26, 32
37 38 39 40 41	Protocol amendments	25	Plans for communicating important protocol modifications (eg, changes to eligibility criteria, outcomes, analyses) to relevant parties (eg, investigators, REC/IRBs, trial participants, trial registries, journals, regulators)	26
42 43 44 45 46			For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	4

BMJ Open

Consent or assent	26a	Who will obtain informed consent or assent from potential trial participants or authorised surrogates, and how (see Item 32)	8
	26b	Additional consent provisions for collection and use of participant data and biological specimens in ancillary studies, if applicable	N/A
Confidentiality	27	How personal information about potential and enrolled participants will be collected, shared, and maintained in order to protect confidentiality before, during, and after the trial	25
Declaration of interests	28	Financial and other competing interests for principal investigators for the overall trial and each study site	32
Access to data	29	Statement of who will have access to the final trial dataset, and disclosure of contractual agreements that limit such access for investigators	25
Ancillary and post- trial care	30	Provisions, if any, for ancillary and post-trial care, and for compensation to those who suffer harm from trial participation	N/A
Dissemination policy	31a	Plans for investigators and sponsor to communicate trial results to participants, healthcare professionals, the public, and other relevant groups (eg, via publication, reporting in results databases, or other data sharing arrangements), including any publication restrictions	25-26
	31b	Authorship eligibility guidelines and any intended use of professional writers	31
Appendices	31c	Plans, if any, for granting public access to the full protocol, participant-level dataset, and statistical code	N/A
	22	Model concept form and other related documentation given to participants and authorized curregates	0. Supplifile 2
Informed consent materials	32	Model consent form and other related documentation given to participants and authorised surrogates	9, Suppl file 2
Biological specimens	33	Plans for collection, laboratory evaluation, and storage of biological specimens for genetic or molecular analysis in the current trial and for future use in ancillary studies, if applicable	21
Amendments to the p	rotoco	that this checklist be read in conjunction with the SPIRIT 2013 Explanation & Elaboration for important clarificant is should be tracked and dated. The SPIRIT checklist is copyrighted by the SPIRIT Group under the Creative Constraints and Unported income in the creative Constraints and Unported income in the creative constraints and uncome in the creative constraints	
		For peer review only - http://bmjopen.bmj.com/site/about/guidelines.xhtml	

-	rticipate in the DISCO trial on 4.0 of 28 Oct 2020
I, the undersigned, Surname:	First name:
Address:	
Phone number:	
E-mail address:	
acknowledge having been informed by the Docto	r:
of the object and modalities of the DISCO study.	
	the study, its constraints, its potential benefits and risks, and to ask all the questions I wanted and I received clear and prec tween the information and this consent.
stop my participation without having to specify th receive nor my relationship with the healthcare t	participate in this research and that I will be free at any time re reasons and without this changing the quality of the care I ream. In the event that I withdraw my consent, the medical a g me, collected before that date, may be used for the study.
and non-identifying manner and will only be cons health authorities. I accept that they may be proc its behalf. I have noted that I have the right to acc (in accordance with EU regulation n°2016/679 on this right at any time with the doctor in charge identity will not appear in any report or publication	rning me will be collected and recorded in a strictly confiden sulted by the organizers of this study and representatives of essed electronically by the promoter (Centre Léon Bérard) or ess, oppose and rectify any personal information concerning the protection of personal data (GDPR)) and that I can exerc of the research, who alone knows my identity. I know that on. I also accept that these data (strictly confidential and trea y be used in subsequent research for scientific purposes. I ise my right to object at any time.
the Centre Léon Bérard (<u>dpd@lyon.unicancer.fr</u>) despite the commitment of the Centre Léon B	doctor who follows me or the Data Protection Officer (DPO to obtain information concerning the protection of my data érard to respect my rights and protecting my data, I rem ervisory authority: the National Commission for Data Protect -violation-de-donnees-personnelles).
I certify that I am affiliated with or beneficiary of	a social security scheme.
I have also been informed of the existence of ins the study.	surance to cover any damage attributable to the procedure
My consent does not relieve the organizers of the rights as guaranteed by law.	e research of their moral and legal responsibilities. I retain all
I can at any time request any further information t on 04 69 16 66 44 or 04 69 85 62 18.	from the doctor in charge of the research, Prof. Béatrice Ferv
In view of the information provided to me, I freel	y and voluntarily agree to participate in this medical researc
The patient	The Investigator
Surname, first name:	Surname, first name:
Done in:	Done in:
Date:	Date: